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Abstract: Targeting Mesenchymal Stem Cells to damaged cartilage in Osteoarthritis 
 
Anaïs Dabbadie 
 
Osteoarthritis is a condition which results in the degradation of cartilage, the protective 
tissue which enables movement of our joints with a low coefficient of friction. No treatment 
is currently available to cure the cause of the disease. The injection of Mesenchymal Stem 
Cells (MSCs) into the joints of osteoarthritic patients has been investigated. Although these 
injections were shown to improve pain, no cartilage repair was observed, and it was shown 
that MSCs did not engraft at the site of injection. 
We hypothesised that increasing the number of cells which can accumulate onto the lesion 
would lead to better cartilage regeneration. This thesis describes the development of a 
method to specifically target MSCs towards type II gelatin, a molecule which is uniquely 
found in damaged cartilage, by coating them with a protein which binds to this substrate. 
MSCs were successfully coated with a chimeric protein named 222, which was engineered 
following the expression and characterisation of the Collagen Binding Domain (CBD) of the 
Matrix Metalloprotease MMP-2. 222 was shown to bind to type II gelatin with a Kd of         
2.46 nM, a value which was 14 times lower than that obtained for the CBD. The protein was 
shown to be present at the cell surface by confocal microscopy, and the viability of coated 
MSCs was similar to that of wild-type cells. Cells coated with 222 were shown to bind 
significantly better to type II gelatin than uncoated cells in vitro, with a median attachment 
of 224.4% for coated cells compared to 23.67% for wild-type cells. 
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1. Introduction 
 
1.1. Anatomy of the joint 
 
A joint is defined as the point of contact between two bones. Depending on the movement 
they allow, joints can be classified as synarthrosis (immovable), amphiarthrosis (slightly 
moveable), and diarthrosis (freely moveable) 1. Diarthrodial joints include the hip, ankle, 
elbow, shoulder and the knee 2, and all of them share common structural features            
(Figure 1- 1). They are enclosed in a fibrous capsule 3, whose inner surfaces are lined with 
the   synovium 2. This tissue, which contains fibroblast-like B cells and synovial macrophages           
(A cells), 3 is responsible for the secretion of the synovial fluid 2, a viscous liquid composed of 
a protein-rich plasma ultrafiltrate and hyaluronan 4. The synovial fluid also contains 
electrolytes such as sodium, potassium, calcium and chloride 4, phospholipids 3 as well as the 
Superficial Zone Protein (SZP) 4, which helps with lubrication. The synovial fluid is also 
responsible for nutrients supply and waste removal 4. Finally the articulating bones are 
covered with a smooth and thin tissue: the articular cartilage. 
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1.2. Cartilage 
 
1.2.1. Overview 
 
Cartilage can be described as elastic, fibrocartilage or hyaline, depending on the composition 
of its matrix 5. Elastic cartilage, which has a high content in elastin fibres 4, is found in the 
ears and the trachea 6, where it helps maintain the shapes and flexibility of these       
structures 6,4. Fibrocartilage can be found in the intervertebral discs, the meniscus and at the 
interface between ligaments and tendons with bones. It is rich in type I collagen and is the 
strongest of the three types of cartilage 4. Finally, hyaline cartilage is present in the nasal 
cavity as well as in the articulating joints such as the elbow, shoulder, hip and knee joints, 
where it is referred to as articular cartilage 5,4. 
 
 
 
Figure 1-1: Anatomy of a diarthrodial joint. The joint capsule is lined with the synovium, 
whose cells are responsible for the secretion of the viscous synovial fluid. This fluid helps 
with the lubrication of the joint. The surface of each bone is covered with articular 
cartilage. 
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1.2.2. Articular cartilage: structure and function 
 
1.2.2.1. Function 
 
Articular cartilage covers the end of opposing bones in a thin layer (2-4mm) 7, providing a 
smooth lubricating surface which allows movement with a low coefficient of friction 7,5,6,4. 
Healthy articular cartilage appears white and smooth 6, and its ability to bear and dissipate 
loads throughout the joint 6,4 is directly related to its structure. 
1.2.2.2. Structure 
 
1.2.2.2.1. Chondrocytes 
 
Cartilage contains only one cell type, the chondrocytes, which are sparsely distributed 
throughout the tissue 7,8. These spheroidal cells 5,4 account for only 1 to 5 % of the volume of 
articular cartilage 8,5  and are not highly active metabolically 4. They rarely form cell-to-cell 
contacts as they are embedded within the Extracellular Matrix (ECM) 7,8,5,4. However, they 
play a major role in cartilage biomechanics as they are responsible for the synthesis, 
degradation and turnover of the components of this matrix 5,4, namely type II collagen and 
proteoglycans, which provide cartilage with its resistance to tensile strength and 
compression 5, respectively. Even though these two components form the basis of the 
biomechanical properties of cartilage, a matrix devoid of cells would not replicate the 
biomechanical properties of cartilage, highlighting the importance of the cellular content of 
cartilage to maintain the homeostasis of this tissue via responses to stimuli such as 
mechanical loads and hydraulic pressures 7,8,4. 
1.2.2.2.2. Extracellular Matrix  
 
The Extracellular Matrix (ECM) of cartilage is itself made of two major components: water 
(accounting for 70% of the wet weight) and the structural macromolecules, which include 
collagens and proteoglycans 7,8. 
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1.2.2.2.2.1. Collagens in articular cartilage 
 
Collagens are the most abundant macromolecule in the ECM of articular cartilage 7, where 
they are organised in fibrils 9 (Figure 1-2). Type II collagen is the most abundant, as it 
represents 80 to 85% of the total collagen content 10. This collagen form fibrils with type XI 
collagen, which is thought to regulate their diameter 10. The fibrils are completed by the 
Fibril-Associated Collagens with Interrupted Triple-helix (FACIT) collagen type IX, which is 
exposed at their surface, where it can cross-link with other collagen molecules as well as 
interact with other proteoglycans in the ECM 11,10.  Finally, type X and VI collagens are also 
found in articular cartilage. The former is present in the calcified cartilage and is a marker of 
hypertrophic chondrocytes 10, while the latter is abundant in the pericellular matrix of 
chondrocytes 12. Some reports have also described the presence of type I collagen at the 
surface of the tissue 4.  
 
Figure 1-2: Composition of the collagen fibrils in articular cartilage. Collagen fibrils in 
articular cartilage are mostly made of type II collagen, which associates with type XI and 
type IX collagen. The latter is exposed at the surface of the fibrils to interact with other 
matrix components. The alpha chain composition of each type of collagen is also displayed. 
Each alpha chain has a different sequence, although all of them will be rich in glycine, proline 
and  hydroxyproline 9. Figure adapted from 10. 
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All collagens share the same structural features, as they are organised in a triple helix made 
of three alpha chains rich in glycine, proline and hydroxyproline 7,4. All three residues confer 
a stability to the triple helix, which is reinforced by intra chains hydrogen bonds with the 
hydroxyproline 11 and electrostatic interactions between aspartate and lysines 9. The helical 
structure of collagen molecules coupled to their organisation in a fribrillar meshwork 
provides cartilage with its resistance to shear and tensile strength 7,8. 
1.2.2.2.2.2. Proteoglycans 
 
 Proteoglycans are made of a protein core to which Glycosaminoglycans (GAGs) are   
attached 8. The most abundant proteoglycan in cartilage is aggrecan, which is made of a core 
protein of more than 200 kDa 13. This protein core possesses more than 100 Chondroitin 
Sulfate (CS) and Keratan Sulfate (KS) chains 7,4  which form long chains of negatively charged 
groups that repel each other 7,5 (Figure 1-3, A).  This structure is able to interact with 
Hyaluronan (HA), a non-sulphated glycosaminoglycan which is present as a coating agent at 
the surface of chondrocytes 14, with the stabilising support of a Link Protein (LP). They form 
large aggrecan molecules 7,5 which are entrapped within the collagen fibrils 8. Up to 100 
aggrecan molecules can bind to a single HA, and their association with the link protein is 
undissociable under physiological conditions 13. Their high negative charge density provides 
cartilage with osmotic properties that trap water in the matrix, thereby enabling the tissue 
to withstand compressive loads 7,5,4. 
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Figure 1-3: Structure of the proteoglycans aggrecan (A) and small leucine-rich proteoglycans 
(B). A: Aggrecan is made of a core protein with 3 interglobular domains (G1, G2 and G3) which 
present sites of attachment for Keratan Sulfate (KS) and Chondroitin Sulfate (CS). The Link 
Protein (LP) mediates its attachment to Hyaluronan (HA). Figure adapted from 14. B: Small 
leucine-rich proteoglycans contain a protein core with leucine-rich repeats and sites of 
attachment for either chondroitin, dermatan or keratan sulfate. Figure from 15. 
 
 
While aggrecan accounts for 90 % of the total proteoglycans mass within articular          
cartilage 8, the other 10 % correspond to small proteoglycans such as the dermatan sulfates 
decorin and biglycan and the keratan sulfates fibromodulin and lumican 14 (Figure 1-3, B). 
Their protein core, which is much smaller than that of aggrecan, with an average size of          
40 kDa 15, contains 10 motifs rich in leucines, which are flanked by disulfide bridges 14. Except 
for biglycan, the interaction of these Small Leucine-Rich Proteoglycans (SLRPs) with collagen 
fibrils have been demonstrated 14. These SLRPs are therefore believed to regulate the 
diameter of the fibrils 13,16 as well as to protect them from degradation, by masking the 
recognition sites of collagenases 14. Finally, all 4 of these SRLPs have been shown to be able 
to bind to other matrix proteins as well as cytokines and growth factors 14,15. A particular role 
has been established for the binding of these SLRPs to Transforming Growth Factor beta 
(TGFβ), allowing  control of its access to the cells, ultimately affecting cell proliferation and 
metabolism 14,16. 
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1.2.2.2.2.3. Water 
 
70% of the wet weight of cartilage is due to water 7,5, which enables the transport of nutrients 
as well as the lubrication of the tissue 7,5,4 . More importantly, it allows for load-dependent 
deformation 5,4  through its interaction with the negatively charged proteoglycans 8,4.  
1.2.2.2.3. Structural organisation 
 
One important structural feature of cartilage is its heterogeneity throughout the depth of 
the tissue. Based on the shape of chondrocytes and the orientation of the collagen fibrils, 4 
zones can be distinguished (Figure 1-4) 7,8. 
 
 
 
 
The superficial zone, which accounts for 10 % to 20 % of the depth of the tissue 7, contains 
flattened chondrocytes and collagen fibrils which run parallel to the surface 7,8,5. The 
proteoglycan content is the lowest, and the amount of water the highest 8,5. This zone also 
contains the protein lubricin or lamina splendens 8,5, which is secreted by both the 
chondrocytes and the synovium 17, and which reduces the coefficient of friction 17. This 
superficial zone is responsible for withstanding sheer and tensile stresses 7,8,5. The high 
Figure 1-4: Structure of articular cartilage. The background displays the different zones of 
cartilage together with the shape and organisation of chondrocytes. The foreground 
represents the orientation of collagen fibrils throughout the depth of the tissue. Figure 
adapted from 6. 
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density of the collagen fibrils also limits the size of the molecules which can go through the 
matrix, hence isolating cartilage from the synovial tissue immune system 8,5. 
The middle zone, which corresponds to 40 to 60 % of the tissue, is made of 
randomly/obliquely organised, thicker collagen fibrils, with a higher content in proteoglycans 
than the superficial zone 7,8,5, and a lower water content 8. The chondrocytes, which are fewer 
than in the superficial zone 7, appear spherical 7,8,5 in this zone, which is the first line of 
resistance to compression 7. 
The deep zone, which corresponds to 30 % of the thickness of the cartilage 7, contains 
chondrocytes organised in columns and the thickest collagen fibres, which are oriented 
perpendicular to the joint surface 8,5. The cell density is lower than in the other two zones 5,4. 
The proteoglycan content is at its highest and the water content at its lowest, providing this 
zone with the highest resistance to compression 7,8. 
Below the deep zone is the calcified zone, which is rich in type X collagen and hypertrophic 
chondrocytes and which protects the subchondral bone 5. The deep zone is separated from 
the calcified zone by the tide mark 5,7. 
1.2.2.3. Challenges associated with cartilage repair 
 
One particularity of articular cartilage is that it is aneural, avascular and alymphatic 7,5,4. One 
direct consequence is that there is no early repair response to injury involving macrophages 
and monocytes 17. The low cell density and low proliferative activity of chondrocytes coupled 
to the lack of blood supply mean that cartilage has a very limited capacity for intrinsic     
healing 7,4. Finally,  the complex three dimensional structure of cartilage, which is needed to 
ensure proper function, is challenging to recreate with regenerative techniques 7,4. Cartilage 
injuries are therefore difficult to treat, and untreated lesions could lead to osteoarthritis.  
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1.3. Osteoarthritis 
 
Osteoarthritis (OA) is a chronic, progressive and degenerative disease 18 which mostly affects 
the load- bearing joints such as the knee, the hip and the shoulder 19,20. It is characterised by 
a narrowing of the joint space 19 which is the result of a thinning of the articular cartilage and 
a thickening of the calcified cartilage. It is often accompanied by the formation of 
osteophytes and, in some cases, an inflammation of the synovium 21,19 (Figure 1-5). OA causes 
pain, stiffness and movement limitation 22,20. It is thought to be favoured by risk factors such 
as obesity, gender, genes, previous history of trauma 23,20 and age 23. 
Figure 1-5: Molecular mechanisms of OA progression. OA is characterised by the degradation 
of the matrix of articular cartilage, which is mediated by the overexpression of several Matrix 
Metalloproteases (MMPs). Cartilage degradative products are also though to recruit the 
immune cells from the lining synovium, initiating an inflammatory response. Chondrocytes 
are also altered in OA, where they can die by apoptosis, de-differentiate (not shown) or 
exhibit a hypertrophic phenotype. These changes lead to cartilage fibrillation and 
calcification, with the formation of osteophytes. Figure from 23. 
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Normal articular cartilage is characterised by the presence of quiescent chondrocytes 20,21 
which tightly control the expression of a cocktail of growth and transcription factors, as well 
as cytokines and enzymes, in order to maintain the tissue homeostasis and its function 20. 
This homeostasis is largely disturbed in OA, where catabolic processes become prevalent. 
OA is indeed characterised by the overexpression of several matrix-degrading enzymes, such 
as the Matrix Metalloproteases (MMPs) MMP-2, MMP-3, MMP-8, MMP-9, MMP-13 and 
MMP-14, which are able to degrade most of the matrix molecules 20. MMP-13 is thought to 
play the most crucial role in the degradation of type II collagen, while the aggrecanases A 
Disintegrin And Metalloproteinase with Thrombospondin Motifs  (ADAMTS) 4 and 5 are 
thought to be involved in the degradation of aggrecan 21,20. The degradation of these key 
components of the cartilage ECM leads to an increased permeability of the tissue and an 
alteration of its biomechanical properties. 
These catabolic responses are further exacerbated by inflammation of the synovial 
membrane 20, which is thought to occur when cartilage fragments resulting from the matrix 
degradation fall in the lining synovium 21,20. This results not only in the activation of both the 
innate and adaptive immune responses 24,21,19, but also drives the expression of inflammatory 
mediators, such as Tumour Necrosis Factor alpha (TNFα) and Interleukin 1 beta (IL-1β), which 
further increase the expression of matrix-degrading enzymes 21,20, and repress the synthesis 
of collagen and proteoglycan 25. Even though some compensatory mechanisms have been 
observed, through the activation of Bone Morphogenic Proteins  (BMPs) and Prostaglandins 
E2 20, the overall process results in cartilage degradation which starts at the surface of the 
tissue, and advances to deeper zones as the condition progresses 20. The expression of these 
inflammatory modulators is further exacerbated in ageing cartilage, where senescent 
chondrocytes secrete additional cytokines, chemokines and proteases belonging to the 
Senescent Associated Secretory Phenotype (SASP), which further contributes to cartilage 
degradation 23,26. 
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The phenotype of chondrocytes is also greatly altered in OA. Normally quiescent, 
chondrocytes adopt, in the deeper zones of the tissue 27, a proliferative phenotype to form 
clusters 22,21, in an attempt to initiate a repair of the damaged tissue 21. However, most of 
them aberrantly express the Type X collagen, Vascular Endothelial Growth Factor (VEGF) and 
MMP-13 genes 28, which are typical of a hypertrophic phenotype 29, and will therefore 
contribute to the calcification of the ECM 21,29. The calcified cartilage will be thickened, and 
its invasion by blood vessels from the subchondral bone will result in a duplication of the 
tidemark, leading to an invasion of cartilage by bone, further contributing to the thinning of 
this load-bearing tissue 22,21. 
In parallel, a subpopulation of chondrocytes at the more superficial zones 30 seem to 
dedifferentiate as they express higher amounts of type I over type II collagen 31, a 
phenomenon which will lead to cartilage fibrillation 31. 
Finally, OA chondrocytes also seem to be more subjected to apoptosis 22. Studies in         
rabbits 32, horses 33 and humans 34 showed that OA cartilage contains higher numbers of 
apoptotic chondrocytes than healthy cartilage, and, in all three studies, a direct correlation 
between the grade of OA and the percentage of apoptotic cells was observed. This increased 
level of apoptosis was shown to start at the superficial and middle zones 32,33, and to co-
localise with regions of degraded matrix 32,34 and secretion of Nitric Oxide (NO), which is 
thought to induce this programmed cell death 32,35. Additional apoptotic chondrocytes were 
also observed at the tidemark 32 and in regions of chondrocytes clustering 32,34.The higher 
degree of apoptosis in OA might be due to a reduction in autophagy, although a direct link 
between the two still needs to be established 36. The degradation of the ECM observed in OA 
might also play a role, as chondrocytes are dependent on their interaction with the matrix 
for survival 37. However, other findings indicate that chondrocytes apoptosis might precede 
cartilage destruction 34, and therefore contribute to the initiation of OA 33. 
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The high level of apoptosis of the unique cells of cartilage has several consequences: this 
hypocellularity means that damage to the ECM are unlikely to be repaired. As the tissue is 
avascular, there are no macrophages present to ensure the clearance of apoptotic           
bodies 38,35 : they therefore remain in the tissue, releasing their content rich in proteases and 
further contributing to the matrix degradation 35. Finally, these apoptotic bodies also favour 
the calcification of the tissue 39. 
OA is the most common degenerative joint disease 19 and, according to reports from Arthritis 
UK, affected 8.75 million of people in the UK in 2013. OA was classified as the 11th highest 
cause of disability in 2010 40 and, with increasing ageing population and obesity, is expected 
to affect 20 % of adults in Europe and Northern America by 2030 23. OA could therefore 
become an even bigger socioeconomic burden for healthcare systems, highlighting the 
importance of developing novel and effective treatments against this condition 23. 
1.4. Osteoarthritis treatments 
 
1.4.1. Drugs and intra-articular injections 
 
1.4.1.1. Non Steroidal Anti-Inflammatory Drugs, corticoids and visco-
supplementation 
 
The first line of treatments against mild to moderate OA involve pain management with Non 
Steroidal Anti-Inflammatory Drugs (NSAIDs), acetaminophen or opioid analgesics 18,41. These 
drugs present various unwanted side effects 41 and only manage the consequences of early 
OA, without addressing its underlying causes 42 nor initiating any repair processes 43. Intra-
articular injections of corticosteroids are an additional option for the treatment relief of pain 
associated with early OA 42, although their efficacy is reduced over time 42. Visco-
supplementation is also performed through intra-articular injections of hyaluronic acid 44, 
whose levels are reduced in OA 42, in an attempt to increase the viscosity of the synovial fluid 
and the motion of the joint 44. However, the optimal dose and number of injections have yet 
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to be found 44, and this technique was shown to provide no additional benefit compared to 
a placebo 42.  
Additional strategies for intra-articular therapies have been investigated with the use of 
Platelet Rich Plasma (PRP). 
1.4.1.2. Platelet Rich Plasma 
 
PRP is obtained following the centrifugation of whole blood, yielding a product which is 
enriched in platelets, by up to a factor 10 45. It is used in an attempt to restore the imbalance 
between anabolic and catabolic factors observed in OA 46. Indeed, the granules contained in 
the platelet solution can release up to 800 mediators, including growth factors, anti-
inflammatory cytokines such as interleukin IL-4, and the antagonist of the Interleukin 1 
receptor IL1-RA, as well as proteins involved in angiogenesis 45,47. The effects of this complex 
preparation are multiple: PRP is thought to inhibit the action of IL1-β and TNFα, and to 
promote the action of cartilage matrix molecules such as Fibroblast Growth Factor (FGF) and 
TGFβ 46. PRP is also thought to enhance the recruitment of Mesenchymal Stem Cells (MSCs) 
as well as to favour their adhesion, proliferation and differentiation towards a chondrogenic 
phenotype 47. PRP could also reduce the elevated levels of NO and exert anti-inflammatory 
properties, which are thought to be mediated by the Hepatocyte Growth Factor (HGF) 46. 
However, in spite of these promises, clinical data on the injection of PRP for the treatment 
of OA have demonstrated only limited success. Although PRP was shown to provide more 
beneficial effects than HA or placebo at 12 months follow-up 48,49, especially on the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and International Knee 
Documentation Committee (IKDC) scores (see Table 1-1 for a description of these scores) 49, 
these benefits were shown to be clearer in patients suffering from early OA 48,50. More 
adverse events such as pain, swelling and inflammation 46, were also observed following PRP 
injections compared to HA injections 50,49. Finally, a longer term follow up of 24 months 
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showed that pain scores had worsened following PRP injection, highlighting the short term 
benefit of this treatment 46. 
Several issues also need to be addressed before this method can be used as a treatment for 
OA. PRP can be injected as an inactivated product, allowing for the slow release of its 
bioactive molecules 46. Alternatively, it can also be activated in order to release the platelet 
content before its delivery 46. Whether activation is required and more efficient needs to be 
investigated 46. Furthermore, the method of activation will lead to variable PRP content 45. 
Other sources of variability include the method of preparation (i.e. number of 
centrifugations), the donor physical condition and its gender 45,47. PRP can also exist as either 
poor or rich in leukocytes 46. The latter will present anti-microbial effects, but may elicit an 
inflammatory response 46. Clearly, standardisation in the preparation of PRP is needed to 
fully understand its efficacy and mode of action. Currently, however, the use of PRP on its 
own is not approved by the Food and Drug Administration (FDA) nor recommended for the 
treatment of OA, as no structural improvement has ever been demonstrated 42,44. 
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Table 1-1: Scores used to evaluate the progression of OA in pre-clinical and clinical trials 
Score Evaluation Scoring system 
Western Ontario and 
McMaster Universities 
Osteoarthritis Index 
(WOMAC) 51 
Evaluates pain, stiffness, and 
physical function with 5, 2, 
and 17 questions, 
respectively 
Ordinal scale of 0 to 4, with 
lower scores indicating 
lower levels of symptoms or 
physical disability 
International Knee 
Documentation Committee 
(IKDC) 52 
Evaluates symptoms (pain, 
swelling, stiffness…) ; daily 
and sports activities ; and 
knee function with 7, 10 and 
1 question, respectively 
The response to each item is 
converted into an ordinal 
score, with lower scores 
representing worse 
symptoms or lowest levels 
of function. A total score is 
then calculated out of a 100, 
with the maximum score 
being equivalent to absence 
of symptoms and no 
limitation in daily or sporting 
activities. 
Whole-Organ MRI Scoring 
Method (WORMS) 53 
Evaluates 14 features such as 
articular cartilage integrity, 
presence of osteophytes, 
cysts and loose bodies, 
meniscal and ligaments 
integrity, synovitis 
Grading scales vary for each 
feature, lower scores 
indicate normal features. 
Visual Analogue Scale  
(VAS) 54 
Evaluates pain intensity. 
Unidimensional measure 
Scale from 0 to 100 with 
larger scores indicating 
greater pain intensity 
Lysholm 52 
Evaluates symptoms of knee 
instability. 8 criteria: limp, 
support, locking, instability, 
pain, swelling, stair climbing, 
squatting 
Individual scores for each 
criteria are added to give a 
total score on a scale of 0 to 
100. A score of 100 indicates 
no symptoms or disability 
 
In parallel to these pain management therapies, surgical procedures are available to repair 
focal cartilage lesions. 
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1.4.2. Surgical procedures 
 
Three main cartilage repair procedures are currently clinically available: microfracture, 
Autologous Chondrocyte Implantation (ACI) and mosaicplasty 4. 
1.4.2.1. Microfracture 
 
Microfracture is the first-line of surgical treatment for full thickness chondral defects 5, 
where the subchondral bone is exposed 5. This bone marrow stimulation technique relies on 
the perforation of the subchondral bone following debridement 5,17, which consists in 
removing, under arthroscopic vision, the damaged bone and cartilage fragments 55. 
Perforation of the subchondral bone releases the resident MSCs into a fibrin clot 5,17, which 
favours their proliferation and differentiation into chondrocytes 5 in a remodelling process 
which can take up to 16 months 4. However, it was reported that this remodelling usually 
leads to the formation of fibrocartilage 5,17, which is not suited to withstand the load 
associated with diarthrodial joints 4. This fibrocartilage was also shown to deteriorate within 
18 to 24 months, suggesting that this technique only delays the tissue degeneration observed 
in OA 43. The penetration of the subchondral bone was also shown to lead to the formation 
of osteophytes 41,43, which might limit the durability of this treatment 41. Finally, patients who 
had undergone microfracture presented higher failure rates when subjected to Autologous 
Chondrocyte Implantation (ACI) 43. 
1.4.2.2. Autologous Chondrocyte Implantation  
 
ACI is another surgical technique to treat focal cartilage lesions. It is a two-step technique 
where a biopsy of healthy tissue is obtained from the patient during a first arthroscopy 56,5,17. 
Chondrocytes are then expanded in culture until reaching densities of between 12 to 48 
million cells 43. These cells are then re-implanted in the patient during a second surgery 4,17. 
In order to avoid leakage, a periosteal patch is added to seal the surface 4. ACI was shown to 
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provide clinical benefits for patients with large focal defects in the knee 43, and is usually 
prescribed following failure of microfracture 4. However, its superiority to the latter was not 
demonstrated after a 15-year follow-up comparing both techniques 57, and neither of these 
methods seemed efficient at protecting patients from developing osteoarthritis 57. This 
technique does not pose any immunogenic risks are the patient’s own cells are used 43; 
however, the two surgeries required and the expansion of chondrocytes in vitro make it 
expensive 18. The tendency of chondrocytes to de-differentiate when expanded in vitro poses 
another  problem 18,43, although chondrocytes were shown to be able to re-differentiate 43. 
A hypertrophy of the flap was also often observed as an undesirable effect 43. Replacement 
of this flap by synthetic collagen was adopted in subsequent techniques 43,4. Other 
advancements were observed with the development of Matrix-Associated Chondrocyte 
Implantation (MACI), a technique which relies on the use of a type I/type III collagen    
scaffold 17. With this technique, chondrocytes are seeded onto this matrix 3 days before their 
implantation, in an attempt to prevent their de-differentiation 43. The matrix was designed 
to allow chondrocyte infiltration on one side and lubrication on the other 43, enabling better 
cell distribution throughout the defect 58. In spite of these changes, the superiority of MACI 
over ACI was not demonstrated in a 1-year follow-up study 59, although studies with longer 
follow-up showed improvements in pain and function 60,61. Importantly, however, MACI was 
shown to provide statistically significantly better outcomes than microfracture for pain and 
function in a 5-year follow-up study, although no statistical significant difference was 
observed structurally 62. Seeding chondrocytes on the matrix for longer period of times, such 
as 4 to 6 weeks, was proposed as a way to improve the clinical benefits of MACI, in which the 
neo-formed tissue is still immature when implanted 43. However, one of the remaining 
drawbacks of both ACI and MACI is the long postoperative treatment 4. Even though MACI 
can be used on larger defects than ACI 58, both techniques are also only suited for focal 
22 
 
cartilage defects, which do not correspond to the generalised degeneration observed in       
OA 18. 
1.4.2.3. Osteochondral autografts and allografts 
 
Finally, the last available surgical method used to correct both chondral and osteochondral 
defects is mosaicplasty. The technique relies on the biopsy of cylindrical osteochondral plugs 
in regions of healthy cartilage 5,17. These plugs are then used to fill the defect in a mosaic 
pattern 5,17. Both auto and allografts can be used 4. However, the latter presents a risk of 
immunogenicity 4, and the former can only be used to treat small sizes defects 42. This 
technique provides a shorter postoperative treatment compared to ACI 4, but complications 
from the donor site are often observed 4, such as haematomas, inflammation or 
deterioration of the articular tissue 44. The gaps between the plugs were also shown to be 
filled with fibrocartilage, creating zones of instability 5. 
 
Overall, the only available therapies at the moment are either surgical procedures for the 
repair of focal lesions, or analgesics and anti-inflammatory drugs for the management of 
early to mild OA. None of the current OA treatments is ideal, and failure of one or a 
combination of them ultimately leads to total knee replacement 5. However, this last resort 
solution is more suitable for older patients, usually aged above 60 5, and presents risks such 
as infection and pulmonary embolisms 41. 
Additional therapies are therefore needed, not only to restore the damaged articular 
cartilage caused by OA, but also to modify the course of the disease and to provide longer 
lasting effects 41,63. To date, no Disease Modifying Osteoarthritis Drugs (DMOADs) are 
available 63, although several are under investigation and have shown promising initial 
results. 
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1.4.3. Disease Modifying Osteoarthritis Drugs 
 
1.4.3.1. Gene therapy 
 
Gene therapy relies on the delivery of nucleic acids to targeted tissues using either viral or 
non-viral vectors, in order to prevent, treat or cure diseases 64. Their delivery can either rely 
on the direct injection of the modified vectors (in vivo approach), or require the extraction, 
transduction and re-implantation of cells of interest into the tissue (ex vivo approach) 64. OA 
is particularly suited for such a local strategy as it is confined to a limited number of joints, 
has no extra-articular or systemic components, and no current alternative treatments are 
available 65. Several types of transgenes can be used in an effort to limit inflammation, 
promote anabolic processes or inhibit catabolic ones 64.  
One of the earliest strategies aimed at delivering the Interleukin 1 Receptor Antagonist (IL1-
RA), in order to inhibit the IL-1 mediated pathway 64. Direct intra-articular injection of 
adenoviruses expressing this transgene have shown to slow disease progression in an equine 
model of Post-Traumatic Osteoarthritis (PTOA) 64. An Adeno Associated Virus expressing the 
human IL1-RA gene was shown to be safe and is currently being tested in a Phase I trial in 
the United States 64. 
Another promising outcome of gene therapy for the treatment of OA has come from the 
development of Invossa. This gene therapy treatment relies on the use of allogeneic 
chondrocytes transduced with a retrovirus expressing TGFβ1, a growth factor which was 
shown to be involved in cartilage development and maturation 64. In order to prevent the 
formation of tumour following the injection of these modified chondrocytes, these cells were 
first irradiated 65. They were also mixed in a 1:3 ratio with untransduced, unirradiated cells 
of the same origin, which were used as a target to benefit from the paracrine effects of   
TGFβ1 64,66. Several preclinical studies have demonstrated that this strategy leads to cartilage 
repair in rabbits, and clinical trials have demonstrated the safety of the procedure 66. Patients 
24 
 
suffering from moderate to severe OA treated with Invossa also showed better clinical 
outcomes in terms of pain and knee movement 67. These encouraging results led to the 
approval of this therapy in Korea for patients with knee OA, but the approval has since been 
revoked following a mislabelling of one of the ingredients used. This therapy was also being 
tested as part of a Phase III clinical trial in the US 64, which has now been stopped. Early 
results from this trial seemed to suggest structural improvement, as cartilage thickness was 
increased by Magnetic Resonance Imaging (MRI), although no statistical significance was    
met 68. 
In parallel, other molecules are also being investigated as potential DMOADs. 
1.4.3.2. Other Disease Modifying Osteoarthritis Drugs 
 
These include inhibitors of NO synthase or of Matrix Metalloproteases, both of which have 
the potential to modify the progression of the disease 63, although clinical trials for both 
drugs did not show structural improvements 69.  
Interest has also been increasing for the development of the growth factors BMP7 and      
FGF-18 as potential drugs 63. The first one exhibits both anabolic and anti-catabolic 
properties, and was shown to initiate cartilage repair in various animal models of OA 63. The 
latter was shown to induce articular cartilage thickness in a rat model of joint degeneration, 
an observation which might be a consequence of its anabolic and chondrogenic         
properties 63. Both drugs were tested in phase II clinical trials in recent years 69.  
Finally, calcitonin was shown to inhibit the formation of osteophytes and to preserve healthy 
bone, and strontium ranelate, a drug initially developed for the treatment of osteoporosis, 
was shown to reduce joint space narrowing in knee OA 63,69, although improvements in pain 
scores were more moderate 69. Glucosamine Sulfate and Chondroitin Sulfate are also 
classified as DMOADs. The former was shown to reduce pain and joint space narrowing in 
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both animal and human knee joints 44. Other developments include inhibitors of MMP-13, of 
aggrecanses 5 and of cathepsin K 69, which are being tested in various clinical trials.  Estrogen, 
parathyroid hormone and doxycycline have also raised interest as potential DMOADs, but 
are further away from clinical development 69. 
The development of these drugs undoubtedly represents exciting opportunities for 
modifying the course of OA, but more clinical studies will be needed before these drugs 
become available to OA patients. As OA is a disease of the whole joint with different 
phenotypes, a correct selection of patients who are more likely to benefit from these 
treatments needs to be performed, and the identification of biomarkers for both phenotype 
identification and disease progression needs further development 69. The complexity of the 
disease might also prevent its treatment with a single drug, and combinatorial treatments 
might be needed. A more direct route to clinical success for a disease modifying treatment 
might therefore lie in the use of Mesenchymal Stem Cells (MSCs). 
1.5. Stem cells  
 
Stem cells are defined, at the single cell level, as able to self-renew and differentiate into 
various cell types 70. The zygote and blastomeres are considered the most potent cells, as 
they are able to differentiate into all tissues of the embryo as well as into the cells from the 
extra-embryonic tissues such as the placenta 70. They are called totipotent 70. Other types of 
stem cells have more limited differentiation potential, and include Embryonic Stem Cells 
(ESCs), Induced Pluripotent Stem Cells (iPSCs) and Adult Stem Cells. 
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1.5.1. Embryonic Stem Cells 
 
Pluripotent embryonic stem cells can be isolated from the inner cell mass of the blastocyst 
and they are able to differentiate into cells from the three different germinal layers 
(ectoderm, mesoderm and endoderm) 70,71. Their differentiation potential have made them 
interesting candidates for regenerative medicine, in which a damaged tissue can be restored 
thanks to the differentiation of stem cells into a specific cell type 71. However, the ethical 
issues associated to their use have limited their therapeutic application, and favoured the 
emergence of cell reprogramming techniques, in which somatic cells are genetically altered 
to be restored to a pluripotent state capable of generating embryonic-like stem cells 71. 
1.5.2. Induced Pluripotent Stem Cells  
 
The generation of pluripotent stem cells has proven successful in 2007, when Yamanaka et 
al. managed to reprogram human adult skin fibroblasts into pluripotent stem cells by 
transducing them with the transcription factors Oct4, Sox2, c-myc and Klf4 71. Techniques for 
transduction include integrating methods relying on retroviruses and lentiviruses as well as 
non-integrating methods, which rely on the use of adenoviruses, plasmid Deoxyribonucleic 
Acid (DNA) and proteins 71. The risk of genetic dysfunction and tumourigenesis associated 
with the former have encouraged safer methods to be developed, and small molecules have 
recently demonstrated to be able to induce reprogrammation in a mouse model 71. The use 
of fibroblasts as the original cell type to be reprogrammed was another limitation, as the 
process was highly inefficient and prevented large-scale production 71. Recently, iPSCs have 
successfully been generated from the widely available blood cells, therefore increasing their 
potential for future commercialisation 71,72. The ability to alter the genome of these cells at 
very specific sites with the Crispr/Cas9 technique also makes their application possible for 
correcting disease-causing mutations 71,72.  
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The clinical applications of iPSCs are varied. They are used to model diseases and recapitulate 
the environmental, genetic and epigenetic factors leading to a pathology, which can 
sometimes be patient-specific 71. They are also used for drug screening as they offer 
physiological human conditions, contrary to animal models 71. The ability to study patient-
specific diseases also enables the development of personalised medicine, with drugs being 
tested on a patient-by-patient basis 71. Finally, iPSCs can be used for regenerative medicine, 
and recent applications have led to the use of iPSCs-derived retinal pigment epithelium in 
the treatment of macular degeneration in Japan 72. Worldwide, several clinical trials are on-
going to test the use of iPSCs-derived cells for the treatment of neurological disorders, heart 
failure and diabetes 72. However, the broad applications of these cells in regenerative 
medicine is not yet a reality 72, as many issues still need to be solved. The best cell type for 
reprogramming needs to be selected, ensuring easy access, limited invasiveness and high 
efficiency of reprogramming 71. iPSCs cells have also shown to be heterogeneous, as genetic 
and epigenetic variations have been observed between different iPSCs cell lines as well as 
between different passages of the same cell line 71. These variabilities might affect the 
differentiation potential of iPSCs or increase their tumourigenecity 71. Intensive 
characterisation, by karyotyping or whole genome sequencing, will certainly be needed 
before these cells can globally progress to the clinic 72. Regulatory guidelines also need to be 
adopted in order to validate the methods of reprogramming, culture and differentiation, 
amongst others 72. Finally, the commercial feasibility of generating individualised iPSC-
derived therapeutics needs to be studied; the alternative would be to generate banks of 
allogeneic iPSCs matching each potential patient, a process which will need to be highly 
regulated and which seems unlikely to happen in the near future 71,72.  
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1.5.3. Adult Stem Cells  
 
For all of these reasons, Adult Stem Cells constitute the best established existing clinical 
therapy at the moment 70. Adult stem cells represent only a fraction of the cells in an 
individual, and have a more limited differentiation potential than iPSCs and ESCs 70. They are 
called multipotent, as they can only differentiate into the cells from the tissue in which they 
reside 70. One of the major sources of adult stem cells resides in the bone marrow, and 
encompasses hematopoietic and mesenchymal stem cells 73. The former are able to restore 
the entire hematopoietic system, and have clinically be used for more than 30 years in 
patients suffering from blood disorders such as leukaemia and anaemias 73. Mesenchymal 
Stem Cells (MSCs), on the other hand, display properties which make them an interesting 
candidate for cartilage regeneration 73. 
1.5.3.1. Mesenchymal Stem Cells generalities 
 
Mesenchymal Stem Cells (MSCs) are precursors of connective tissues 74 with a capacity for 
self-renewal and stemness maintenance 75 . They can be isolated from many different tissues, 
including bone marrow, adipose tissue, spleen, lungs 18, as well as muscle, dermis, both the 
synovial fluid and membrane, and articular cartilage 23. Some MSCs can also be found in the 
umbilical cord blood and in the infrapatellar fat pad 75. Although all MSCs will exhibit the 
same phenotypic characteristics, irrespective of their source, their proliferation and 
differentiation potential will depend on their origin 75. The large variety of tissues they can 
be isolated from has led to the suggestion that MSCs could originate from a perivascular 
niche 74. 
MSCs are adherent to plastic, which is one of the three features that are used to characterise 
them 20,75. They should also, by definition, be positive for the cell markers CD105, CD73, and 
CD90 and negative for CD45, CD34, CD14 (or CD11b), CD79a (or CD19), and HLA-DR 75, 
although other markers can also be used (positive for CD 44, CD 145, CD 166 and STRO-1 and 
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negative for CD 31 and CD 117) 20,23. Finally, they exhibit a tri-lineage differentiation 
potential, with an ability to differentiate into chondrocytes, osteoblasts and                
adipocytes 20,23,74. They can also be differentiated into intervertebral disc, muscle and 
ligaments 23. 
Although MSCs are very easily expanded 47,76, one of their main drawbacks is that they are a 
very heterogeneous population 76,75. Only one third of primary MSCs are actually able to 
differentiate into the three main cell types mentioned above, while the other two thirds 
exhibit an either bipotent or unipotent phenotype 76. 
1.5.3.2. Why use Mesenchymal Stem Cells for cartilage regeneration 
 
In spite of these limitations, MSCs are of great interest in regenerative medicine. They are 
particularly attractive in cartilage regeneration, due to their chondrogenic potential 77, as 
they could replenish the stock of chondrocytes which is declining in OA. 
However, their therapeutic effect could also come from paracrine and immunomodulatory 
effects, which could alter the progression of OA by restoring the balance between anabolic 
and catabolic factors 78. 
Upon the expression of inflammatory cytokines such as IL-1 and TNFα, MSCs are known to 
secrete a range of bioactive molecules, such as the growth factors TGFβ, HGF, FGF2, 
Epidermal Growth Factor (EGF), Insulin-like growth factor 1 (IGF1) and VEGF, as well as NO, 
prostaglandins E2, and the anti-inflammatory interleukins IL-4, IL-6 and IL-10 79. These factors 
are thought to favour cell proliferation, prevent apoptosis and stimulate chondrogenic 
differentiation and cartilage matrix formation 78,79. Recently, it was suggested that one 
additional mechanism of action of this paracrine effect could be the secretion of extracellular 
vesicles, called exosomes, by MSCs 41. Their content is believed to induce the migration of 
endogenous stem cells into cartilage defects, leading to a partial repair of the damage 43. 
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MSCs were also shown to be immunosuppressive 77, directly interacting with immune cells 
to modulate their activities 23, especially their secretion of cytokines 41. They are able to 
inhibit the proliferation of both T and B lymphocytes 80 as well as to suppress the activation 
of natural killer cells 75 and the maturation of monocytes and dendritic cells 78, therefore 
creating a zone of immune tolerance around the site of damage 77,23. These effects are mostly 
mediated by prostaglandins E2, HGF, TGFβ1 81 and IL-6 80. In addition, the secretion of IL-4 
and IL-10 enables the restoration of the balance between the T cell helpers H1 and H2, which 
was shown to favour cartilage regeneration 79. IL-4 is also responsible for restoring the 
balance between the pro inflammatory, anti-angiogenic M1 macrophages and the anti-
inflammatory, pro remodelling M2 macrophages towards the latter 79.  
MSCs were also shown to migrate selectively to the site of damage (homing potential), which 
adds to the rationale of using these cells in regenerative medicine 18,23,75,76. They also express 
low levels of class II Human Leukocyte Antigen (HLA), which enables them to avoid 
recognition by the immune system and facilitates their use for allogeneic therapies 79.  
Finally, MSCs from the joints of patients suffering from end-stage OA have been shown to 
have altered proliferative and differentiation capacities, with reduced chondrogenic and 
adipogenic activities compared to MSCs from healthy age-matched patients 74. These 
observations add to the rationale of using MSCs as a potential treatment for OA, in order to 
replace the existing, defective population of MSCs present in the affected joints 74. 
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1.5.3.3. Sources of Mesenchymal Stem Cells 
 
MSCs isolated from the Bone Marrow (BM-MSCs) have been, so far, the most commonly 
used for cartilage repair. But the painful harvesting procedure and the risks of infection and 
sepsis has led scientists to investigate the potential of MSCs from various other sources 74.  
1.5.3.3.1. Adipose Derived Mesenchymal Stem Cells 
 
Adipose-Derived MSCs (AD-MSCs) present the advantage of being easily harvested from 
liposuction waste  20,75, which is generally preferred by patients 41. They are also present in 
much larger quantities, up to 500 fold more 76, than MSCs in the bone marrow, and their 
differentiation and proliferation potential is less likely to be affected by the donor’s age 43. 
They exhibit the same immunomodulatory and anti-inflammatory properties compared to 
BM-MSCs 43, and can be differentiated into chondrocytes, muscle cells and adipocytes 20,75. 
However, their chondrogenic potential is more limited than that of BM-MSCs, although this 
limit may be overcome by the addition of appropriate growth factors 75. Another feature 
which may limit their use is their higher propensity to undergo chondrocyte hypertrophy 20.  
Notably, Stromal Vascular Fraction (SVF) is sometimes used as a therapeutic source of 
adipose derived MSCs. This product is obtained from liposuction aspirates, which are 
digested by collagenases, centrifuged and diluted prior to injection 82. SVF is a highly 
heterogeneous product as it contains pericytes, fibroblasts, monocytes and macrophages as 
well as adipose-derived MSCs 82, which only account for 15 to 30 % of the total cell          
content 83. 
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1.5.3.3.2. Synovium Mesenchymal Stem Cells 
 
Considering the limitations displayed by the adipose derived MSCs, those isolated from the 
synovium could represent an interesting alternative. They indeed present the same 
advantage as AD-MSCs as they can be easily harvested, directly extracted from OA patients 
during a classic arthroscopic procedure 18. In addition to presenting the typical trilineage 
differentiation potential of MSCs 76, they also exhibit a higher chondrogenic potential 
compared to BM-MSCs 76. More evidence will be needed to confirm their potential in 
cartilage repair 75. 
1.5.3.3.3. Chondroprogenitors 
 
Finally, the third most interesting candidate as a source of stem cells might be the surface of 
the articular cartilage itself. It has been shown that resident chondroprogenitors are present 
in this zone 20,23, although probably at a much lower density in adults compared to young 
patients. These cells have demonstrated a proliferative potential combined with an ability to 
differentiate into chondrocytes in 3D pellet cultures 20,23. An additional advantage is that they 
do not present any risk of hypertrophic differentiation 20. It was also suggested that using 
resident cells might be more relevant to treat cartilage defects, both biologically and 
physiologically 23. 
Other potential sources, such as umbilical cord blood and skeletal muscles, may also be 
considered in the search for an ideal source of MSCs. They both present the advantage of  
easy harvesting procedures, offer a large availability of MSCs with a chondrogenic potential 
and, in the case of cord blood cells, immunomodulatory properties 23,76. 
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Overall, MSCs present many interesting characteristics for the treatment of OA: they can 
differentiate into chondrocytes and replenish this cell population which is declining in OA. 
Their immunomodulatory and anti-inflammatory properties mean that they could modulate 
the inflammation observed with this condition. The fact that they are easy to cultivate and 
can be harvested from multiple sites in the body makes them easier to work with than other 
cell types, such as chondrocytes. MSCs have therefore been used for the regeneration of 
cartilage in two different ways: either coupled to scaffolds for tissue engineering, or via direct 
intra-articular injections into the joints of patients suffering from OA. 
1.5.3.4. Tissue engineering with Mesenchymal Stem Cells 
 
Tissue engineering relies on a biological substitute to restore a damaged tissue or organ 44. 
Traditional tissue engineering strategies consist in preparing the scaffold before seeding it 
with cells and culturing the mixed phase in a static manner in vitro, leading to the formation 
of immature tissue 4. The tissue is then transferred into a bioreactor which will mimic the 
mechanical load found in physiological conditions 4. The tissue in its more mature form is 
then implanted into the body, where it will still undergo remodelling to reach complete 
maturation 4. The challenges associated with tissue engineering lie in the choice of the best 
cell population, the right scaffold and the appropriate signals to induce cell differentiation 
and proliferation 44,4. 
MSCs are an interesting cell source for the reasons mentioned above, and seem more 
promising than articular chondrocytes, which are present in small numbers in cartilage, de-
differentiate when expanded in culture, and seem to age faster 4. However, there are still a 
number of challenges associated with the use of MSCs in tissue engineering. 
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The choice of the right scaffold is one of them. The ideal material should be biocompatible 
and biodegradable 44,4, and would provide cells with a 3D micro-environment that favours 
their proliferation, differentiation and the synthesis of an ECM 17. However, this synthesis 
will be slow 17 and the biomaterial degradation should ideally happen at the same rate as the 
tissue formation 44,4. The biomaterial should also withstand the load applied on cartilage until 
it is completely replaced by the neo-formed tissue 44,4. In order to facilitate tissue formation, 
the material should be porous to allow for cell and fluid migration, and support cell      
proliferation 4.  
Common biomaterials used as scaffolds are of two types: either natural, which comprises 
collagen, fibrin, gelatin, hyaluronic acid, alginate, chitosan and agarose, or synthetic 
polymers, such as polylactide, PolyGlycolic Acid (PGA) or polyethylene glycol. The former 
contain ligands which are recognised by the cell receptors, facilitating the adhesion of cells 4 
as well as the insertion of the engineered grafts in the defect. They have also been shown to 
support chondrogenesis 4. However, they lack the biomechanical properties needed to 
withstand the stresses associated with diarthrodial joints, are rapidly degraded 44,42, and their 
architecture is harder to modify 4. On the other hand, the synthetic biopolymers provide 
mechanical strength and their degradation rate is much slower 44,42. Their production is more 
reproducible 44, and their mechanical and chemical properties can be tuned to different 
needs 44. However, they limit cellular interactions and cell-cell signalling compared to natural 
scaffolds 44, preventing cell attachment and proliferation 4.  
The ideal scaffold candidate might lie in the combination of both natural and synthetic 
polymers 44,4. The ability to tune the architecture of the engineered tissue with the use of 
stratified scaffolds 4 or, more recently, 3D bioprinting 76, which will likely help to mimic the 
complex architecture of native cartilage, are definite advantages for the use of such 
techniques for cartilage repair.  
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However, none of these tissue engineering techniques have yet made it to 
commercialisation. Some preclinical studies failed to show significant improvements 
compared to control when OA patients were treated with bone marrow MSCs seeded onto 
a collagen scaffold 76. Another study showed that cartilage tissue engineered with bone 
marrow MSCs has led to a tissue with poorer biomechanical properties than when the same 
biomaterial was seeded with chondrocytes 4, a phenomenon which was thought to be due 
to the differentiation of MSCs towards the osteogenic lineage 4. This finding reinforces the 
need to find adequate cocktails of growth factors to control the differentiation of MSCs in 
vitro, but also highlights that the best cell population for tissue engineering might still need 
to be found. Interestingly, a study by Kafienah et al. showed that BM-MSCs from OA patients 
could be used to successfully engineer hyaline cartilage, opening up the possibility to develop 
an autologous treatment for cartilage lesions 84. OA BM-MSCs were seeded onto Poly Glycolic 
Acid scaffolds pre-coated with fibronectin, and appropriate molecular signals were applied 
using TGFβ3, FGF-2, insulin and parathyroid hormone related protein. The engineered tissue 
was shown to be histologically comparable to that engineered with nasal chondrocytes. 
However, the collagen content of the engineered tissue was shown to be lower than that 
found in native cartilage, a phenomenon which was observed with all the cartilage tissues 
grown in vitro 84. The formation of immature tissue leading to mechanical failure is indeed 
the highest risk with tissue engineering 4, and the high cost associated with this technique, 
coupled to the need for assessing the safety of each component of the engineered construct, 
renders its commercialisation more complicated 17. In comparison, direct injection of MSCs 
into an OA joint is technically easier, and the regulatory path of this technique towards 
commercialisation could be more straightforward 74. 
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1.5.3.5. Intra-articular injections of Mesenchymal Stem Cells: pre-clinical 
evidence  
 
Considering all of these factors, it is not surprising that several groups have tested the 
efficacy of intra-articular injections of MSCs in different OA animal models, with various 
degrees of success. 
1.5.3.5.1. General data 
 
The injection of allogeneic adipose derived MSCs in the joints of rabbits where OA was 
surgically induced led to better gross appearance of damaged cartilage, which correlated 
with both higher histological and radiographic scores compared to a control, untreated 
group 85. Similar positive outcomes were observed in a sheep model of OA, where the 
injection of MSCs led to partial cartilage regeneration both macroscopically and by     
histology 86. Notably, when MSCs were cultured in a chondrogenic medium, they led to the 
additional partial repair of the meniscus 86. However, these results were not confirmed in 
horses, where the injection of stromal vascular fraction and bone marrow MSCs were 
compared to a placebo. The only observed difference was a reduction in the levels of 
prostaglandins E2 in the group treated with BM-MSCs 87,75. However, this difference did not 
lead to an improvement in pain or function, nor in an increase in proteoglycan synthesis 87. 
In order to explain these findings, authors have suggested that the retention time of the 
injected MSCs may have not been long enough to lead to a therapeutic effect 87. The use of 
hyaluronic acid as a cell carrier was suggested as a way to improve this outcome 87. 
1.5.3.5.2. Results of cell tracking experiments 
 
In order to further investigate the fate of injected MSCs, several studies have been developed 
in an attempt to track cells once injected. Using a method which enables cell tracking in vivo, 
human adipose MSCs injected in rats were shown to engraft on OA cartilage for 10 weeks, 
while they persisted for only 4 weeks on healthy cartilage 88. This difference was thought to 
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be due to the presence of inflammatory cytokines in the joints of OA animals, which could 
attract MSCs. The persistence of MSCs for 10 weeks correlated with biological effects, 
namely, a higher proteoglycan content, lower collagen type I levels and increased cartilage 
thickness 88. Injected MSCs were also shown to proliferate at the site of engraftment, and to 
be contained within the joint, as other tissues such as the brain, lungs and heart were shown 
to be devoid of expression of the human gene FOXP2 88. Interestingly, a similar observation 
was made by a different group who tracked human adipose MSCs in rabbits ex vivo 89. Again, 
MSCs were shown to persist at the surface of articular cartilage for up to 10 weeks. The group 
treated with MSCs displayed better cartilage repair macroscopically, higher levels of 
proteoglycans and type II collagen, and lower levels of MMP-13 as well as thicker cartilage, 
compared to the control group which was treated with HA only 89. The fact that, in both of 
these studies, the biological effects correlated with the persistence of MSCs in the damaged 
tissue led the authors to suggest that cartilage regeneration required a persistent cell    
activity 88. However, both investigations were performed on non-upright walking animals, 
where the joint morphology differs from that of humans. Additionally, both models of OA 
were surgically induced, a procedure which does not necessarily replicate the inflammatory 
process happening in human OA joints.  
Another study, however, was performed on Guinea pigs which spontaneously develop OA, 
in a model which resembles more the secondary OA observed in humans. Interestingly, 
authors reported the successful engraftment of injected human MSCs when coupled to HA 
as a vehicle 90. Guinea pigs were treated with either MSCs + HA or MSCs+ Phosphate Buffer 
Saline (PBS), while control groups were treated with HA or PBS alone. The group treated with 
MSCs + HA showed significantly better macroscopic OA scores than all the other groups, and 
these results were corroborated with histological findings. More importantly, levels of type 
II collagen were significantly higher in the MSCs+HA group than in the MSCs+PBS group, and 
levels of MMP-13 were significantly lower in the former. The cell tracking evaluation revealed 
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that MSCs injected in PBS were present in low numbers and kept decreasing at each time 
point (1, 3 and 5 weeks). MSCs delivered with HA were present in higher numbers at all time 
points. Finally, double immunofluorescence staining showed expression of type II collagen 
around the injected MSCs as well as around the resident chondrocytes, suggesting that the 
delivered cells contribute to cartilage regeneration through both direct differentiation and 
stimulation of endogenous cells, potentially via trophic effects 90. In this study, HA was 
therefore critical to allow cell adhesion, engraftment, and proliferation leading to cartilage 
regeneration. However, the benefits of this vehicle were not replicated in a larger animal 
model. Following-up on their early observations in rabbits, authors from the above 
mentioned study 89 investigated the effects of MSCs injection in sheep, in an attempt to 
determine whether MSCs could slow down OA progression in a large animal model 91. Sheep 
were injected with allogeneic adipose MSCs and HA, HA alone or saline. Interestingly, and 
contrary to their observations in rabbits, MSCs were detected in the synovium 14 weeks after 
injection. However, sheep treated with MSCs + HA still displayed better cartilage both 
macroscopically and by histology. High levels of TGFβ and IGF1 were also detected, 
suggesting that the injected MSCs were promoting chondrogenesis via the secretion of these 
factors. Type II collagen levels were also increased, and the levels of Tissue Inhibitor of 
Metalloproteinase-1 (TIMP-1), an inhibitor of matrix metalloproteinases, decreased, 
although differences were not significant. Finally, the levels of expression of IL-6 and TNFα 
were also reduced, leading the authors to suggest that the injected MSCs were slowing down 
OA progression through their anti-inflammatory properties 91. They however did not exclude 
the possibility that the cells might have engrafted onto cartilage before their 14-week time 
point, and recruited endogenous cells to perform cartilage repair 91. 
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Other pre-clinical studies, however, do suggest that MSCs act via paracrine effects only. In a 
study of collagenase induced OA in mice 92, adipose derived MSCs injected 7 days after 
induction led to a reduction in the thickness of the synovial layer, together with a reduction 
in the number of macrophages and in the levels of expression of ADAMTS-5. Interestingly, 
when cells were injected 14 days after induction of OA, when inflammation is reduced, no 
beneficial effect was observed, suggesting that the therapeutic window is important. The 
tracking of these cells showed their presence in the synovium 24 hours after their injection; 
cells were no longer detected 5 days after their injection, although the observed therapeutic 
effects persisted up to day 42.  
There is clearly a debate at the moment as to whether MSCs act via direct differentiation or 
through the release of trophic factors, and, as suggested by the results of the studies 
mentioned above and by other authors 90, it is possible that both phenomena happen 
concomitantly to contribute to cartilage regeneration.  
However, for MSCs differentiation to happen, it seems clear that these cells need to be 
retained for long enough periods of time in the joint. In an interesting comparative study of 
direct injection of MSCs + PRP versus their transplantation with fibrin glue 93, authors have 
reported that, even though both techniques led to positive clinical outcomes, the scaffold 
implantation led to significantly better results. Cartilage repair was also shown to be longer-
lasting in the tissue engineering group and, interestingly, the correlation between clinical 
outcomes and the number of cells was only observed in the injection group 93. Authors have 
suggested that the lack of retention, survival and engraftment of MSCs following their 
injection could be a potential explanation for the limited clinical benefits of this          
treatment 93. These results strongly suggest that strategies should be implemented to favour 
the engraftment of MSCs onto cartilage lesions. Results obtained in clinical trials following 
the injections of MSCs in OA joints seem to support this statement. 
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1.5.3.6. Intra-articular injections of Mesenchymal Stem Cells: clinical trials 
results  
 
1.5.3.6.1. Safety 
 
The injection of MSCs was shown to be safe when using bone-marrow autologous                   
cells 94,95,96 and long-term safety was demonstrated at 30 months following injection 97. 
Autologous injections of adipose derived MSCs were also performed and showed no adverse 
effects, even after repeated injections, as mentioned in a review by Lopa et al  98, or with cell 
doses as high as 100 million 99. Finally, allogeneic bone-marrow MSCs were also shown to be 
safe for doses as high as 50 million cells 100,101. 
1.5.3.6.2. Clinical outcomes 
 
These injections were also shown to provide reduction in pain and improved knee function, 
with both bone-marrow 94,95,102,103,96 and adipose derived MSCs 104 or the synovial vascular 
fraction 105. These observations were sometimes associated with structural changes, such as 
increased cartilage thickness 95,96, for up to 24 months 104 or increased cartilage                   
quality 102,97,103, which was again sustained at 24 months 106, as assessed by Magnetic 
Resonance Imaging (MRI) T2 mapping. However, these data were acquired on small numbers 
of patients, ranging from 4 94 to 24 104, and histological analysis of the newly formed cartilage 
were not provided.  In addition, some of the early positive observations made by Davatchi et 
al. at a 1 year follow-up 94 were shown to have deteriorated at a 60 month follow-up, 
highlighting the short-term benefit of their treatment 107. Other studies did not show 
structural improvements 105. 
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1.5.3.6.3. Cell dose 
 
Further discrepancies were observed when investigating the effect of cell doses on clinical 
outcomes. Jo et al. tested the injection of adipose derived autologous MSCs at either 10 
million, 50 million or 100 million cells per patient 99. Significant improvements in pain and 
knee function were observed only in the high cell dose group, and were accompanied by a 
significant decrease in cartilage defect size. Interestingly, histological analysis showed the 
formation of a hyaline-like cartilage 99. A 2-year follow-up further confirmed these early 
observations, as both the clinical and structural improvements were maintained only in the 
high cell dose group 108. These findings were corroborated by the work of Song et al., who 
tested the effects of 3 repeated injections of adipose derived MSCs at either 10 million, 20 
million or 50 million per patient. All the tested doses led to improvements in pain and knee 
function, but the increased cartilage volume was longer lasting in the high cell dose group, 
as reviewed by Lopa et al. 98. However, contradictory results were obtained by Pers et al., 
who evaluated the effects of injecting adipose derived MSCs at either 2 million, 10 million or 
50 million 109. Again, all the scores evaluating pain were improved, but significance was only 
obtained in the low cell dose group. MRI at 4 months revealed possible improvements in only 
half of the patients, and cell engraftment was observed in only 1 patient 109. Altogether, these 
data suggest that improvements in pain and knee function are not necessarily associated 
with cartilage repair, and clearly highlight a lack of reproducibility in the clinical trials. 
1.5.3.6.4. Injections of Mesenchymal Stem Cells with vehicles 
 
As mentioned in the preclinical data section, HA was shown to improve the engraftment of 
MSCs onto cartilage defects, and was associated with cartilage regeneration. Several groups 
have therefore tested the effects of injecting MSCs with HA as a vehicle in clinical trials, 
although with limited success. Gupta et al. tested the effect of a single injection of bone 
marrow MSCs using either 20 million, 50 million, 75 million or 150 million cells 100. 
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Improvements in pain scores were observed in the low dose group only, and did not reach 
significance 100. Similarly, Lamo Espinosa et al. tested the injection of either 10 million or 100 
million cells with HA 110. Pain scores were improved in both groups, but, contrary to the 
observations made by Gupta et al., only the high dose group showed better improvements 
in pain and knee function 110. The quality of cartilage was also improved in this group only. 
WORMS scores (see Table 1-1) were maintained at 12 months in the high dose group, while 
they were shown to be worse than baseline in the low dose and control groups 110. 
PRP was also investigated as a vehicle for MSCs injection. Several case series studies have 
reported improvements in pain and knee function 111,112 for up to 24 months 112 when using 
SVF in combination with PRP. Additional reports described an increase in cartilage thickness 
by MRI associated with reduced pain 113, although this observation was not observed on all 
patients tested in the study by Bansal et al. 112. An improved or maintained status of cartilage 
at 24 months was also observed by Koh et al. 114, as assessed by a second look arthroscopy. 
Finally, partial cartilage regeneration was observed by Bui et al. and associated with 
improvements in Visual Analogue Score (VAS) and Lysholm score (see Table 1-1) 113. 
However, another study reported functional improvements with no relevant changes by   
MRI 115, and the use of PRP with bone marrow MSCs failed to provide a significant benefit in 
pain and function in a randomized control trial when compared to MSCs alone 116. Finally, 
PRP was tested with SVF in combination with HA 117  and HA + dexamethasone 118  and led to 
improved clinical outcomes, along with increased thickness of cartilage 117. However, these 
data were acquired on only 3 patients and, overall, the studies led on PRP do not provide 
convincing evidence that this adjuvant would contribute to better cartilage regeneration. 
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1.5.3.7. Why enhance cell engraftment 
 
Overall, available data from clinical trials and case series studies on the injection of MSCs  
have only demonstrated short-term effects on pain and knee function. These improvements 
do not always correlate with structural changes of the damaged tissue, and histological 
analysis of the newly formed cartilage are lacking in all the reviewed studies but one 99. 
Finally, the results obtained by several groups have shown inconsistencies, especially as to 
which cell dose would be optimal. The fact that the doses used in the above mentioned 
papers ranged from 2 million to 150 million highlight the need for further investigation, as 
the use of very high cell doses would increase the cost of such treatments and prevent their 
development into commercially available therapies.  
These inconsistencies in both the outcomes of these clinical trials and the optimal cell dose 
could be explained by the lack of careful patient selection. Indeed, it seems critical to define, 
for each clinical trial, a set of criteria to select a homogeneous subpopulation of patients 
which are likely to respond to the treatment being tested. This would not only provide better 
clinical outcomes, but would also help define the best endpoints to measure therapeutic 
benefits. So far, no such work on patients stratification has been described.  
Another limitation which could explain the lack of reproducibility in the results obtained from 
these clinical trials is that none of these studies have developed strategies to retain the stem 
cells at the site of their injection, where their properties are the most needed. The use of 
vehicles such as PRP and HA have not provided clear additional benefits, highlighting the 
need to develop more effective delivery methods to achieve better clinical outcomes, as 
suggested by others 119.  
Generally, only 1 to 5 % of MSCs were shown to engraft onto their target tissue, irrespective 
of their delivery routes 120, and when these cells were injected in cartilage, they were shown 
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to disappear from the sites of injections only after a few days by Pers et al 120. This poor cell 
retention could be due to mechanical damage during injections 119, cell death by apoptosis, 
recognition by the immune system 121 or leakage to surrounding tissues 119. Several authors 
have therefore expressed the need to not only investigate the fate, behaviour and kinetics 
of MSCs following their injection 122,123, but also to develop methods to enhance their 
attachment onto the damaged tissue and promote their long-term engraftment 119,124. 
Achieving this objective would allow for the full exploitation of the potential of MSCs, and 
might lead to a reduction of the required cell dose. Notably, improved engraftment of the 
injected MSCs in preclinical models led to drastic positive effects on cartilage repair, with 
better cartilage regeneration mediated by MSCs differentiation. Several methods have 
therefore been investigated in an attempt to artificially increase the retention of MSCs at the 
site of injection. 
1.5.3.8. Strategies for artificial enhancement of Mesenchymal Stem Cells 
engraftment 
 
In the work by Koga et al. 125, both rabbit and human MSCs were injected, ex vivo, on chondral 
defects facing upwards and immobilised for 10 minutes. This immobilisation led to the 
attachment of 60 % of the cells, a drastic improvement compared to previously observed 
adhesion efficiencies. The use of this method in vivo in rabbits showed a higher number of 
cells present in the defects compared to control rabbits which underwent normal injection. 
Cells were shown to be attached 1 day after injection following immobilisation of the joint, 
leading to a reduced cartilage defect at 24 days as well as to better histological scores.  
Another strategy was developed for larger animals which relies on the use of magnetically-
labelled MSCs coupled to an external magnetic device 124. Mini pigs were submitted to this 
injection, while control groups were injected with either MSCs or saline with their patella 
facing upwards. An arthroscopy showed the immediate and specific accumulation of the 
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magnetically-labelled MSCs at the site of damage. Cells were retained after the external 
device was removed, and were shown to be fully integrated and differentiated in the tissue 
1 week after their injection. These observations were associated with better cartilage repair 
compared to the control groups at 24 weeks, as the newly formed cartilage appeared white 
and smooth. Better histological scores were obtained for this hyaline-like tissue compared 
to that formed in the control groups, which were shown to be fibrous and hypertrophic 124. 
Interestingly, in both of these studies, the improved attachment of either human MSCs on 
ex vivo cartilage implants, or of the magnetically labelled MSCs was shown to be mediated 
by an increase in the expression of cell adhesion molecules such as integrins 124 and 
intercellular adhesion molecule 1 125.  
Similarly, a paper published by the company Xintela 126 reported the use of Fluorescence 
Activated Cell Sorting (FACS)-sorted adipose derived equine MSCs presenting the collagen 
binding integrin α10β1 at their surface. The sorted cells were shown to retain the trilineage 
potential of unsorted MSCs as well as their immunomodulatory properties. Sorted cells also 
demonstrated a higher chondrogenic potential in pellet cultures, and a significantly higher 
adhesion capacity to both chondral and osteochondral defects ex vivo when compared to 
the unsorted population 126. 
Altering the expression of molecules present at the cell surface was therefore pursued by 
other groups in an attempt to improve cell adhesion onto cartilage. Dennis et al. described 
the use of Palmitated Protein G as an intermediate to coat chondroprogenitors with various 
antibodies directed against matrix molecules 127. The presentation of these antibodies at the 
cell surface led to a higher adhesion of the coated cells to a rabbit articular cartilage explant 
with a partial thickness.  
However, these last two strategies do not specifically target MSCs towards damaged 
cartilage, as the matrix molecules used as baits to direct MSCs are also present in healthy 
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cartilage, although they might be less exposed. Other groups have therefore developed 
strategies to target MSCs to molecules which are only present in OA. 
In a study by Leijs et al. 128, authors observed that, in vitro, MSCs migrated more towards OA 
synovium and OA cartilage Conditioned Medium (CM) than towards control medium. They 
thought that the inflammatory cytokines expressed in OA were recruiting MSCs. 
Interestingly, they also showed that MSCs migrated more towards OA synovium CM than OA 
cartilage CM 128. Authors attempted to enhance the migration of MSCs towards OA tissues in 
vivo by pre-treating them with the inflammatory cytokine TNFα or by cultivating them in 
hypoxia, in an attempt to increase the expression of their cell surface receptors 128. However, 
this pre-treatment did not influence the migration of cells injected in vivo. In addition, cells 
were shown to engraft to the synovium or to be present as free MSCs in the joints, and very 
few cells were observed onto the damaged cartilage 128.  
This study demonstrates that the observed migration of MSCs in vitro is not recapitulated in 
vivo, and that the homing potential of MSCs is not enough to have them adhere onto the 
damaged tissue. It also shows that targeting inflammatory molecules expressed in OA might 
not be a successful strategy to improve their retention. 
Taking all these observations together, our group decided to develop a strategy in which the 
adhesion of MSCs towards a matrix molecule present only in OA cartilage would be 
improved. Instead of targeting native type II collagen or other matrix molecules, as described 
by others, our strategy was to target a molecule which is specifically present in damaged 
cartilage: denatured type II collagen. 
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1.6. Type II collagen denaturation in Osteoarthritis  
 
Indeed, several reports have described the increased cleavage, unwinding and subsequent 
degradation of type II collagen in OA 129,130,131. Dodge et. al. were the first to demonstrate 
this phenomenon using an antibody directed against epitopes corresponding to the 
unwound helix of type II gelatin. Human arthritic tissues displayed stronger staining than 
healthy ones, especially at the superficial and middle zones 130. These observations were later 
confirmed by Hollander et al., who have developed a new antibody, namely Col2-3/4-m, 
which specifically recognises an 11 amino acid-long epitope of type II collagen, which is only 
exposed when the helix is unwound 129. This antibody was also able to recognise heat-
denatured type II collagen 129. The increased levels of denatured type II collagen were 
observed mostly at the surface of articular cartilage 132 in both ageing and OA cartilage, a 
localisation which also correlates with the presence of the matrix metalloproteinases     
MMP-1 and MMP-13 131. Both enzymes were shown to be able to cleave this substrate in 
vitro, at the same site (Gly-Leu/Ile bond), generating the characteristic ¼ and                                     
¾ fragments 133,134 , but MMP-13 was shown to cleave this substrate more quickly 133 (Figure 
1-6).  
 
 
 
 
Figure 1-6: Cleavage of collagen by Matrix Metalloproteinases. The collagenases MMP-1, MMP-8 
and MMP-13 have been reported to be the prevalent enzymes involved in the cleavage of type II 
collagen in OA, although MMP-14 and MMP-2 can also exhibit some collagenolytic activities. 
Cleavage of the collagen molecule generates a ¾ N terminal and a ¼ C terminal fragment, and 
several data have reported that this cleavage leads to the unwinding of its helix. Gelatin can be 
further degraded by the gelatinases MMP-2 and MMP-9. Figure adapted from 209. 
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The prevalence of these enzymes, together with MMP-8, in the degradation of type II 
collagen in OA was further confirmed in another study 135 which relied on the use of 
antibodies directed against epitopes found in the fragments generated by the cleavage of 
collagen by these enzymes. The authors observed increased levels of these epitopes in 
human OA samples compared to normal tissues, highlighting the importance of collagenases 
in the degradation of type II collagen in OA. Notably, a correlation was observed between 
the levels of degraded and denatured collagen 135, the latter being detected by the previously 
mentioned Col2-3/4-m antibody. The fact that this antibody was able to recognise the                 
¾ fragment of cleaved type II collagen 129 further reinforces the assumption that cleavage of 
type II collagen by collagenases leads to its denaturation (unwinding). The fact that 
chondrocytes in both normal and OA tissues express MMP-1, 8 and 13 135, coupled to the 
observation that the staining of denatured type II collagen was mostly found in the 
pericellular region 132, suggest that cells from the cartilage are directly responsible for the 
increased breakdown of type II collagen observed in OA. 
Altogether, these studies have demonstrated that increased amounts of denatured type II 
gelatin are present in OA cartilage. Importantly, in normal human articular cartilage, only   
1.1 % of type II collagen is in its denatured form 136, against 6 % in OA cartilage 136, which 
justifies the use of this protein as a bait to target MSCs specifically to damaged cartilage. The 
fact that type II gelatin degradation starts at the articular surface, before progressing to 
deeper areas with disease progression 132 adds to the rationale of this strategy. 
Interestingly for the purpose of targeting MSCs towards this substrate, collagen fragments 
generated after its cleavage naturally denature into the non-helical gelatin to become 
substrates of various MMPs 135. 
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1.7. Matrix Metalloproteases  
 
1.7.1. Matrix Metalloproteases generalities 
 
Matrix Metalloproteases (MMPs) are a family of 23 proteins 137,138 which belong to the larger 
group of metzincins 138. They have been further divided into the subgroups of collagenases 
(MMPs-1, 8 and 13), stromelysins (MMPs-3 and 10), a more heterogeneous subgroup 
containing matrilysin (MMP-7), enamelysin (MMP-20), the macrophage metalloelastase 
(MMP-12) and MMP-19, membrane-type metalloproteinases (MT-MMPs-1 to 4 and 
stromelysin-3, MMP-11), and gelatinases (MMPs-2 and 9) 139. Its members are characterized 
by the presence of a conserved zinc ion in the catalytic site of the enzymes 140,141. MMPs are 
multidomain proteins, sharing the same structural features 138,142 (Figure 1-7). 
 
 
 
 
 
 
 
 
 
 
Figure 1-7: Structural organisation of MMPs. MMPs contain a signal peptide (A) followed by 
a prodomain (B), a catalytic domain (C) and a hemopexin domain (D). MMP-2 and MMP-9 
contain three additional Fibronectin-like domains (E) which are inserted in the catalytic one. 
MT-MMPs also contain a transmembrane domain (F) and a cytoplasmic tail (G). Figure 
adapted from 138. 
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These common features include: 
 A prodomain which keeps them in an inactive state through the interaction of a 
conserved cysteine with the zinc ion of their catalytic site; disruption of this 
interaction leads to the activation of the MMP via the so called cysteine-switch 
mechanism. 
 The catalytic site which is responsible for the proteolysis activity of the proteases. It 
is connected to the hemopexin domain via a proline-rich linker. 
 The C-terminal hemopexin domain, which confers substrate specificity 140. It is 
absent from MMP-7 139 and is required for the cleavage of triple helical collagens by 
collagenases 138. 
Among this family, MMP-2 and MMP-9 (also known as gelatinase A and B, respectively) are 
unique in that they contain 3 additional and contiguous Fibronectin type II-like domains. 
These modules are also found in blood clotting factor XII, bovine seminal fluid proteins PDC 
109 and BSP-A3, Insulin-like Growth factor II receptor, the mannose 6 phosphate receptor, 
the mannose receptor and the phospholipase A2 receptor 143.  
Both gelatinases share the following substrates: type IV, type V, type VII and type X 
collagens, fibronectin, elastin, and all types of denatured collagens 144. Their Fibronectin type 
II-like domains are inserts into their catalytic domain and resemble the collagen binding 
regions of the type II repeats found in Fibronectin 138. In MMP-2, the Fibronectin type II-like 
domains 1, 2 and 3 span from residues 222 to 276, 279 to 333 and 337 to 391, respectively 
(Figure 1-8) and form the Collagen Binding Domain (CBD). 
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Figure 1-8: Cartoon representation of the CBD of MMP-2 derived from the published 
structure of MMP-2 (Protein Data Bank (PDB) Accession Number 1CK7) using Pymol. The 
sequence of the CBD (residues 222 to 391) was extracted from the published structure of 
MMP-2 to isolate the three Fibronectin-type II like domains. 
 
1.7.2. The Collagen Binding Domain of Matrix Metalloprotease-2 
 
 
The combined three Fibronectin-type II like domains of MMP-2, also referred to as the 
Collagen Binding Domain (CBD), have been extensively studied over the past few years. It 
has been shown to interact with both native and denatured type I collagen, denatured type 
IV and V collagen and elastin 141. A weak interaction has also been identified for native type 
IV and V collagen as well as laminin and heparin 141. Another paper from the same group 145 
has also shown that the CBD is able to bind native and denatured type III collagen, denatured 
type IV, denatured and native type V and denatured type X collagens. However, the CBD 
does not bind to Secreted Protein Acidic and Cysteine Rich (SPARC), fibronectin, nor to 
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matrigels films or gels 141, although some binding to denatured matrigel films was        
observed 145. 
The interaction of the CBD with these substrates is thought to be critical for the catalytic 
activity of the full length MMP-2. When deleted from the CBD, the activity of MMP-2 towards 
type I gelatin was indeed reduced to 10 % 146, and soluble CBD was shown to inhibit the 
gelatinolysis of MMP-2 137,147, demonstrating the role of the CBD in substrate positioning.  
It was also shown that all the collagen binding properties of MMP-2 could be attributed to 
the CBD, as a mutant deleted from this domain was unable to interact with type I           
collagen 146, or to inhibit binding of MMP-2 to gelatin 148. The fact that soluble recombinant 
CBD inhibited the binding of MMP-2 towards gelatin in a concentration-dependent manner 
further reinforces this theory 137. However, both full-length MMP-2 and 9 were shown to 
bind more tightly to gelatin than their isolated CBDs 148,149, suggesting that the other domains 
within the enzyme stabilize the interaction with the ligand. 
Interestingly for the purpose of this project, the CBD of MMP-2 was shown to bind with a Kd 
of 50 nM to type II gelatin in a plate binding assay 145, but did not bind to native type II 
collagen 145. This specificity towards denatured type II collagen justifies the choice of working 
with this CBD instead of that from MMP-9. The latter binds with a slightly higher affinity to 
type II gelatin (Kd of 8.0 nM), but also showed strong binding to its native form (Kd of 50 
nM) 148.  
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1.8. Aim of the project 
 
This project poses the hypothesis that targeting MSCs to damaged cartilage following their 
injection into OA knees would favour their engraftment and improve cartilage repair 
compared to previously published studies. 
In order to do so, our aim was to target MSCs towards denatured type II collagen (i.e. type 
II gelatin), which is specifically found at the surface of OA articular cartilage. The strategy for 
targeting MSCs towards this substrate relies on coating their cell surface with a protein which 
binds avidly to type II gelatin: the CBD of MMP-2. 
In order to achieve this aim, this protein was first expressed, purified, and its affinity for type 
II gelatin quantified. The following aim was to further characterise its interaction, as well as 
that of its individual modules, with type II gelatin by Nuclear Magnetic Resonance (NMR), in 
order to identify the most potent module for binding to this substrate. Next, chimeric 
proteins made of 3 identical modules were generated and a mutant protein with increased 
affinity for type II gelatin was obtained. The coating of MSCs with this protein was then 
tested, optimised and validated, before testing the ability of coated MSCs to bind to type II 
gelatin in vitro. 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Equipment 
Polymerase Chain Reactions (PCR) were performed using the Mastercycler from Eppendorf.  
E.coli cells were grown in shaking incubators from New Brunswick Scientific. Optical Density 
(OD) measurements were performed using either a WPA Biowave instrument or the UV-Vis 
spectrometer CARY 300-BIO (Varian). Centrifugation steps were carried out using either the 
benchtop centrifuge Minispin (Eppendorf), the Beckman Coulter Allegra X-30R centrifuge or 
the Sorvall centrifuge from Thermo Scientific.  
Proteins were purified using either the AKTA purifier or AKTA start systems from GE 
Healthcare. 
Protein samples were denatured using a heat block CH-100 from BioSan. Sodium Dodecyl 
Sulphate-PolyAcrylamide Gel Electrophoresis (SDS PAGE) gels were ran using the Power Pac 
300 from Biorad and scanned using the Image Scanner III from GE Healthcare. 
Plates prepared for the binding assay were dried using a UNITEMP incubator. Absorbance 
signals for the assay were read using the Multiskan Ascent plate reader from Labsystems. 
The pH of all buffers was measured using the JENWAY 3505 pH meter. 
All cell culture was performed in class II laminar flow hoods (NUAIRE) and incubated in 
humidified incubators (NUAIRE) at 37°C and 5 % carbon dioxide. 
2.1.2. DNA sequences  
The following DNA sequences were ordered from Invitrogen. They contain no start and 
stop codons as both of them were provided by the vectors used for expression. 
55 
 
Module 1 (Residues 223 - 282): 
gtgaaatatggtaatgccgatggcgaatattgcaaatttccgtttctgtttaacggcaaagagtataatagctgtaccgataccggt
cgtagtgatggttttctgtggtgtagcaccacctataactttgagaaagatggcaaatatggcttttgtccgcatgaagcactgttta
ccatg 
 
Module 2 (Residues 278 – 336): 
gcactgtttaccatgggtggtaatgcggaaggtcagccgtgtaaatttccttttcgctttcagggcaccagctatgatagttgtacca
ccgaaggtcgtaccgatggttatcgttggtgcggtacaaccgaagattatgatcgtgacaaaaaatacggtttctgtccggaaacc
gca 
 
Module 3 (Residues 337– 394): 
atgagcaccgttggtggtaatagtgaaggtgcaccgtgtgtttttccgtttacctttctgggtaacaaatatgaaagctgtaccagtg
caggtcgttcagatggtaaaatgtggtgcgcaaccaccgcaaattatgatgatgatcgtaaatggggtttttgcccagatcagggt 
 
CBD (Residues 222 – 396): 
Cgtgtgaaatatggtaatgccgatggcgaatattgcaaatttccgtttctgtttaacggcaaagagtataatagctgtaccgatacc
ggtcgtagtgatggttttctgtggtgtagcaccacctataactttgagaaagatggcaaatatggcttttgtccgcatgaagcactgt
ttaccatgggtggtaatgcggaaggtcagccgtgtaaatttccttttcgctttcagggcaccagctatgatagttgtaccaccgaag
gtcgtaccgatggttatcgttggtgcggtacaaccgaagattatgatcgtgacaaaaaatacggtttctgtccggaaaccgcaatg
agcaccgttggtggtaatagtgaaggtgcaccgtgtgtttttccgtttacctttctgggtaacaaatatgaaagctgtaccagtgcag
gtcgttcagatggtaaaatgtggtgcgcaaccaccgcaaattatgatgatgatcgtaaatggggtttttgcccagatcagggttata
gc 
 
111: 
gaaggtcaggttgttcgtgtgaaatatggtaatgcagatggcgagtattgcaaatttccgtttctgtttaacggcaaagagtataat
agctgtaccgataccggtcgtagtgatggttttctgtggtgtagcaccacctataactttgagaaagatggcaaatatggcttttgtc
cgcatgaagcactgtttgtgatgtatggcaatgccgatggtgaatactgtaaattcccatttctgttcaatggtaaagaatacaactc
atgcaccgatacaggccgttcagatggctttcgttggtgttcaaccacctacaatttcgaaaaagacggtaagtatggtttctgtccg
gaaaccgcagtgcgcgttaaatatggcaacgcggacggggaatattgtaagtttccgttcttattcaacgggaaagaatataaca
gttgcacagacaccggtcgctcagatggttttttatggtgctcaacaacgtataacttcgaaaaggatgggaagtacggattttgtc
cggatcagggttatagcctg 
 
222: 
Gaaggtcaggttgtgtttaccatgtatggtaatgccgaaggtcagccgtgtaaatttccgtttcgttttcagggcaccagctatgata
gttgtaccaccgaaggtcgtaccgatggttatcgttggtgtggtacgaccgaagattatgatcgtgataaaaagtatggcttttgtcc
gcatgaagccctgtttacaatgggtggcaatgcagagggccagccttgcaaattcccttttcgcttccagggtacatcttatgattca
tgcacaacggaaggtcgcacagatggctaccgctggtgcggcaccacagaggattatgaccgcgacaaaaaatacggtttttgtc
cggaaaccgcactgttcaccatgggtggtaatgcggaaggacaaccatgcaagtttccattccgctttcagggaacctcatatgat
agctgcacaacagagggacgtacggatggatacagatggtgcggtacaaccgaggactacgatagagataagaaatatggtttc
tgtcccgatcagggttatagcctg 
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333: 
Gaaggtcaggttgttagcaccgtttatggtaatagcgaaggtgcaccgtgtgtttttccgtttacctttctgggtaacaaatatgaaa
gctgtaccagcgcaggtcgtagtgatggttttctgtggtgtgcaaccaccgcaaattatgatgatgatcgtaaatggggtttttgtcc
gcatgaagcactgtttaccatgggtggcaattctgaaggtgccccttgcgtgtttccttttacatttttaggcaacaagtacgaaagc
tgcacctcagccggtcgttcagatggtaaacgttggtgcgccaccacagccaactatgatgacgacagaaaatggggcttctgtcc
tgaaaccgcaatgagcaccgttggtggcaacagtgaaggcgctccatgcgttttcccgttcacattcctgggcaataaatacgaat
catgtacctctgcaggtcgctctgatggcaaaatgtggtgcgcgacaacggccaattacgacgatgaccgcaagtggggcttttgc
ccagatcagggttatagcctg 
 
2.1.3. Protein sequences 
The DNA sequences presented in section 2.1.2 encoded for the following protein 
sequences 
CBD: R V K Y G N A D G E Y C K F P F L F N G K E Y N S C T D T G R S D G F L W C S T T Y N F E K 
D G K Y G F C P H E A L F T M G G N A E G Q P C K F P F R F Q G T S Y D S C T T E G R T D G Y R 
W C G T T E D Y D R D K K Y G F C P E T A M S T V G G N S E G A P C V F P F T F L G N K Y E S C 
T S A G R S D G K M W C A T T A N Y D D D R K W G F C P D Q G Y S 
Module 1: VKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTM 
Module 2: ALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETA 
Module 3:MSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQG 
 
Trimodular proteins containing repeats of identical modules were then designed with the 
aim of maintaining the overall structure observed in the CBD. In the sequences below, 
residues in blue are those conserved from the original CBD in order to maintain 
intramolecular interactions, residues in black are linkers and residues in red are from each 
module. 
111: E G Q V V R V K Y G N A D G E Y C K F P F L F N G K E Y N S C T D T G R S D G F L W C S T 
T Y N F E K D G K Y G F C P H E A L F V M Y G N A D G E Y C K F P F L F N G K E Y N S C T D T G 
R S D G F R W C S T T Y N F E K D G K Y G F C P E T A V R V K Y G N A D G E Y C K F P F L F N G 
K E Y N S C T D T G R S D G F L W C S T T Y N F E K D G K Y G F C P D Q G Y S L 
222: E G Q V V F T M Y G N A E G Q P C K F P F R F Q G T S Y D S C T T E G R T D G Y R W C G T 
T E D Y D R D K K Y G F C P H E A L F T M G G N A E G Q P C K F P F R F Q G T S Y D S C T T E G 
R T D G Y R W C G T T E D Y D R D K K Y G F C P E T A L F T M G G N A E G Q P C K F P F R F Q 
G T S Y D S C T T E G R T D G Y R W C G T T E D Y D R D K K Y G F C P D Q G Y S L 
333: E G Q V V S T V Y G N S E G A P C V F P F T F L G N K Y E S C T S A G R S D G F L W C A T T 
A N Y D D D R K W G F C P H E A L F T M G G N S E G A P C V F P F T F L G N K Y E S C T S A G R 
S D G K R W C A T T A N Y D D D R K W G F C P E T A M S T V G G N S E G A P C V F P F T F L G 
N K Y E S C T S A G R S D G K M W C A T T A N Y D D D R K W G F C P D Q G Y S L 
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2.2. Methods 
 
2.2.1. Cloning 
The InFusion (Clontech) cloning technology is a ligase independent cloning method which 
enables an insert to be inserted into a linearized vector if each share 15-nucleotide-long 
complementary sequences at both extremities (Figure 2-1).  
 
 
 
 
 
 
 
 
This was the cloning method chosen for all constructs and it was used according to the 
manufacturer’s recommendations. The vectors used were all from the pOPIN suite 
developed by OPPF, Oxford. 
 
 
 
 
 
Figure 2-1: Principle of the InFusion cloning. The Infusion cloning is a ligase independent 
method that relies on the recombination between the insert and the linearised vector when 
both share 15-nucleotide-long complementary sequences at their extremities. Figure 
adapted from the Infusion manufacturer’s manual 
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2.2.1.1. Construct design 
 
The synthetic genes encoding for the above mentioned protein sequences were purchased 
from Invitrogen and codon-optimised for expression in E.coli. Primers were ordered from 
Sigma and were used to subclone the genes into either the pOPINM or pOPINS vectors 
(Figure 2-2), which were provided by OPPF, Oxford. The sequences of the primers can be 
found in Table 2-1. 
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Figure 2-2: Maps of the vectors pOPINS and pOPINM. Both vectors were obtained from OPPF, 
Oxford. The pOPINM vector carries a hexahistidine tag followed by the Maltose Binding 
Protein (His6-MBP tag) and the cleavage site of the 3C protease. The pOPINS carries the 
SUMO tag downstream of the SUMO protease cleavage site. The gene encoding for the 
protein was cloned downstream of each of these tags, as indicated in this Figure for the CBD 
gene. 
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Table 2-1: Sequences of the primers used for cloning. The sequences in red are vector specific 
and were used as instructed on the OPPF website. Sequences in black are insert-specific. 
Protein Vector Forward (5’ to 3’) Reverse (5’ to 3’) 
CBD 
pOPINM 
AAGTTCTGTTTCAGGGCCCGCGTGTGAAATATGGTAATGC
CGAT ATGGTCTAGAAAGCTTTAGCTATAACCCTGATCTG
GGCA 
pOPINS 
GCGAACAGATCGGTGGTCGTGTGAAATATGGTAATGCCGA
T 
Module 1 pOPINS GCGAACAGATCGGTGGTGTGAAATATGGTAATGCC 
ATGGTCTAGAAAGCTTTACATGGTAAACAGTGCTT
C 
Module 2 pOPINS GCGAACAGATCGGTGGTGCACTGTTTACCATG 
ATGGTCTAGAAAGCTTTATGCGGTTTCCGGACAGA
A 
Module 3 pOPINS GCGAACAGATCGGTGGTATGAGCACCGTTGGT 
ATGGTCTAGAAAGCTTTAACCCTGATCTGGGCAAA
A 
111 pOPINS GCGAACAGATCGGTGGTGAAGGTCAGGTTGTTCGTGTG 
ATGGTCTAGAAAGCTTTACAGGCTATAACCCTGAT
CCGG 
222 pOPINS GCGAACAGATCGGTGGTGAAGGTCAGGTTGTGTTTACC 
333 pOPINS GCGAACAGATCGGTGGTGAAGGTCAGGTTGTTAGCACC 
 
The amplification of the synthetic gene with the correct extremities for cloning into each 
vector was performed with the PCR program described in Table 2-2. 
Table 2-2: PCR program used for amplification of the gene of interest with the correct 
extremities. The annealing temperature was adjusted for each PCR reaction, and set 5 
degrees below the lowest melting temperature of both primers.  
Step Temperature (oC) Time 
(min) 
Initial 
denaturation 
98  2 
Denaturation 95  0.5 
Annealing N/A 0.5 
Amplification 72  1.5 
Final 
amplification 
and clearance 
72  7 
 
The amplified products were then ran on an agarose gel electrophoresis (see section 2.2.1.3). 
 
29 cycles 
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2.2.1.2. Vector linearisation 
 
5 µg of the pOPINS vector were digested with the enzymes HindIII HF and KpnI HF (NEB) for 
6 hours at 37oC in the provided CutSmart buffer (NEB). The reaction was terminated by the 
addition of 0.5M Ethylenediaminetetraacetic acid (EDTA), pH 8.0. The success of the 
linearisation was confirmed with an agarose gel electrophoresis (see section 2.2.1.3). The 
pOPINM vector had already been linearised before. 
2.2.1.3. Agarose gel electrophoresis 
 
A 1 % agarose gel was run to confirm either the successful amplification of the construct or 
the linearisation of the plasmid. Briefly, 1 g of agarose (Bioline) was dissolved into 100 mL of 
TAE buffer (2M Tris, 0.1M EDTA, 1M acetic acid) and heated. Once cooled down, the solution 
was used to cast a gel and either 10 µL of 0.5 µg/ml ethidium bromide or 5 µL of Mildori 
Green (NIPPON genetics) was added and mixed. Once set, 5 µL of each sample, previously 
mixed with the same amount of loading buffer (NEB), was loaded and the gel was run at     
120 V for 30 minutes. The visualisation was performed under UV light. 
2.2.1.4. In Fusion cloning (Clontech) 
 
Briefly, 5 µL of the PCR product (amplified synthetic gene) was purified by adding 2 µL of 
Cloning Enhancer and incubating for 15 minutes at 37oC and for a further 15 minutes at 80oC.  
The In Fusion reaction was then prepared with the corresponding 50-100 ng of linearised 
pOPIN vector, 1 µL of cleaned PCR product, 1 µL of In Fusion enzyme, in a final volume of       
5 µL. 
The mixture was incubated for 15 minutes at 50oC before proceeding to bacteria 
transformation. 
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2.2.1.5. Bacteria transformation 
 
Briefly, 50 µL aliquots of competent cells were thawed on ice before adding 1.5 µL of DNA to 
the cells. After incubating for 30 minutes on ice, bacteria were heat-shocked for 30 seconds 
at 42oC. Cells were put back on ice for 3 minutes before adding 450 µL of either S.O.C or 
Lysogeny broth (LB, Melford) medium and incubating for 1 hour at 37oC with shaking. 
The samples were then spun at 4 000 g for 30 seconds and resuspended in 50 µL before being 
spread onto LB agar plates containing the appropriate antibiotic for selection (Kanamycin: 
Gibco; Ampicillin: Melford). The plates were incubated at 37oC overnight and then kept at 
4oC for a maximum of one week. 
Either Stellar (Clontech) or XL1 blue (Agilent) E.coli competent cells were submitted to this 
process for plasmid amplification. DNA was extracted using the miniprep kit from Qiagen. All 
constructs were confirmed by sequencing. 
The same protocol was followed with various expression strains for protein expression.  
 
 
 
 
63 
 
2.2.2. Protein expression in E.coli 
2.2.2.1. pET expression system 
 
One of the most commonly used vector systems is the pET expression system, which places 
the gene of interest under the control of a T7 promoter, which is itself recognised by the 
phage T7 RNA polymerase (Figure 2-3). The gene encoding for the polymerase is usually 
inserted in the bacterial genome through a prophage named lambda DE3, and is placed 
under the control of a lac UV5 promoter, which is inducible with lactose or Isopropyl-ß-D-
thiogalactopyranoside (IPTG). Addition of IPTG to the culture will enable expression of the 
T7 RNA polymerase, which will then be able to start the transcription of the gene of interest. 
In order to avoid basal leaky expression of the T7 RNA polymerase, a T7 lysozyme can be 
Figure 2-3: Principle of the pET expression system. The gene of interest (target gene) is 
placed under a T7 promoter. The gene encoding for the T7 Ribonucleic Acid (RNA) 
polymerase is itself under the control of a lac promoter, which is inducible with Isopropyl-
ß-D-thiogalactopyranoside (IPTG). Addition of IPTG will lead to the transcription of the gene 
encoding for the polymerase, and the subsequent transcription of the gene of interest. 
Figure from Novagen user’s manual. 
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provided by an additional plasmid (either pLys S or pLys E), which will limit the transcription 
by the T7 RNA polymerase without inducer 150. 
2.2.2.2.  Protein expression trials – Small scale 
 
Either BL21 (DE3) (Novagen) (for expression with the pOPINB and pOPINS vectors), Rosetta-
pLysS (DE3) (Novagen) (for expression with the pOPINM vector) or Shuffle T7 express (NEB) 
were transformed on selective LB agar plates. 
When required, minimal media was prepared by adding a filter-sterilised solution B (0.1 M 
MgSO4, 7.5 mM CaCl2, 0.75 mM MnCl2, 0.25 mM FeSO4 supplemented with Glucose (20% 
w/v)) to an autoclaved solution A (100 mM Na2HPO4, 40 mM KH2PO4, 18.3 mM 15N NH₄Cl). 
1 colony from the transformation plate was then picked and inoculated into 10 mL of either 
LB or minimal media containing the appropriate antibiotics and the culture was left to grow 
overnight at 37oC. 10 µL of the overnight culture was then inoculated into 10 mL fresh media 
and grown at 37oC before inducing with various concentration of IPTG (Apollo Scientific) 
when the optical density at 600 nm (OD600) reached 0.6. Cultures were then maintained at 
18oC overnight or at 37oC for 5 hours before being harvested by spinning at 5000 rpm for 5 
minutes. The cells were then subjected to one cycle of freeze-thaw before being lysed in 1 
mL of lysis buffer (20 mM Na2HPO4, 500 mM NaCl, 20 mM Imidazole, 1mg/mL lysozyme 
(Sigma), 1 % Tween 20 (v/v) (Sigma), DNAse I (Roche) and protease inhibitors (Roche), pH 
7.4) for 1 hour. The lysate was then cleared by spinning at 13 300 rpm for 10 minutes. The 
insoluble pellet was resuspended in 1 mL lysis buffer containing 8 M urea and spun at 13 300 
rpm for 10 minutes. The supernatant was kept and both the soluble and insoluble fractions 
were purified using the Ni-Nta agarose resin (see section 2.2.4.1). 
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2.2.2.3. Protein expression– Large scale 
 
E.coli expression strains were transformed as described above with the appropriate 
expression vector and selected on agar plates containing the corresponding antibiotics. One 
colony was inoculated in 10 mL of LB containing antibiotics overnight. 5 mL of the overnight 
culture was used to inoculate 500 mL of media containing appropriate antibiotics into a 2L 
flask. Growth was carried out at 37oC, 180 rpm, until reaching an OD at 600 nm of 0.7-0.9. 
Cells were induced with the following concentrations of IPTG: 
 CBD: 600 μM 
 222: 1000 μM  
 333: 800 μM,  
 Module 1: 400 μM 
 Module 2: 20 μM 
 Module 3: 20 μM 
and the production performed overnight at 18oC, except for 333, which was left for 5 hours 
at 25oC following induction. Cells were harvested at 8 000 g for 15 minutes and lysed by 
sonication in 20 mL lysis buffer (20 mM Na2HPO4, 500 mM NaCl, 20 mM Imidazole, 1mg/mL 
lysozyme (Sigma), 1% Tween 20 (v/v), DNAse I (Roche) and protease inhibitors (Roche), pH 
7.4). The lysate was cleared by spinning at 18 000 g for 40 minutes before being filtered and 
purified on a His Trap Fast Flow 5 mL column (HiFIIQ NiNTA) using an AKTA system (GE 
healthcare) (see section 2.2.5.1). 
2.2.2.4. Protein refolding 
 
As 111 was shown to be highly insoluble, the refolding protocol described by Steffensen et 
al. 141 was tested. Briefly, the insoluble pellet was sonicated before being washed in 100 mM 
Tris·HCl, pH 7.0, 5 mM EDTA, 2 M Urea, 2 % (v/v) Triton X-100 and spun for 30 min at 22 000 
g, 4oC. This washing step was repeated 4 times. The pellet was then resuspended in 100 mM 
Tris·HCl, pH 7.0, 5 mM EDTA, sonicated and spun at 22 000 g, 4oC for 30 min. The washed 
pellets were then stored at -80oC until use. 
66 
 
Once thawed, the pellets were then resuspended in 6M GdnHCl, 0.1M sodium phosphate, 
10 mM Tris, pH 8.0, sonicated and incubated for 1 hour at room temperature rotating. The 
non-dissolved aggregates were removed by centrifugation at 12 000 g for 15 min at 4oC. The 
supernatant was then dialysed from 2 hours to overnight against aerated 0.1 M sodium 
borate buffer, pH 10.0. The sample was then diluted and dialysed against 4L of 100 mM NaP, 
0.5 M NaCl, pH 8.0 at 4oC. The sample was then spun at 12 000 g for 15 min at 4oC, dialysed 
against His Trap A buffer (20 mM Na2HPO4, 20 mM Imidazole, 500 mM NaCl, pH 7.4) and 
subjected to the same purification protocol as the other constructs (see section 2.2.5). 
2.2.3. Protein expression in HEK cells 
One of the main cell lines used for protein expression is the Human Embryonic Kidney (HEK) 
293. It was established by the transformation of human embryonic kidney cells with sheared 
human adenovirus DNA. The HEK 293T cell line was derived from the original HEK 293 one 
by integrating genes encoding the Simian Virus 40 (SV40) Large antigen T (LT). This genetic 
modification has enabled transient gene expression methods to be developed. The SV40 LT 
is indeed able to bind to expression vectors containing the SV40 origin of replication, 
enabling activation of the DNA replication machinery and episomal replication of the 
recombinant plasmid, leading to high copy numbers of recombinant DNA and, subsequently, 
higher protein yields 151,152. These elements are also thought to favour nuclear import of the 
expression plasmid, making more of it available for transcription 152. 
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2.2.3.1. Cell transfection with Lipofectamine 
 
HEK 293T cells were seeded in 10-cm dishes at 3.5 x 106 cells. 48 hours later, they were 
transfected with Lipofectamine 2000 (ThermoFisher Scientific), according to the 
manufacturer’s instructions. Cells were harvested 24 hours after transfection. 
Considering the cost of Lipofectamine 2000, more transfection trials were carried out using 
either Calcium Chloride or Polyethylenimine (PEI) as the transfection reagents, which are 
cheaper, in preparation of large scale experiments. 
2.2.3.2. Cell transfection with Polyethylenimine 
 
HEK 293T cells were seeded at 600 000 cells/well in 6-well plates 24 hours before being 
transfected.  The PEI solution (25kDa, linear, Polysciences Inc.) was prepared by dissolving 
100 mg in 70 mL of milliQ water, heating to 80 oC and allowing to cool down at Room 
Temperature (RT). The pH was adjusted to 7.0, the volume brought up to 100 mL and the 
mixture filter sterilized.  3.5 μg of DNA was mixed with OptiMEM while PEI was added to 
OptiMEM in a different tube. 3 ratios of DNA:PEI were tested. PEI was then added to the 
DNA, the solution mixed and incubated for 10 minutes at RT before adding the mixture to 
the cells (300 μL/well). 
Cells were harvested either 24, 48 or 72 hours after transfection. 
2.2.3.3. Cell transfection with Calcium Chloride  
 
HEK 293T cells were seeded at 600 000 cells/well in 6-well plates 24 hours before being 
transfected. The media was also changed 3 hours before transfection. 
Either 1, 3 or 5 μg of DNA/well was used and mixed with a 2M CaCl2 solution. The mixture 
was added dropwise to 420 μL of 2X HBS solution (50mM HEPES, 280 mM NaCl, 1.5 mM 
Na2HPO4) and gently tapped before adding the mixture directly to the cells (210 μl/well). The 
plate was tilted back and forth and cells were put back into the incubator. The media was 
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changed either 2, 6 or 16 hours post transfection and cells were harvested 48 hours after 
transfection. 
Protein expression was scaled up accordingly using the Calcium Chloride transfection 
method and 20 hours incubation before changing the media. The purification was carried 
out as outlined below. 
2.2.4. Protein purification: Small scale 
The first stages of purification exploit the affinity of the histidine tag for nickel. The mode of 
binding of nickel to histidine is shown in the figure below (Figure 2-4, (1)) and the elution 
with imidazole is also displayed (Figure 2-4, (2)) 
Figure 2-4: Mode of binding of histidine to nickel (1) and its elution with imidazole (2). Figure 
from 153. 
 
2.2.4.1. Small scale purification from E.coli cells 
 
All spinning steps were performed at 3000 rpm for 30 seconds. 
60 μL of Ni-Nta agarose resin (Qiagen) was spun and the ethanol removed. 60 μL of milliQ 
water was then added before spinning the resin again and discarding the water. Finally,         
60 μL of binding buffer (20 mM Na2HPO4, 500 mM NaCl, 20 mM Imidazole, pH 7.4) was added 
before applying the sample. The flowthrough was recovered by centrifugation, before 
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washing the column twice with 60 μL of the binding buffer. The bound fraction was recovered 
from the washed resin by adding 30 μL of  2X SDS loading buffer (0.05 M Tris HCl pH 6.8, 2 % 
Sodium Dodecyl Sulfate (SDS) (w/v), 10% glycerol (v/v), 0.1 % bromophenol blue (w/v),         
1.4 M Beta-Mercaptoethanol (BME)) and was loaded on a SDS PAGE gel (see section 2.2.9.1). 
2.2.4.2. Small scale purification from HEK 293T cells   
 
Cells pellets were kept at -20 oC. When thawed, they were washed 2 times with PBS (Sigma) 
and collected by spinning at 1000 g for 5 minutes. Cells were then lysed with either 900 μL 
(10-cm dish) or 175 μL (6-well plate) of NPI-10-TIg buffer (50 mM NaH2PO4, 300 mM NaCl, 10 
mM Imidazole, 0.05 % Tween 20 (v/v), 1 % Igepal (v/v), pH 8.0) containing DNAse I and 
protease inhibitors (Roche). Cells were incubated on ice for 15 minutes and on a roller shaker 
at 4oC for a further 15 minutes. The lysate was then cleared by spinning at 10 000 g for 10 
minutes at RT. The supernatant was saved while the insoluble fraction was solubilized with 
the lysis buffer supplemented with 8M urea. The sample was cleared as previously described. 
Both fractions were then subjected to purification with Ni-Nta agarose, as described for the 
bacterial expression (section 2.2.4.1), with the following changes: the sample was allowed to 
bind to the resin overnight at 4oC on a roller shaker; the washes were performed with NPI-
20T Buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole, 0.05 % Tween 20 (v/v),              
pH 8.0) ; the bound fraction was eluted with NPI-500-T elution buffer (50 mM NaH2PO4, 300 
mM NaCl, 500 mM Imidazole, 0.05 % Tween 20 (v/v), pH 8.0) and the resin was also 
solubilized in 2X SDS loading buffer. 
 
 
 
 
 
70 
 
2.2.5. Protein purification: large scale 
All buffers were prepared fresh, filtered through 0.22 μm filters (Millipore) and degassed 
prior to being used on the AKTA systems. 
2.2.5.1. His Trap and Reverse His Trap 
 
The strategy of purification is outlined in Figure 2-5. 
Briefly, either a His Trap Fast Flow (FF) 5mL column (for purification from expression in E.coli) 
or His Trap FF 1mL column (for purification from expression in HEK 293T cells) (Generon) was 
washed with milliQ water before being equilibrated with 5 Column Volumes (CV) of His Trap 
buffer B (20 mM Na2HPO4, 500 mM NaCl, 500 mM Imidazole, pH 7.4) followed by 5 CV of His 
Trap buffer A (20 mM Na2HPO4, 500 mM NaCl, 20 mM Imidazole, pH 7.4). The filtered 
clarified supernatant was then loaded at 2.0 mL/min and eluted with a linear gradient of 
100 % His Trap buffer B applied on 10 CV. Fractions of 2 mL were collected and those 
containing the target protein pooled and dialyzed overnight (Medicell dialysis membrane, 
3500 Da molecular weight cut-off) at 4°C in 20 mM Na2HPO4, 500 mM NaCl, pH 7.4 in the 
presence of either a histidine-tagged SUMO protease (to remove the SUMO-histidine tag) or 
a histidine-tagged 3C protease (to remove the 3C-MBP-histidine tag). Both proteases were 
produced in-house.  
The following day, samples were spun at 6000 rpm for 30 minutes at 4°C to remove any 
precipitate prior to the reverse purification. The sample was then passed back down the 
equilibrated His Trap column at 2.0 mL/min, and the flowthrough containing the native 
protein was collected. This step was repeated a second time to ensure efficient removal of 
contaminants. 
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2.2.5.2. Gel Filtration 
 
Either a HiLoad 16/60 s75 (GE Healthcare) or a Superdex 75 10/300 column (GE Healthcare) 
were used. For both of them, the column was equilibrated with milliQ water for 0.75 CV and 
with buffer (either 150 mM NaCl, 50 mM Tris, pH 7.4 or 300 mM NaCl, 50 mM Tris, pH 7.4) 
for 1 CV. The sample, concentrated in less than 2 mL, was then loaded, and the isocratic 
elution allowed to take place. 2.5 mL fractions were collected and those containing the 
protein pooled. 
 
 
 
 
A 
B 
Figure 2-5: Strategy of purification of both MBP and SUMO CBD constructs. (A) The 
construct are designed so that the CBD sequence is preceded by the hexahistidine and 
either the MBP or SUMO tag. The cleavage site of either of the SUMO or 3C protease is 
inserted between the tag and the CBD. (B) The protein carrying the hexahistidine tag is 
captured on a nickel column (His Trap) and eluted with a gradient of imidazole. The cleavage 
of the tag is mediated by histidine tagged 3C and SUMO proteases (red and green arrows, 
respectively) while the concentration of imidazole is lowered down by dialysis. The mixture 
is then passed back through the nickel column, which retains the tags and the proteases, 
while the CBD is collected in the flowthrough. 
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2.2.5.3. Ion Exchange Chromatography  
 
A Q FF 5 mL column (GE Healthcare) was equilibrated with 5 CV of Ion Exchange 
Chromatography (IEC) A buffer (20 mM Tris, 10 mM NaCl, pH 8.0 ), 5 CV of IEC B buffer (20 
mM Tris, 1 M NaCl, pH 8.0) and a final 5 CV of IEC A buffer. The sample, which had been 
previously desalted on a HiPrep 26/10 column (GE Healthcare), was loaded at 2.0 mL/min. 
A step gradient was applied, using 24 % of IEC B buffer on 5 CV to specifically elute the CBD, 
before applying a gradient to 100 % of IEC B buffer on 10 CV. A 12% gradient of IEC B buffer 
was used for module 1 while modules 2 and 3, as well as 111, 222 and 333 were eluted with 
linear gradients. 2 mL fractions were collected for all proteins, and pooled after running a 
SDS PAGE gel (see section 2.2.9.1).  
2.2.6. Protein concentration  
Once the correct fractions were pooled, the protein concentration was measured with a 
Nanodrop by reading the absorbance at 280 nm, using the Beer-Lambert formula: 
𝐴 = 𝐶 ∗  𝜀 ∗  𝑙 
Where A is the absorbance, C the concentration (mol/L), ε the molar absorption coefficient 
(L.mol-1cm-1) and l the path length (cm). When needed, the molar concentration was 
converted into a concentration in mg/mL using the molecular weight. 
The values for the molar absorption coefficient and the molecular weight were obtained for 
each protein using the prot param online tool from Expasy. These values are reported in 
Table 2-3 below. 
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Table 2-3: Absorption extinction coefficient and molecular weight of the expressed proteins 
 ε (L.mol-1cm-1) Molecular weight (Da) 
CBD 40 630 19 640 
Module 1 13 200 6 902 
Module 2 11 710 6 665 
Module 3 14 230 6 265 
111 41 090 20 714 
222 38 110 20 650 
333 45 670 19 750 
 
If needed, the protein concentration was increased by centrifugation using centricons 
(Millipore, molecular weight cut off of 3500 Daltons). Briefly, the centricons were 
equilibrated in the corresponding buffer, spun for 10 min at 4500 g, before discarding the 
buffer. A maximum volume of 15 mL of protein sample was then added and spun for 20 min 
at 4500g, 4°C. The process was repeated until reaching the desired concentration. The 
protein sample was pipetted up and down between each spin to prevent protein 
aggregation. 
2.2.7. Protein storage 
Protein samples were stored in aliquots in the IEC buffer, snap frozen in liquid nitrogen and 
stored at -80°C until use. 
2.2.8. Buffer exchange with PD10 
A PD 10 Sephadex G-25 M column (GE Healthcare) column was used for buffer exchange 
procedures. The column was first rinsed with 30 mL of milliQ water before being equilibrated 
with 25 mL of final buffer. 
2.5 mL of protein in the initial buffer were applied to the column and allowed to run through. 
3.5 mL of final buffer were added to elute the bound protein in the final desired buffer. 
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2.2.9. Protein Characterisation 
2.2.9.1. Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis 
 
The levels of expression and purity of the expressed protein were analysed by Sodium 
Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) using 15 % polyacrylamide 
gels in a Bio-Rad gel electrophoresis system. A volume of 5 µl of protein samples were added 
to 5 µl of 2X SDS loading buffer (0.05 M Tris HCl pH 6.8, 2 % SDS (w/v), 10 % glycerol (v/v), 
0.1 % bromophenol blue (w/v), 1.4 M BME), boiled at 100°C for 5 minutes and loaded onto 
the gel. All gels were run at 180 V for 60 minutes, stained with Magic Stain (60 mg Coomassie 
G-250, 3.4 mL HCL concentrated, 1L solution) and de-stained with milliQ water. 
 
2.2.9.2. 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) assay 
 
 
 
 
 
 
 
 
The principle of the assay is outlined in Figure 2-6. 
Briefly, 4 mg of Ellman’s reagent (Thermo Scientific) were dissolved in 1 mL Reaction Buffer 
(0.1 M sodium phosphate, pH 8.0). A set of standard concentrations was prepared using 
Dithiothreitol (DTT), ranging from 0.001 to 0.1 mM. Each standard or sample reactions were 
mixed as follows: 250 µL sample, 2.5 mL reaction Buffer, 50 µL Ellman’s reagent. The reaction 
Figure 2-6: Principle of the DTNB assay. The DTNB reagent reacts with molecules containing 
sulfhydryl to produce TNB2-, a coloured product, whose absorbance is measured at 412 nm. 
Figure from the manufacturer’s instructions manual (Thermo Scientific). 
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was allowed to develop for 15 minutes at Room Temperature (RT) before reading the 
absorbance at 412 nm. The number of free cysteines in the sample was determined using 
the standard curve obtained from the DTT standards. 
2.2.9.3. Western Blot 
 
15 % SDS-PAGE gels were run as described previously before transferring onto a 
nitrocellulose membrane in transfer buffer (25 mM Tris, 190 mM Glycine, 20 % methanol, 
pH 8.3) at 100 V for 1 hour. The membrane was washed with PBS (Sigma), blocked for 40 
minutes to 1 hour in 5 % milk (Marvel)/PBS-T (8 mM Na2HPO4, 150 mM NaCl, 2 mM KH2PO4, 
3 mM KCl, 0.05 % Tween (v/v), pH 7.4). The primary mouse anti-histidine antibody was used 
at a 1:1000 dilution in 5 % milk/PBS-T and incubated for either 1 hour at RT or overnight at 
4°C. The membrane was then washed 3*10 minutes with PBS-T before adding the anti-
mouse secondary antibody, diluted 1:1000 in 5 % milk/PBS-T. The membrane was washed 
again 3 times for 10 minutes with PBS-T and revealed with the Enhanced Chemiluminescence 
(ECL) substrate (Pierce). 
2.2.9.4. Mass Spectrometry analysis  
 
The two most common uses of Mass Spectrometry (MS) are the determination of the identity 
of a protein after its digestion, and that of its intact mass. Both rely on the ionization of either 
the protein or of the peptides obtained from its digestion. The mass to charge ratio of the 
sample is then measured. When digested, the sequence of the peptides can be determined, 
and matched to the protein sequence to confirm that the host has expressed the protein of 
interest. When using accurate instruments, the determination of the mass of the intact 
protein can not only confirm its identity, but also its post-translational modifications 154,155. 
A MALDI TOF (Matrix Assisted Laser Desorption Ionisation – Time Of Flight) instrument was 
used to confirm the identity of the digested protein, which was extracted from a SDS PAGE 
gel band.  
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The intact mass analyses were run on an Electrospray instrument. Samples were first reverse 
desalted using C4 trap prior to mass analysis. 1 to 3 pmol of proteins were applied to the 
column. 
Both MS analyses were carried out by internal collaborators (Centre for Proteome Research, 
University of Liverpool). 
2.2.9.5. Circular dichroism 
 
Another important aspect of protein characterization is to check for the correct protein 
structure. Circular Dichroism (CD) enables to check the secondary structure of proteins by 
relying on the differential absorption of right and left circularly polarised light by their 
chromophores. When the circular dichroism is measured against the wavelength of the light, 
a CD spectrum is obtained and can be matched to specific secondary structural elements of 
a protein, namely its alpha helix and beta sheet content 156,157. 
Protein solutions (0.1 to 0.15 mg/mL) in 2.5 mM to 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer, pH 6.5 were applied to a 0.5 cm path length cuvette. 
The signal was measured between 260 and 190 nm using a JASCO CD instrument. Ellipticity 
data were obtained in millidegrees and converted into molar ellipticity to correct for protein 
concentration, using the formula:  
θ = m ∗ M/(10 ∗ l ∗ C) 
Where θ: Molar Ellipticity (deg.cm2/dmol), m: ellipticity (degrees), M: average molecular 
weight (g/mol), l: path length (cm), C: concentration in protein in g/L. 
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2.2.10. Binding assays 
2.2.10.1. Gelatin sepharose binding assay 
 
The binding to gelatin was first qualitatively assessed using a gelatin sepharose 4B resin (GE 
Healthcare). All spinning steps were performed at 3000 rpm for 30 seconds.  
A volume of 100 µL of resin was spun down and the ethanol removed. 100 µL of milliQ water 
was then added before spinning the resin again and discarding the water. Finally, 100 µL of 
binding buffer was added before applying 50 µg of the protein sample. The flowthrough was 
recovered by centrifugation, before washing the column twice with 100 µL of the binding 
buffer. The bound fraction was recovered from the washed resin by adding 30 µL 2X SDS 
loading buffer and was loaded on a SDS PAGE gel. 
2.2.10.2. Plate binding assay 
 
2.2.10.2.1. Protein biotinylation 
 
Protein samples were dialysed overnight in 1L of 0.1M NaHCO3, pH 7.4, at 4°C with stirring. 
Biotin (EZ-Link™ Sulfo-NHS-LC-Biotin, Thermo Fisher) was then added with a 20-fold molar 
excess, according to the manufacturer’s instructions. The samples were incubated for 20 
minutes at 22°C and then for 2 hours at 4°C. Samples were then dialysed against 1L of PBS 
(145 mM NaCl, 11.3 mM Na2HPO4, 3.97 mM KH2PO4, 7.69 mM NaN3), pH 7.4 overnight at 
4 °C, with stirring. Both dialysis were performed with a cellulose membrane with a molecular 
weight cut-off of 3500 Daltons. 
The biotinylation efficiency was tested with a HABA/Avidin assay according to the 
manufacturer’s instructions (Pierce™ Biotin Quantitation Kit, ThermoFisher) and the number 
of biotin added per protein was quantified. 
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2.2.10.2.2. Plate preparation 
 
Either type I (Collagen Solutions) or type II collagen (Bioiberica) solution or skin gelatin 
(Sigma) was heat-denatured at 80°C for 20 minutes, vortexing every 5 minutes. The collagen 
was then diluted to 0.01 mg/mL in 0.1 M carbonate buffer, pH 9.2. 50 µL were added to each 
well of a 96 well plate (ThermoScientific, Immulon 2HB, high binding), except the outer ones, 
giving a coating at 0.5 µg/well. 
The plates were wrapped in cling film and left at 4°C for 3 days and then washed 3 times with 
PBS-Tween, blocked with 100 µL of PBS-2.5% BSA (Sigma) for 30 minutes at RT, washed one 
more time with PBS-Tween and dried in an oven at 50 °C for 15 minutes. Plates were kept at 
4°C and used within 4 weeks. 
2.2.10.2.3. Binding assay 
 
Biotinylated proteins were added over a concentration range on plates coated with 0.5 µg of 
gelatin/well and incubated for 1 hour at 22°C. Plates were washed 3 times with 200 µL PBS-
2.5% BSA before being blocked with BSA for 30 minutes at RT. Plates were washed again 3 
times with 200 µL PBS-2.5% BSA before alkaline phosphatase conjugated to streptavidin 
(diluted 1:10 000 in PBS, Pierce) was added for 30 minutes at 22°C. Plates were washed 3 
times with 200 µL PBS-2.5% BSA and 100 µL of P-Nitrophenyl Phosphate (PNPP) solution was 
added. It was incubated for 8 minutes at RT before reading the plate absorbance at 405 nm. 
 
The signal from the blank wells was removed from the sample wells and a binding curve was 
generated using a non-linear regression fit (four parameters) in GraphPad Prism. 
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2.2.11. Nuclear Magnetic Resonance experiments 
2.2.11.1. 1D Nuclear Magnetic Resonance 
 
Protein samples were concentrated to a maximum volume of 400 µL. D20 was added (10 % 
(v/v)) and 8 to 32 spectra were acquired on an 800 MHz Bruker, at 298 K. 
2.2.11.2. 2D Nuclear Magnetic Resonance 
 
Proteins were expressed in 15N ammonium chloride minimal media. They were expressed 
and purified as previously described (see sections 2.2.2.3 and 2.2.5). Proteins were then 
buffer exchanged in 25 mM sodium phosphate at pH 6.5 using a PD10. NMR data were 
acquired at 298K on an 800 MHz Bruker. The data were processed using TopSpin and CCPN. 
The CBD chemical shift assignments as well as those of the individual modules were 
identified using previously published results 140,158,159,160. 
2.2.12. Protein conjugation 
When appropriate, a Fluorescein-5-isothiocyanate (FITC) tag (Sigma) was added to the 222 
protein according to the manufacturer’s instructions, giving FITC-222. Protein samples were 
then buffer exchanged against either 20 mM HEPES, pH 6.5 or 20 mM sodium phosphate, pH 
6.5 using a PD 10 Sephadex G-25 M column (GE Healthcare). The protein was then 
concentrated up to 0.7 mg/mL before proceeding to the cationisation. 
2.2.12.1. Cationisation 
 
The ratio of (N,N`-dimethyl-1,3-propanediamine) (DMPA, Sigma) and N-(3-
Dimethylaminopropyl)-N`-ethylcarbodiimide hydrochloride (EDC, Sigma) to the native 
protein anionic residues were kept consistent at 150 and 34, respectively, to calculate the 
required amounts of reagents to add. 
Under a fume hood, the required amount of DMPA was added to either 20 mM HEPES buffer, 
pH 6.5 or 20 mM sodium phosphate, pH 6.5. The pH of the solution was adjusted to 6.5 
80 
 
before adding it to the protein sample. The required amount of EDC was then weighed and 
added. The sample was left at 4°C for 24 hours with stirring. 
The sample was then purified from the excess reagents using 50 mL concentrators - Amicon 
Ultra 15 - Regenerated cellulose 10 NMWL (Merck) with a 10 kDa molecular weight cut-off.  
The protein was spun five times for 15 minutes at 4 900 g. The volume of the protein sample 
was brought up to 20 mL by adding either 20 mM HEPES buffer, pH 6.5, or 20 mM sodium 
phosphate, pH 6.5 between each spin. 
2.2.12.2. Surfactant addition 
 
A ratio of 1.4 surfactant chains per cationic residue was kept constant. The amount of 
surfactant needed was calculated based on a cationisation efficiency of 100 % and added to 
the protein sample, which was left overnight at 4°C with stirring. The resulting protein will 
be referred to as Surfactant-222 or, when appropriate, Surfactant-FITC-222. 
2.2.12.3. Dynamic Light Scattering  
 
Particle size and zeta potential analyses were performed using a ZetaSizer Nano ZS (Malvern 
Instruments, UK) and ZetaSizer software (Malvern Instruments, UK). Samples were filtered 
through a 0.22 µm filter prior to the analysis. Zeta potential measurements were made after 
a 120 second equilibration with 10-100 runs per sample. Size measurements were made 
after a 120 second equilibration, with the backscatter measured at 173°. The values reported 
in this thesis correspond to the radius expressed in number of the total sample. Each zeta 
potential and particle size measurements were performed in triplicates.  
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2.2.13. Cell coating 
2.2.13.1. Cell culture and conditions 
 
All cells were cultured in monolayer using either T25, T75 or T175 flasks (Corning) and, 
respectively, 5, 15 or 20 mL of expansion medium (low glucose (1000 mg/L) Dulbecco's 
Modified Eagles Medium (DMEM) (Sigma) with 100 units/ml penicillin, 100 μg/mL 
streptomycin (Sigma) (later referred to as P/S), 2mM GlutaMAX supplement (Gibco), 10% 
(v/v) Foetal Bovine Serum (FBS, Gibco) and 5 ng/ml freshly supplemented basic human 
fibroblast growth factor (Peprotech). The media was replenished every 2 to 3 days. Cell 
confluence was monitored using bright field microscopy. 
2.2.13.2. Cell counting and viability 
 
Cells were harvested by aspiring the expansion medium, washing with PBS (Sigma) and 
adding a trypsin/EDTA solution (Sigma). Cells were incubated for 3-5 minutes at 37°C before 
the flask was tapped. Cell detachment was monitored under a bright field microscope. 
Expansion medium was added to stop the action of the trypsin, and cells were then spun for 
5 min at 1500 rpm. The supernatant was removed and cells were resuspended in a known 
volume of expansion medium. A 10 μL aliquot was taken and mixed in a 1:1 ratio with trypan 
blue (Sigma) before counting the cells with a haemocytometer.  
Both white and blue cells were counted and the viability was obtained as follows: 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤ℎ𝑖𝑡𝑒 𝑐𝑒𝑙𝑙𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
∗ 100 
2.2.13.3. Coating adherent MSCs with Surfactant-FITC-222 
 
The outline of the experiment is illustrated in Figure 2-7. 
50 000 cells were seeded onto 35-mm dishes (Corning) 4 hours prior to the coating. The 
expansion medium was aspirated before adding 0.5 mL of 18 μM of Surfactant-FITC-222 in 
20 mM HEPES, pH 6.5. Cells were incubated with the protein conjugate for 30 minutes in the 
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incubator. The protein solution was then removed and cells were washed with 0.5 mL of 0.04 
mg/mL heparin ammonium salt (Sigma), resuspended in PBS (Sigma).  
 
 
Figure 2-7:  Coating adherent MSCs. The media is removed before adding the Surfactant-
FITC-222 protein solution at 18 μM. Cells are incubated with the protein for 30 minutes at 
37°C before being washed with heparin salt. Figure from 153. 
 
Imaging medium (phenol-free, low glucose (1000 mg/L) DMEM (D5921) with 100 units/mL 
penicillin, 100 μg/mL streptomycin, 2 mM GlutaMAX supplement and 10 % (v/v) FBS, 
buffered with 20 mM HEPES (Sigma) was then added and cells were observed by confocal 
microscopy. 
2.2.13.4. Coating MSCs in suspension with Surfactant-FITC-222 
 
The outline of the experiment is illustrated in Figure 2-8. 
Cells cultivated in proliferation medium were trypsinised, counted, and resuspended at 1 
million cells/mL. The cells were then spun down for 5 min at 1500 rpm and resuspended in 
300 μL of 5 μM of either Surfactant-222 or Surfactant-FITC-222. The protein samples were 
either in 20 mM HEPES buffer, pH 6.5 or 20 mM sodium phosphate, pH 6.5. Control samples 
were also incubated with 300 μL of either 5 μM of native 222, or buffer. Cells were incubated 
for 30 minutes at 37°C with shaking and manually agitated every 10 minutes to prevent cell 
aggregation.            
  
Figure 2-8: Coating MSCs in suspension. Cells were trypsinised and counted. Each million of 
cells was incubated with 300 µL of protein for 30 min at 37°C. Cells were then spun down 
and washed with heparin salt before being spun down and plated. 
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Following the incubation, cells were spun down for 5 minutes at 1500 rpm and washed once                                                                                                                                                                                                                                                                                        
with 300 μL of 0.04 mg/mL heparin ammonium salt (Sigma), resuspended in PBS (Sigma), 
before being spun down again and resuspended in 1 mL of imaging medium. 250 μL were 
plated in glass-bottomed dishes and observed by confocal microscopy.  
2.2.13.5. Cell adhesion assay 
 
96-well Tissue culture plates (Costar) were coated with type II gelatin as described for the 
binding assay, under sterile conditions. Cells were coated in suspension with either 
Surfactant-FITC-222 or Surfactant-222 as described in the previous section. Coated cells were 
resuspended in low glucose (1000 mg/L) DMEM (Sigma) with 100 units/mL penicillin, 100 
μg/mL streptomycin (Sigma), 2mM GlutaMAX supplement (Gibco) at a density of 4 000 000 
cells/mL. 200 μL of this cell suspension were added in the first 2 wells of the 96-well plate, 
before performing 1:2 serial dilutions in the same medium. Dilutions were performed on 
alternating columns only. This process was repeated a second time on the empty columns, 
giving 4 replicates for each cell density (200 000, 100 000, 50 000 and 25 000 cells). Control 
cells were treated with native 222. Cells were also seeded on an untreated tissue culture 
plate for comparison purposes. The layout of the plate is outlined in Figure 2-9. 
 
 
 
 
 
 
 
 
Figure 2-9: Layout of the plate used for the cell adhesion assay. The numbers indicate cell 
densities. Cells were either uncoated (Wild Type (WT) MSCs, coated with Surfactant-222 
(222-MSCs) or with Surfactant-FITC-222 (FITC-222-MSCs) 
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Plates were incubated overnight in the incubator. The media was then removed, and each 
well was washed with 200 μL sterile PBS (Sigma). Imaging medium containing FM-4-64 
(InVitrogen) was then added to each well, and plates were imaged using an epifluorescent 
microscope. 
2.2.13.6. Microscopy 
 
All confocal and epifluorescence microscopy experiments were performed with internal 
collaborators (Centre for Cell Imaging, University of Liverpool). The LSM 710 microscope was 
used for confocal microscopy purposes. When required, cells were imaged without and with 
the membrane dye FM-4-64 (InVitrogen). 
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3. New expression system identified for the expression of a 
soluble, folded and functional Collagen Binding Domain of 
MMP-2 
 
3.1. Introduction: Characterisation of the interaction between the Collagen 
Binding Domain of Matrix Metalloprotease-2 and gelatin 
 
The type of interactions which mediate the binding of the CBD to gelatin was studied by 
Steffensen et al 141, who showed that dimethylsulfoxide (DMSO), but not sodium chloride, 
could displace either the bound CBD or the full length MMP-2 from gelatin sepharose. This 
suggests that hydrophobic interactions are prevalent in the binding of the protein to the 
substrate, an observation which was confirmed by others, on both MMP-2 137, MMP-9 161 
and Fibronectin 145. 
Another important feature of the binding of the CBD to gelatin is the structural integrity of 
the protein. This relies mostly on the presence of six disulfide bonds; each individual module 
contains 4 cysteines, and each one is involved in the formation of an intramodule disulfide 
bridge 141,149 . While preliminary data 141 suggested that the binding to gelatin was maintained 
after reduction of the disulfide bridges, others have shown the opposite 143. It is important 
to note that the study by Steffensen et al 141 has, however, shown that the reduction and 
carboxymethylation of the disulfide bridges abrogated the binding to gelatin. One of the 
main aims of the project was, therefore, to express a correctly folded and functional CBD in 
a suitable host for recombinant expression.  
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3.2. Recombinant protein expression: generalities 
 
Recombinant protein expression relies on using a genetically-modified, easy to grow host for 
the expression of a heterologous protein. The aim of recombinant protein expression is to 
obtain high yields of pure and functionally folded protein 150.  
Various hosts are available for this purpose, such as bacteria, yeasts, insects or mammalian 
cells 162. Each of them offers advantages and disadvantages, and the choice of the ideal host 
very much depends on the characteristics of the protein to express, such as its size, origin, 
and post-translational modifications 162. The cost of culturing the hosts and the yield of 
protein that can be obtained are other factors which influence the choice of the organism 
used for protein expression 162. 
3.2.1. Recombinant protein expression in E.coli 
E.coli has been the workhorse of recombinant protein expression. This gram-negative, 
mesophilic prokaryote has a doubling population time of 20 minutes 150. It is easy to grow, 
inexpensive and easy to scale-up 150,163. Various vectors have been developed to enable the 
transformation of E.coli strains with the gene of interest, with various promoters and plasmid 
copy number 150. One of the most commonly used is the pET vector system, which enables 
the induction of protein expression upon addition of Isopropyl-ß-D-thiogalactopyranoside 
(IPTG) 150. 
3.2.1.1. Protein insolubility and inclusion bodies formation 
 
It is not unusual to encounter solubility issues when expressing recombinant proteins.  High 
rates of protein synthesis, coupled to high levels of expression, can saturate the folding 
machinery of the host, leading to the accumulation of misfolded protein intermediates 164. 
These intermediates present exposed hydrophobic patches which facilitate their self-
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aggregation into the so-called inclusion bodies 165, which mostly contain heterogeneous 
populations of misfolded proteins 165,166. 
This problem is further exacerbated when expressing eukaryotic proteins in E.coli, as this 
host lacks the folding machinery of higher organisms. In particular, the cytoplasm of E.coli is 
maintained in a reduced environment by both the glutaredoxin and thioredoxin pathways, 
which prevents the formation of disulfide bridges 166. Bacterial proteins that need disulfide 
bridges are naturally secreted to the periplasm, where the enzymes of the Dsb family, 
especially the oxidase DsbA and the isomerase DsbC, perform this post-translational 
modification 167. 
3.2.1.2. Recobinant expression of the CBD of MMP-2  
 
The CBD of MMP-2 contains 12 cysteines, each being involved in an intramolecular disulfide 
bond. Previous publications on the production of the CBD of MMP-2 in E.coli have described 
the accumulation of the CBD in inclusion bodies. Authors have therefore developed a 
strategy of denaturation/refolding of the CBD from these inclusion bodies 141,144,145,148. This 
approach was also adopted for the expression of single modules 168 and the CBD of            
MMP-9 161. The advantage of this strategy is that it prevents the heterologous protein from 
being degraded, usually leading to high levels of pure protein. However, the procedure can 
be tedious, time consuming, and does not guarantee that the protein is folded in a native-
like structure (Chapter 12 of reference 176). In order to circumvent this limitation, the 
protocol described for the expression of the CBD added a purification step onto a gelatin 
sepharose column, in order to select only the functional protein 141. However, eluting the 
protein from the column involved disrupting the binding with DMSO, which should be 
avoided in order to maintain the structural integrity of the protein, since DMSO as a 
propensity to denature proteins even at modest concentrations (>5 %).  Finally, this method 
involved the use of a Histidine-tagged CBD instead of a protein with a native N-terminus. 
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Overall, it was decided that a more preferable strategy would be to ensure that the native 
CBD is expressed as a correctly folded and soluble form. Several strategies were adopted in 
that attempt.  
3.2.1.2.1. Codon optimisation 
 
As the abundance of tRNA varies from one organism to another, the sequence of the 
gene of interest needs to be codon-optimised, to favour the use of tRNAs which are 
present in large concentration in the host 169. This strategy was shown to favour, in 
some cases, soluble expression of recombinant proteins in E.coli 169.  
3.2.1.2.2. Addition of a tag 
 
In addition to facilitating protein purification 150, the use of a fusion partner can help 
improve protein solubility by preventing the fusion protein from aggregating 150,165. 
The Maltose Binding Protein (MBP)  (40 kDa 163) and Small Ubiquitin-related Modifier 
(SUMO) (11.5 kDa ) tags 170, 171 are two commonly used fusion partners. They have 
been shown to improve the solubility of proteins normally accumulated in inclusion 
bodies 172,171. MBP was also shown to act as a chaperone by improving the folding of 
proteins it was fused to 172, while the SUMO tag offers advantages regarding its 
removal by proteolytic cleavage: the SUMO protease recognises the folded 3D 
structure of SUMO, preventing it from cleaving an identical sequence in the protein 
of interest 171. The cleavage also generates a native N-terminal protein 171,173. 
3.2.1.2.3. Use of engineered strains 
 
Several E.coli strains have been engineered to improve the levels of expression or 
solubility of recombinant proteins. BL21 star strains are mutated for the Lon and 
OmpT proteases, which protects the recombinant protein from being degraded after 
cell lysis. They also carry a hsdSB mutation which prevents plasmid loss and 
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degradation 150 as well as a mutation in the rne131 allele, which attenuates the 
activity of the RNAse E, leading to increased mRNA stability and higher expression 
levels 174. Rosetta cells have the additional advantage of expressing rare tRNA to 
overcome codon bias (Chapter 2 of reference 176). 
The thioredoxin and glutaredoxin pathways are responsible for maintaining the 
cytoplasm in a reduced environment in E.coli. Mutations in both of these pathways 
cause the two thioredoxins in E.coli to be maintained in their oxidised state and to 
catalyse the oxidation of disulfide bridges, in a reversal of their physiological  
function 167,174. Strains mutated in their thioredoxin and glutareodxin pathways were 
commercialised under the name Origami 167,174.  In order to facilitate the correct 
oxidation of cysteines in the cytoplasm, the isomerase DsbC was also overexpressed 
in the cellular compartment of another commercial strain with the Origami 
background, which was named the SHUffle cells (trxB, gor, ahpC* strain) 167,174. 
Interestingly, authors have previously successfully expressed a soluble and 
functional module of the CBD using E.coli strains mutated for thioreductases 175. 
3.2.1.2.4. Optimisation of growth and expression conditions 
 
Optimal growth conditions are required to favour high levels of protein expression. 
The induction of protein expression is usually performed in the mid-log phase, when 
protein synthesis is optimal 150. The concentration of IPTG can also be optimised. 
Finally, expression of the protein at low temperature (15-25°C) can favour proper 
protein folding by slowing down the rate of expression 150. This slower expression 
rate reduces the concentration of folding intermediates 165 and prevents 
hydrophobic interactions which are responsible for inclusion bodies formation 163.  
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3.2.2. Recombinant protein expression in mammalian cells 
Mammalian cells are often considered less attractive than E.coli for recombinant protein 
expression, as cultivating them is more expensive 162, their transfection requires large 
amounts of DNA, and the yield obtained after expression is generally low (Chapter 14 of 
reference 151). 
However, they are a particularly useful host for expressing proteins with post-translational 
modifications, as they have the required machinery to add these modifications to yield a fully 
folded and functional protein 176,162.  
Consequently, several methods for Transient Genetic Expression (TGE) have been developed, 
which rely on either chemical, physical or biological means of delivering the expression 
plasmid to the nucleus of mammalian cells 177, such as Lipofection, Calcium Chloride and 
Polyethyleneimine-mediated methods. 
3.2.3. Strategy of expression of the CBD 
Considering all these aspects, we first designed a strategy for expressing the CBD in E.coli, 
and aimed to maximise its solubility using some of the strategies outlined earlier. BL21 Star 
and Rosetta cells were tested in the first instance, in order to determine if these strains could 
express the CBD with its 6 disulfide bridges. This chapter describes the results obtained with 
these initial strains, as well as in the mammalian cell line HEK 293T, which was used in an 
attempt to favour the folding of the human CBD, using all three transfection methods 
mentioned earlier.  
Finally, this chapter describes the successful use of the engineered E.coli strain Shuffle for 
the expression of a fully folded CBD, as well as its purification to 90 % purity and its 
characterisation.  
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3.3. Materials and Methods 
 
3.3.1. Cloning 
The CBD of MMP-2 had the following sequence:  
R V K Y G N A D G E Y C K F P F L F N G K E Y N S C T D T G R S D G F L W C S T T Y N F E K D G K 
Y G F C P H E A L F T M G G N A E G Q P C K F P F R F Q G T S Y D S C T T E G R T D G Y R W C G 
T T E D Y D R D K K Y G F C P E T A M S T V G G N S E G A P C V F P F T F L G N K Y E S C T S A G 
R S D G K M W C A T T A N Y D D D R K W G F C P D Q G Y S 
 
The DNA encoding for this protein sequence was codon optimised and cloned into either the 
pOPINS or pOPINM (OPPF-UK) vector using the ligase independent InFusion cloning 
methodology. The two constructs which were generated carried either a His6-SUMO or a 
His6-MBP tag, followed by a cleavage site for a SUMO and 3C protease, respectively         
(Figure 3-1).  
 
 
 
 
 
 
 
 
 
Figure 3-1: Schematic representation of the two constructs used for expression of the CBD. 
Two constructs were generated, one carrying a His6-SUMO tag, and one a His6-MBP tag, each 
at the N-terminus of the protein. The tags were separated from the sequence of the CBD by 
the cleavage site of the SUMO and 3C proteases, respectively. 
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3.3.2. Expression in E.coli strains 
E.coli cells were transformed with the sequenced expression plasmids. Conditions of 
expression such as the temperature and length of the production phase as well as the 
concentration of inducer were optimised on a small scale.  On a larger scale, protein 
expression was carried out in 2L flasks. Cells were grown either in LB or minimal media at 
37°C, induced for protein expression with IPTG, harvested following the production phase 
and stored at -80°C. 
3.3.3. Expression in mammalian cells 
HEK 293T cells were cultivated as mentioned in the Materials and Methods section. They 
were transfected with the recombinant pOPINM construct using either Lipofectamine, 
Calcium chloride or Polyethylenimine. Conditions of transfection such as the amount of DNA, 
the length of incubation of cells with the DNA:transfection reagent complex or the time of 
harvesting were optimised.  
3.3.4. Purification strategy 
Following cell lysis, the released recombinant protein was captured on a nickel column, 
exploiting the affinity of the hexahistidine tag for this resin. The protein was eluted with a 
gradient of imidazole, and the tag cleaved with the corresponding histidine-tagged protease.  
A reverse nickel purification enabled the isolation of the cleaved protein from the tag and 
protease. A third step of purification was needed; for this both Ion Exchange and Gel 
Filtration Chromatography were tested. The former was optimised to enable the recovery of 
a native CBD with more than 90 % purity. 
 
 
93 
 
3.3.5. Characterisation 
The expressed protein was characterised for its identity using Mass Spectrometry by MALDI-
TOF, while the correct folding was investigated with an intact mass analysis with Electrospray 
Ionisation. The secondary structure was analysed by circular dichroism, while the folding into 
a tertiary structure was assessed by 2D NMR. The number of disulfide bridges in the protein 
was quantified with a DTNB assay. Finally, the functionality of the protein was tested on a 
gelatin sepharose resin, and its affinity for type II gelatin quantified using a plate binding 
assay. 
3.4. Results 
 
3.4.1. Expression of the CBD in E.coli BL21 and Rosetta cells 
3.4.1.1.  Small scale screening for optimal expression in Lysogeny 
Broth (LB) 
 
E.coli Rosetta pLysS (DE3) and E.coli BL21 Star were first transformed with either the pOPINM 
(carrying the gene encoding for His6-MBP-CBD) or the pOPINS vector (carrying the gene for 
His6-SUMO-CBD), respectively.  Cells were cultured at 37°C before induction, induced with a 
range of concentrations in IPTG (200 – 400 µM), and then either left for a further 5 hours at 
37°C or overnight at 18°C. 
Figure 3-2 shows the results of expression of His6-MBP-CBD in Rosetta pLysS cells at 18°C. 
Gels show that the CBD was expressed as a soluble protein with every condition tested, with 
a higher proportion of insoluble protein with increasing concentrations of IPTG. The same 
pattern was observed in these cells at 37°C, with an overall reduced level of expression (not 
shown), as well as in the BL21 Star cells expressing the His6-SUMO-CBD (not shown). 
It was, therefore, decided from this screening step to carry out the production on a larger 
scale with a concentration of 200 µM IPTG at 18°C overnight for both constructs. 
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His6-MBP-CBD 
His6-MBP-CBD 
Figure 3-2: SDS PAGE showing the screening for expression of the His6-MBP-CBD in LB in 
Rosetta pLysS (DE3) cells. Rosetta pLysS E.coli cells were transformed with a plasmid 
encoding for the CBD of MMP-2, carrying a His6-MBP tag. Cells were grown in 10 mL LB 
until reaching an OD (600 nm) of 0.6. Cells were induced with various concentrations of 
IPTG overnight at 18°C. Cells were then lysed and both the soluble and insoluble fractions 
were subjected to a nickel purification. L: Lysate; S: Supernatant; Bd: Nickel bound; U: 
Unbound. 
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3.4.1.2.  Large scale expression with the optimised conditions in LB 
 
The protein expression was then carried out in 2L Flasks, as described in the Materials and 
Methods section. Results show a successful expression of both the His6-MBP-CBD and His6-
SUMO-CBD in the soluble fraction (Figure 3-3). The cleavage of the tags was also performed 
successfully, although it seemed incomplete for the MBP tag (Gel A, Figure 3-3). The reverse 
purification enabled the recovery of the protein in the flowthrough. 
The protein was further concentrated and the untagged CBD could be detected on a gel with 
both the CBDM construct (initially carrying the MBP tag) and the CBDS construct (initially 
carrying the SUMO tag) (Gel C, Figure 3-3). 
The samples were further concentrated to 1mg/mL before being analysed by 1D NMR. The 
spectra showed that the proteins were folded like a molten globule (not shown). In order to 
further clarify the folding state of the protein, it was decided to express it in labelled minimal 
media to assess the foldedness of the protein by 2D NMR. 
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His6-MBP-CBD 
CBD 
His6-SUMO-CBD 
CBD 
Figure 3-3: SDS PAGE showing the expression of the His6-MBP-CBD (A) and His6-SUMO-
CBD (B) in LB and the level of purity of the CBD (C). Rosetta pLysS and BL21 (DE3) E.coli 
cells were transformed with a plasmid encoding for the CBD of MMP-2, carrying either a 
His6-MBP tag or a His6-SUMO tag, respectively. The cells were grown in LB at 37°C and 
induced with 200 µM IPTG overnight at 18°C. The cleared lysate was purified using a nickel 
column (His Trap). The eluted fractions were pooled and the tag was removed by cleaving 
with a histidine-tagged 3C protease or a histidine-tagged SUMO protease overnight at 
4°C. Finally, the mixture was then passed back down the nickel column (reverse 
purification) and the protein collected in the flow through, while the protease and the 
tags were in the elution fraction. L: Lysate; S: Supernatant; I: Inclusion Bodies; FT: 
Flowthrough; W: washes; 5-8: His Trap fractions; P: Pool of His-Trap fractions; PD: Post 
Dialysis; FTr: Flowthrough reverse; Er: Elution reverse; CBDM: CBD initially carrying the 
MBP tag; CBDs: CBD initially carrying the SUMO tag 
A 
B 
C 
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3.4.1.3.  Small scale screening for optimal expression in minimal 
media 
 
Considering the cost of the labelling, the expression was carried out in unlabelled media at 
first to ensure successful expression. Subcloning from the pOPINM to the pOPINB vector 
containing a MBP tag was also required for the MBP construct as Rosetta pLysS (DE3) cells 
were unable to grow in minimal media. 
A small scale screening experiment was performed again to determine the optimal 
conditions for expression of a soluble CBD in minimal media.  
The results below (Figure 3-4) enabled us to identify only two conditions where some soluble 
protein was obtained, namely a production phase of 5 hours at 25°C with 1 mM of IPTG and 
an overnight production at 18° C with 800 µM IPTG.  
Those were only successful with the SUMO construct. They were both scaled up to 1L and 
subjected to the His Trap and reverse purification as described in the Materials and Methods 
section. 
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His6-MBP-CBD 
His6-SUMO-CBD 
Figure 3-4: SDS PAGE showing the screening for expression of the His6-MBP-CBD (A) and 
His6-SUMO-CBD (B) in minimal media. E.Coli BL21 (DE3) cells were transformed with a 
plasmid encoding for the CBD of MMP-2, either carrying a His6-MBP tag or a His6-SUMO tag. 
Cells were grown in 10 mL minimal media until reaching an OD (600 nm) of 0.6. Cells were 
induced with various concentrations of IPTG overnight at 18°C, or for 5 hours at 25°C. Cells 
were then lysed and both the soluble and insoluble fractions were subjected to a nickel 
purification. The same conditions were tested for both constructs, but only a subset is 
presented in this figure. L: Lysate; S: Supernatant; Bd: Nickel bound; U: Unbound; HS: heat-
shocked: growth at 30 °C, switch at 42°C when OD=0.1 (heat-shock), induction when 
OD=0.6, for 5 hours at 25 °C. 
A 
B 
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3.4.1.4. Large scale expression with the optimised conditions in 
minimal media 
 
The scale-up led to an expression pattern where most of the protein was found in the 
inclusion bodies, although a small proportion was recovered in the soluble fraction (not 
shown). This process and the final yield were not suitable for further NMR experiments and 
an alternative method for studying the folding of the protein was required. 
3.4.1.5.  DTNB assay 
 
Folded CBD contains 6 disulfide bonds; these are found in the native protein and are 
important to enable the CBD to bind gelatin with the optimal efficacy. An assay which 
quantifies the number of disulfide bridges within a protein was used to verify the presence 
of these bridges and enabled an early assessment of whether the expressed protein was 
likely to be folded or not. 
The DTNB assay was therefore used to quantify the number of free cysteines within a 
molecule. It showed that only half of the disulfide bridges were formed in the protein 
originally carrying the MBP tag, and 3 free cysteines were found in the protein originally 
carrying the SUMO tag. This result correlated with our previous 1D NMR data highlighting 
the sub-optimal folding of the CBD in E.coli.  
Alternative protocols and expression systems were therefore envisioned in order to obtain 
a correctly folded protein. The ability of mammalian cells to express a correctly folded CBD 
was therefore tested. 
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3.4.2.  Expression of the CBD in HEK 293T cells 
3.4.2.1. Transfection with Lipofectamine: proof of concept 
 
Mammalian cells are thought to be better suited for the expression of proteins with post-
translational modifications. HEK 293T cells were therefore tested for their ability to express 
the CBD. Transfection of the cells was carried out with the His6-MBP-CBD construct, which 
vector pOPINM is suitable for mammalian expression. Results showed successful expression 
of the protein by Western Blot in the lysate and on the nickel resin (Figure 3-5). This was 
achieved using Lipofectamine 2000 as the transfection reagent, which would have been cost-
prohibitive for a large scale expression of the protein. Other transfection methods were 
therefore tested in HEK 293T cells with cheaper transfection reagents, such as 
PolyethyleneImine and Calcium Chloride. 
 
 
 
 
 
 
 
 
Figure 3-5: SDS PAGE and Western Blots showing successful expression of the His6-MBP-
CBD in HEK 293T cells transfected with Lipofectamine 2000. HEK 293T cells were 
transfected with a plasmid encoding for the CBD of MMP-2, carrying a His6-MBP tag with 
Lipofectamine 2000. Cells were harvested and lysed 24 hours after being transfected. Both 
the soluble and insoluble fractions were subjected to a nickel purification. SDS PAGE was 
run and proteins were then transferred onto a nitrocellulose membrane under both 
reducing and non-reducing conditions. Proteins were detected with a mouse anti-Histidine 
antibody followed by an anti-mouse antibody. L: Cleared Lysate; FT: Flowthrough; W: 
Washes; E: Elution; I: Inclusion Bodies; R: Nickel resin  
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3.4.2.2. Transfection with Calcium Chloride and Polyethylenimine: Small 
scale screening for optimal expression 
 
Both Polyethylenimine (PEI) and Calcium Chloride were used as transfection reagents. In the 
former case, the ratio of PEI:DNA (1:1, 3:1 and 5:1) was optimised, as well as the time of 
harvesting cells (24, 48 or 72 hours post-transfection). For transfection with Calcium 
Chloride, 3 amounts of DNA per well (1, 3 and 5 µg) were tested, as well as 3 incubation times 
of the complex (2, 6 and 20 hours).  Cells were harvested 48 hours after transfection. 
Cells were lysed and the cleared supernatants were loaded on a gel, transferred onto a 
membrane and blotted using a mouse anti-Histidine/anti-mouse antibody combination.  
Results showed very low levels of expression in all samples, except for cells transfected with 
Calcium Chloride with either 3 or 5 µg of DNA and incubated for 20 hours with the DNA-
Calcium Chloride complex (Figure 3-6). The GAPDH control confirmed an even lysis efficiency 
for all the samples transfected with Calcium Chloride. However, the molecular weight of the 
expressed protein seemed slightly lower than expected, suggesting that a cross-reaction of 
the antibody with a different protein could have happened. In spite of this observation, it 
was decided to scale up the expression in HEK 293T cells using the Calcium Chloride 
transfection method with 5 µg of DNA per well and an incubation of the complex for 20 
hours. 
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3.4.2.3. Large scale expression with the optimised conditions  
 
Transfection of HEK 293T cells with 5 µg of DNA and Calcium Chloride, incubated for 20 
hours, was chosen as the best condition and scaled-up to 6 15-cm dishes seeded at 9 500 
000 cells per dish. 
Cells were lysed and a His Trap purification was performed on the cleared lysate using a 1 mL 
column. 
Unfortunately, the expression levels appeared to be very low as a very faint band was 
observed at the expected size (62.5 kDa) in only 3 fractions (Lanes W3, F4 and F5,                
Figure 3-7).  The level of expression in these conditions in HEK 293T cells was therefore too 
low for follow-up studies, and this strategy was put on hold as a more promising one was 
being developed, using Shuffle E.coli cells. 
PEI CaCl2 
Figure 3-6 Western Blots showing screening for expression of the His6-MBP-CBD in HEK 
293T cells transfected with either PEI (left) or Calcium Chloride (right). HEK 293T cells 
were transfected with a plasmid encoding for the CBD of MMP-2, carrying a His6-MBP 
tag with either PEI or Calcium Chloride (CaCl2). SDS PAGE was run on the lysates and 
proteins were then transferred onto a nitrocellulose membrane. Proteins were detected 
with a mouse anti-Histidine antibody followed by an anti-mouse antibody. An anti 
GAPDH antibody was used as a control of the lysis efficiency in all samples. The numbers 
labelled on the gels either correspond to the PEI:DNA ratios (left, PEI transfection) or to 
the amount of DNA used (right, CaCl2 transfection) . 
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Figure 3-7:  SDS PAGE (A) and chromatogram (B) showing the expression of the His6-MBP-
CBD in HEK 293T cells transfected with Calcium Chloride. HEK 293T cells were transfected 
with 5 µg of a plasmid encoding for the CBD of gelatinase, carrying a His6-MBP tag, using 
Calcium Chloride. Cells were incubated with the plasmid for 20 hours and harvested and 
lysed 48 hours after being transfected. The cleared supernatant was subjected to an affinity 
chromatography using a 1mL His Trap column. A SDS PAGE was run on different fractions. 
L: Lysate; S/N: cleared supernatant; I: Inclusion bodies; FT: Flowthrough; W: Washes; F: 
Fractions (from corresponding chromatogram) 
A 
B 
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3.4.3. Expression of the CBD in E.coli Shuffle cells 
3.4.3.1. Small scale screening for optimal expression 
 
Small scale expression trials were set up with Shuffle cells, which were transformed with 
either the pOPINS or pOPINB construct, optimising the concentration of IPTG only. Proteins 
were expressed at 18°C overnight. From this screening, 200 µM and 600 µM of IPTG were 
selected as the optimal concentrations for induction for the MBP and SUMO constructs 
(Figure 3-8), respectively, and scaled up to 2L flasks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8: SDS PAGE showing the expression of the MBP-CBD (A) and SUMO-CBD (B) in 
E.coli Shuffle cells. E.Coli Shuffle (DE3) cells were transformed with a plasmid encoding for 
the CBD of MMP-2, carrying either a His6-MBP tag or a His6-SUMO tag, respectively. Cells 
were grown in 10 mL minimal media until reaching an OD (600 nm) of 0.6. Cells were 
induced with various concentrations of IPTG overnight at 18°C. Cells were then lysed and 
the soluble fraction was subjected to a nickel purification, while the insoluble fraction was 
solubilised in 8M urea. L: Lysate; S: Supernatant; U: Unbound; Bd: Nickel bound; I: 
Inclusion Bodies 
His6-MBP-CBD 
His6-SUMO-CBD 
A 
B 
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3.4.3.2. Large scale expression with the optimised conditions in LB and 
minimal media 
 
These conditions enabled soluble expression of proteins from both constructs, as shown in 
Figure 3-9, in both minimal media and LB (not shown). However, some high molecular weight 
contaminants were observed after the reverse purification, highlighting the need for a third 
purification step. Both Ion Exchange and Gel Filtration Chromatography were tested.  
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His6-MBP-CBD 
CBDM 
His6-SUMO-CBD 
CBDS 
A 
B 
C 
Figure 3-9: SDS PAGE gel showing the expression of the His6-MBP-CBD (A) and His6-SUMO-
CBD (B) in minimal media and the corresponding chromatogram (C). A and B: E.coli  Shuffle 
T7 Express (DE3) cells were transformed with a plasmid encoding for the CBD of MMP-2, 
carrying a His6-MBP tag  or a His6-SUMO tag, respectively. The cells were grown in minimal 
media at 37°C and induced with 200 µM IPTG or 600 µM IPTG (for the MBP tagged and 
SUMO tagged constructs, respectively) overnight at 18°C. The cleared lysate was purified 
using a nickel column (His Trap). The eluted fractions were pooled and the tag was 
removed by cleaving with Histidine-tagged 3C or SUMO proteases overnight at 4°C. Finally, 
the mixture was then passed back down the nickel column (reverse purification) and the 
protein collected in the flow through, while the protease and the tags were in the elution 
fraction. L: Lysate; S: Supernatant; I: Inclusion Bodies; U: Unbound; W: washes; 5-9: His 
Trap fractions; PDs: Post Dialysis soluble; Pdi: Post dialysis insoluble FTr: Flowthrough 
reverse; Er: Elution reverse. C: Chromatogram corresponding to the His Trap purification 
of the His6-SUMO-CBD. Fractions 5 to 9 were loaded on the gel. Blue line: UV trace; Green 
line: Concentration of imidazole 
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3.4.4. Optimisation of the purification method: polishing step 
3.4.4.1. Gel Filtration 
 
The size exclusion chromatography enabled pure proteins to be obtained, but most of it was 
lost on the HiLoad 16/60 column (Figure 3-10). This strategy also gave different elution 
profiles according to the construct which was used: the SUMO construct gave one single peak 
while the MBP one provided two consecutive peaks, suggesting the presence of two different 
species, which will be further investigated in the next section. 
Because protein precipitation could explain the low recovery, a different column was tested 
(Superdex 75 10/300) and the concentration of salts was increased from 150 to 300 mM. 
None of these options significantly improved the amount of protein which was recovered 
(not shown). 
It was concluded that the Gel Filtration was not a suitable polishing step to recover enough 
functional CBD, and it was decided to test an Ion Exchange Chromatography (IEC) instead. 
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CBDS 
Figure 3-10: SDS PAGE and corresponding chromatograms showing the elution profile and 
purity of both the CBDM (A) and CBDS (B) construct on a Gel Filtration column. The CBD of 
MMP-2, originally carrying either a His6-MBP tag or a His6-SUMO tag, was purified by 
nickel column and reverse nickel column purification, as previously described. The protein 
samples were then concentrated to up to 2 mL and loaded on an equilibrated HiLoad 
16/60 s75 Superdex column and eluted isocratically.   
 
 
B 
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3.4.4.2. Ion Exchange Chromatography  
 
The Ion Exchange strategy did not increase the purity of the originally MBP-tagged sample, 
as high molecular weight contaminants were still present in the eluted fractions (Figure 3-
11, lanes 8 to 12). However, the construct originally carrying the SUMO tag gave a better 
outcome, as the CBD eluted specifically at a lower salts concentration than the contaminants 
(lanes 8 and 9, Figure 3-12).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3-11: SDS PAGE and corresponding chromatogram showing the elution profile and 
purity of the CBDM sample following linear elution from the Ion Exchange Q FF 5 mL column. 
The CBD of MMP-2, originally carrying a His6-MBP tag, was purified by nickel column and 
reverse nickel column purification, as previously described. The protein sample was then 
desalted and loaded onto a 5 mL Q FF column, and eluted with a linear gradient of sodium 
chloride. L: Lysate; S: Supernatant; I: Inclusion Bodies; UH: unbound from His Trap; HT: 
Fraction from His Trap; FTR: Flowthrough reverse; UI: Unbound from IEC; 8-12: Fractions 
from IEC. 
His6-MBP-CBD 
CBD 
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It was therefore decided to test a gradient elution on the CBDS construct, using a step elution 
at 24% of IEC Buffer B, which was the concentration at which the CBD started to get eluted 
in the previous experiment. 
A sample free from high molecular weight impurities was obtained, although a low molecular 
weight contaminant could still be observed (Figure 3-12). This contaminant was later 
identified as being the cleaved histidine-tagged SUMO. 
 
 
 
 
 
 
 
 
His6-SUMO-CBD 
CBD 
Figure 3-12: SDS PAGE and corresponding chromatogram showing the elution profile and 
purity of the CBDS sample following linear elution from the Ion Exchange Q FF 5 mL column. 
The CBD of MMP-2, originally carrying a His6-SUMO tag, was purified by nickel column and 
reverse nickel column purification, as previously described. The protein sample was then 
desalted and loaded onto a 5 mL Q FF column, and eluted with a linear gradient of sodium 
chloride. L: Lysate; S: Supernatant; I: Inclusion Bodies; UH: unbound from His Trap; HT: 
Fraction from His Trap; FTR: Flowthrough reverse; UI: Unbound from IEC; 8-12: Fractions 
from the IEC; 13: Fraction from the second peak of the IEC 
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In order to get rid of this contaminant, a mono Q column was tested at pH 6.5 and 7.0, which 
are closer to the isoelectric point of the protein (i.e. 5.0). Unfortunately, this strategy did not 
allow enough recovery of pure protein to be considered as a suitable method (not shown). 
Overall, it was decided that the step elution of the CBDS construct from the Ion Exchange 
column, described in Figure 3-13, was the best strategy to recover enough protein with a 
high level of purity (equal to 90 %). The next step was to characterise the integrity of the 
protein fold and the function of this CBDS sample. 
 
 
 
 
Figure 3-13: SDS PAGE and corresponding chromatogram showing the elution profile and 
purity of the CBDS sample following a step elution from the Ion Exchange Q FF 5 mL column. 
The CBD of MMP-2, originally carrying a His6-SUMO tag, was purified by nickel column and 
reverse nickel column purification, as previously described. The protein sample was then 
desalted and loaded onto a 5 mL Q FF column, and eluted with a step elution of 24 % of IEC 
B. FT: Flowthrough from IEC; 3-19: Fractions from the IEC. 
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3.4.5. Protein characterisation 
3.4.5.1. Identity and structure 
 
3.4.5.1.1. Identity 
 
The protein identity was confirmed by a MALDI-TOF Mass Spectrometry analysis on a sample 
digested with trypsin. 67 ions were identified with more than 99 % of probability, each 
corresponding to a part of the sequence of the CBD of MMP-2. The identified peptides span 
the sequence highlighted in yellow in the figure below, covering almost the entirety of the 
CBD sequence (Figure 3-14). 
 
Figure 3-14: Mass Spectrometry results confirming the identity of the CBD. Ions obtained 
from tryptic digests of the CBDS sample were analysed by MALDI-TOF. Their masses 
corresponded to peptides within the CBD sequence, which are indicated in yellow. 
 
3.4.5.1.2. Disulfide bridges 
 
One of the main structural features of the CBD is the presence of 6 disulfide bonds, which 
are also critical for the correct function of the protein. Their presence was first confirmed 
with a DTNB assay, which quantifies the number of disulfide bridges within a protein. The 
CBDM samples from the Gel Filtration chromatography described in Figure 3-10 were also 
submitted to the DTNB assay. The results are summed up in Table 3-1 below. They show that 
the CBDs sample obtained after a step elution on the Q FF column was predominantly folded, 
with no free cysteines observed. The two species identified earlier with the CBDM sample (i.e. 
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the CBD originally carrying a MBP tag) showed different folding states: the one 
corresponding to the first peak on the chromatogram in Figure 3-10 was unfolded, with 3 
free cysteines, while that corresponding to the second peak was mostly folded, with no free 
cysteines. These results correlated with the 1D NMR spectra traces which were obtained for 
each sample (not shown). Obtaining mixtures of folded and partially folded proteins using 
the E.coli expression system is not uncommon since there is a fine balance between protein 
synthesis and protein folding in vivo. 
 
Table 3-1: Characterisation of the CBD in terms of folding. The DTNB assay enables 
quantification of the number of free cysteines in each protein samples, as the reagent, 
namely, 5-dithio-bis-(2-nitrobenzoic acid), reacts with free sulphydryl, producing a coloured 
species, TNB2-. The characteristics of the 1D proton NMR spectra correlated with the data 
from the DTNB assay. The CBDS sample was obtained after the Ion Exchange purification with 
a step gradient, as described in the previous section. The CBDM samples come from the Gel 
Filtration chromatography. 
 
An intact mass analysis was used to further confirm this finding. The measured intact mass 
of the CBDS sample was 19 628 Daltons, which corresponds to a 12-dalton deficit compared 
to the theoretical mass derived from the sequence (19 640 Da). This difference correlates 
with the formation of 6 disulfide bridges and the concomitant loss of 12 hydrogens.  
 
 
 
 
 CBDS CBDM peak 1 CBDM peak 2 
DTNB assay 
0.05 free 
cysteine/protein 
3.3 free 
cysteine/protein 
0.4 free 
cysteine/protein 
1D NMR spectra Predominantly folded Unfolded 
Predominantly 
folded 
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3.4.5.1.3. Secondary structure 
 
The secondary structure of the CBDS protein was then studied by Circular Dichroism (CD). 
The CD spectrum obtained showed characteristics consistent with a folded Fibronectin 
domain-rich protein, with a maximum absorption at 224 nm and a minimum at 198 nm, with 
a mixture of alpha turn and beta sheet 143. A spectrum of a thermodenatured CBDS was also 
acquired at 90°C to show the disappearance of the maxima at 224 nm (Figure 3-15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-15: CD spectrum of the native (A) and thermodenatured (B) CBDS sample. The CBDS 
sample purified with a step elution from the Ion Exchange QFF column was buffer 
exchanged and submitted to CD analysis. Both spectra were acquired with a protein 
concentration of 0.15 mg/mL in 2.5 mM HEPES, pH 6.5. The CD signal was acquired from 
260 to 190 nm with a JASCO instrument. 
A 
B 
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3.4.5.1.4. Tertiary structure: NMR characterisation 
 
A 2D NMR spectrum of the free protein, expressed in 15N labelled minimal media, was then 
acquired. The spectrum was similar to previously published data 140; some precipitation or 
aggregation was observed. Some additional peaks of minor intensity were also observed 
(Figure 3-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16: 1H-15N Heteronuclear Single Quantum Correlation (HSQC) spectrum of the 
CBDS sample at 298 K in 25 mM sodium phosphate, pH 6.5, 10 % D2O, 115 µM. The 
spectra were acquired on a 800 Hz Bruker spectrometer instrument (Bruker Avance III 
fitted with [1H, 15N, 13C]-cryoprobes). Each peak on the spectrum corresponds to an 
amide proton in the CBD. The position of the peaks in the spectrum is determined by 
the chemical environment of the atoms of the protein. 
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When overlaying the spectrum of the CBDS with that of the His6-SUMO tag, it appeared that 
the observed additional peaks matched, indicating that the final protein sample was 
contaminated with the SUMO tag (Figure 3-17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Different purification strategies were therefore envisioned to try to purify the CBD further 
and isolate it from the tag. 
As there is no cysteine in the sequence of the SUMO tag, we concluded that its interaction 
with the CBD was not covalent. A hydrophilic interaction would not have been maintained 
with the 500 mM NaCl already present in the purification buffers. It is, therefore, possible 
that the interactions between the CBD and contaminant protein(s) are mediated by 
hydrophobic contacts. Hence, 0.05 % Tween (v/v) was included in all purification buffers, 
Figure 3-17: Overlay of the 1H-15N HSQC spectrum of the CBDS sample at 298K in 25 mM 
NaP, pH 6.5, 10 % D2O (black) with that of the His6-SUMO tag (red). The purified CBDS sample 
was buffer exchanged against 25 mM sodium phosphate (NaP), pH 6.5, concentrated to 115 
µM and 128 spectra were acquired at 25°C on a 800Hz Bruker spectrometer instrument. 
Each peak on the spectrum corresponds to an amide proton in the CBD. The position of the 
peaks in the spectrum is determined by the chemical environment of the atoms of the 
protein. The fact that peaks from the CBD and from the SUMO tag overlap indicates that a 
residual SUMO tag is found in the CBD sample. 
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except those of the Ion Exchange step. Unfortunately, this led to more protein precipitation 
and no improvement in purity (not shown). 
As this project does not require a degree of purity higher than 90 %, it was decided to keep 
the purification protocol as previously described, and to accept the presence of the SUMO 
tag as a contaminant. 
3.4.5.2. Activity 
 
After expressing the protein with an adequate level of purity and characterizing its folding, 
we went on to determine whether the expressed protein was able to bind to its target, i.e. 
gelatin.  
3.4.5.2.1. Gelatin sepharose binding 
 
The CBDS protein sample purified with a step gradient elution from the Q FF column was first 
tested for its ability to bind to gelatin using a small scale gelatin sepharose affinity 
chromatography. Although some protein was lost in the flow through, most of it was 
recovered on the resin, demonstrating that the protein which has been obtained is both 
folded and functional as it was able to bind to the immobilised gelatin (Figure 3-18).  
 
 
 
 
 
 
 
Figure 3-18:  SDS PAGE showing the binding of the CBDS to gelatin sepharose. The CBDS 
protein sample from the Ion Exchange was tested for its ability to bind gelatin using a gelatin 
sepharose resin. 100 µL of resin was spun down, washed with ethanol and equilibrated 
before applying the samples. The mixture was spun again and the flowthrough removed (FT) 
before washing two times with the binding buffer (W: Washes). The bound protein was 
mixed with 2X SDS loading buffer and loaded on the gel (Gel: gelatin-bound). 
119 
 
3.4.5.2.2. Binding assay 
 
A more quantitative gelatin-binding test was then carried out using type II gelatin coated 
plates. As described in the Materials and Methods section, the protein was first biotinylated 
before being added over a range of concentrations to gelatin-coated plates. The ability of 
alkaline phosphatase-streptavidin to convert its substrate, P-Nitrophenyl Phosphate (PNPP), 
into a coloured product was measured at 405 nm, and used as an indirect indication of the 
amount of protein bound to gelatin (Figure 3-19, panel A). The specificity of the signal was 
demonstrated by the fact that a reduced and alkylated version of the CBD did not show any 
binding (not shown), highlighting the need of the six disulfide bonds for the correct function 
of the protein. The CBDS was shown to bind with a Kd of 20.4 ± 2.83 nM (Kd ± SEM, n = 3) 
(Figure 3-19, panel B, for a representative binding curve), in line with previous findings in an 
identical assay which yielded a Kd of 50 nM for a CBD construct containing a Histidine tag. 145 
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Figure 3-19: Binding of the CBD to type II gelatin plates. A: The binding assay relies on the 
use of plates coated with type II gelatin (thermodenatured collagen). The biotinylated 
protein was added over a concentration range before adding streptavidin-coupled alkaline 
phosphatase. Its substrate, namely PNPP, was added and converted into a coloured product 
which formation was measured by absorbance at 405 nm. B: An example of one of the 
binding curves is shown. Error bars represent standard deviations of three replicates. 
 
 
 
 
 
S S 
PNPP PNPP 
Gelatin 
CBD 
Biotin 
Streptavidin-conjugated  
alkaline phosphatase 
A 
B 
121 
 
3.5. Discussion 
 
3.5.1. General conclusion 
This chapter has described the successful expression and purification of a folded and 
functional CBD in the cytoplasm of the Shuffle E.coli strain. To the best of our knowledge, 
this is the first time that this protein has been expressed in the soluble fraction of E.coli. The 
protein was expressed in 2L Flasks, giving a consistent yield of 3.5 mg/L of culture. This yield 
is lower than that obtained in the original protocol for expressing the CBD, as the refolding 
strategy gave a yield of 15 mg/L. However, our strategy seems easier, quicker, and more 
reproducible, and it does not require elution of the protein from its substrate in the 
purification protocol. In addition, and contrary to the original refolding protocol, our strategy 
yields a native CBD, as its N-terminal is intact after cleavage of the SUMO tag by the SUMO 
protease. 
This outcome was achieved after the more classical strains of E.coli, i.e. Rosetta and BL21 
Star, had failed to enable the expression of a correctly folded protein in the soluble fraction, 
despite extensive optimisation of the expression conditions. The reducing environment of 
the cytoplasm of these strains is probably the reason why most of the protein accumulated 
in inclusion bodies. This might also explain why the soluble fraction contained misfolded 
versions of the CBD. 
Mammalian expression was also tested in HEK 293T cells, whose folding machinery is more 
adequate for the expression of disulfide-bridged proteins. However, using this host led to a 
very low level of expression and this was not suitable for the subsequent work to be 
undertaken in this project. 
As mentioned earlier, the purification protocol was specifically designed for the chosen 
construct. It exploits the affinity of the histidine tag for nickel, enabling the capture of the 
protein on a His Trap column. A polishing step was added with an anion Ion Exchange 
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Chromatography using a Q column, which enabled the purification of the protein to 90 %, 
even though some of the initial SUMO tag remained in the final sample.  
This contaminant did not affect the folding nor the function of the protein, which was shown 
to be able to bind to type II gelatin with a Kd of 20.4 nM, a value which was similar to that 
previously described for  a refolded His6-CBD (50 nM), confirming the validity of our method 
of expression and purification. 
3.5.2. Future work 
Are there other ways to express the CBD with a higher yield? 
This chapter has demonstrated that it is possible to express the CBD of MMP-2 as a folded 
and fully functional protein, in the cytoplasm of Shuffle E.coli strains with a consistent yield 
of 3.5 mg/L of culture. 
Although fairy low compared to the common expression levels obtained in E.coli, this yield 
was nevertheless sufficient to carry out the first part of this project. However, when thinking 
about potential translation of this project into the clinic, a higher yield of protein will be 
needed to optimise time and resources. 
The first and more immediate step to take would be to try to scale up the expression in the 
same host, using a bioreactor. The advantages of using a bioreactor, apart from the fact that 
higher volumes of culture are used, is that critical growth conditions such as pH and dissolved 
oxygen are controlled. The literature is limited on the use of the Shuffle cells in bioreactors, 
although one paper reported optimised conditions for growth for this specific strain 178. It 
describes the use of glycerol as the carbon source and a temperature of growth of 30°C. 
These optimised conditions have led to yields as high as 3.2 grams of protein/10L of         
culture 178. 
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Another strategy to explore would be to target the protein to the periplasm of E.coli, where 
disulfide-bridged proteins are naturally expressed in this host. This would require the 
addition of a leader peptide in the cloning vector to target the protein to one of the sec or 
SRP pathways (chapter 2 of reference 176).  The advantages of expressing a protein in this 
compartment is that it contains fewer proteases than the cytoplasm (chapter 5 of reference 
176), and is generally less complex, leading to easier purification procedures (chapters 2 and 
5 of reference 176). Chaperones are also naturally available in the periplasm to help with the 
folding of the recombinant protein (chapter 5 of reference 176). 
An alternative option to periplasmic expression would be to co-express the CBD with 
chaperones in the cytoplasm of the host, which could favour its folding (chapter 3 of 
reference 176). 
Alternatives to these options would be to express the protein in a different host with a more 
complex post-translational machinery, as that of the Shuffle cells still led to the accumulation 
of some of the CBD in the insoluble fraction. Yeasts might be an interesting host to test, as 
they combine the advantages of E.coli (fast growth, inexpensive) and of a eukaryotic system, 
enabling them to perform correct disulfide bridges formation 164. They are easier to scale up 
than mammalian cells and present a secretion capacity which would facilitate downstream 
purification 164. Interestingly, Pichia Pastoris was used to express one of the fibronectin 
domains of Fibronectin 179. 
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Why is the SUMO tag co-purified with the CBD and how to purify it further? 
The NMR spectrum of the CBD showed that the final protein solution was contaminated with 
~10 % of the SUMO tag. Even though it was decided that having the protein at a 90 % purity 
level was enough for the purpose of this project, it would be interesting to find out why the 
SUMO tag is still present after the last step of purification. 
One simple explanation would be that the SUMO tag does not bind to the resin of the His 
Trap column during the reverse purification. There could be several reasons explaining the 
absence of binding: 
1. The use of imidazole in the His Trap A buffer of the reverse purification. A low 
concentration of imidazole (i.e. 20 mM) is indeed usually used in the His Trap 
purification to prevent contaminants from binding to the column. However, the use 
of imidazole, even at a low concentration, in the reverse step could prevent the 
SUMO tag from binding onto the column.  
2. The histidine tag present at the N-terminal of the SUMO tag sequence could also be 
subject to degradation, preventing the SUMO tag protein from binding onto the 
column. 
3. Finally, the resin could also be saturated with the SUMO protease itself, preventing 
the tag from binding. Using stronger resins, such as the Cobalt ones, or even bigger 
columns, could be used to test this hypothesis and potentially solve the issue. 
Another reason why the SUMO tag is found in the final CBD product could be that both 
proteins interact with each other. As outlined earlier, the proteins cannot interact covalently, 
as there is no cysteine in the sequence of the SUMO tag. The interaction could then happen 
through hydrophobic or hydrophilic interactions. However, neither the addition of Tween 
(for hydrophobic interactions) nor the presence of 0.5 M NaCl abolished these interactions. 
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Another underlying question is why the SUMO tag was not separated from the CBD during 
the Ion Exchange Chromatography. This may be due to the fact that both proteins share the 
same charge at the pH used for the purification, i.e. at pH = 8.0. As the theoretical pI of the 
CBD is actually much lower (5.0), using a lower pH could have solved the issue, although the 
pI of the His6-SUMO tag is very close (5.71). This might explain why, when running Ion 
Exchange purifications on a mono Q column at pH 6.5 and 7.0, the CBD was either not 
recovered fully or none of the SUMO tag nor the CBD were binding to the column. A cation 
exchange column could have been tested to see if a different outcome was obtained. 
Overall, running a Q FF purification at pH 8.0 gave the best balance between recovery of 
protein and purity out of the different methods that were tested, which justifies why this 
method of purification was adopted.  
Is the SUMO tag affecting the binding of the CBD to gelatin? 
The presence of the his-tagged SUMO also questions whether it affects the function of the 
CBD. Even though it is hard to answer this question without having a control CBD free of any 
contaminant, several clues indicate that the function of the CBD is probably not altered by 
the presence of the cleaved his-tagged SUMO.  
First, the lane corresponding to the bound proteins on the gelatine sepharose resin (Figure 
3-18) only contains the CBD, indicating that the his-tagged SUMO might not bind to this 
substrate. This would also mean that the his-tagged SUMO is probably washed away during 
the first washes in the binding assay. This assumption is further corroborated by the fact that 
the Kd obtained for the CBD on type II gelatin is in line with previously published papers 
(20.4 nM for our construct, 50 nM for a refolded His6-CBD).  
The successful expression and purification of a functional CBD was a prerequisite for testing 
our hypothesis that MSCs coated with this protein would adhere to type II gelatin. It was 
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then decided to study in finer details the mechanism of binding of the CBD to this substrate, 
in order to design mutant proteins with higher binding affinities. 
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4. Characterisation of the binding of the CBD and its modules 
to gelatin 
 
The first chapter described the successful expression and purification of a fully functional 
CBD with a dissociation constant for type II gelatin of 20.4 nM. The next goal was to design 
mutant proteins with increased affinity for this substrate. It was, therefore, necessary to first 
characterize in finer details the mechanism of binding of the CBD and its individual modules 
to gelatin. Previously published results on the key residues involved in the binding of the CBD 
to different gelatin-like substrates will first be carefully reviewed, before applying a similar 
approach to study the binding of our proteins of interest to both type I and II gelatin. 
4.1. Introduction: Binding of the CBD to gelatin 
 
4.1.1. Role of the modules 
The resolution of the crystal structure of the full-length MMP-2 has demonstrated that each 
fibronectin module within the CBD is oriented outward of each other in a 3-pronged fishhook 
configuration 142. It was, therefore, hypothesized that this structure would enable each 
module to act as an independent binding site for gelatin. Building upon these results, it was 
shown that a recombinant CBD can bind at least two molecules of collagen at a time 141, and 
three collagen-like peptides 140. 
Further investigations on the individual domains of the CBD have shown that each of them 
is indeed able to bind to immobilized gelatin sepharose (i.e type I gelatin), with different 
affinities 144. The first module was shown to have the lowest affinity for this substrate, an 
observation which was confirmed by the fact that the protein made of the two modules 2+3 
had a higher affinity than those made of the modules 1+2 and 1+3 144. In these experiments, 
module 2 was also identified as the most potent module 144. These observations were 
confirmed by Xu et al., who measured the dissociation constants of each module for a type 
I collagen-like peptide by NMR 140. Module 1 was again identified as the weakest module, 
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with a Kd of 6.0.10-4  M, while module 2 had a slightly lower Kd than module 3 (2.8.10-4 M 
against 3.4.10-4 M for modules 2 and 3, respectively)  140.  The prevalence of modules 2 and 
3 was further confirmed by some mutational work, where alanine mutations in either 
module 2 or 3 affected the binding of the CBD to type I gelatin more than mutations in 
module 1 140. However, other authors, through similar alanine mutagenesis work, have 
attributed most of the binding properties and activity of the CBD towards type I gelatin to 
module 3 149. 
The full-length CBD was also shown to have a higher affinity for gelatin sepharose than the 
single modules or any combination of two modules 144, suggesting a cooperative mechanism. 
Interestingly, the opposite was observed for the CBD of MMP-9, where the second module 
was shown to provide most of the type I gelatin binding properties of the protein. Its 
association with the first and third module was shown to give a trimodular CBD with a lower 
affinity than the module itself 161. 
4.1.2. Key residues 
Several authors have described the key residues forming the binding pocket of each module, 
using different gelatin-like peptides. A generic collagen-like peptide, namely PPG6 ((Pro-Pro-
Gly)6) was used by a group of authors, and its binding to the individual modules as well as to 
the full-length CBD was studied by NMR 158–160,180. These data were compared to those 
obtained with a different peptide, p33-42, whose sequence, PIIKFPGDVA, corresponds to a 
segment of the propeptide of MMP-2 159, 160.  
Another group used a type I gelatin peptide with a high degree of sequence similarity with 
the residues 715 to 721 of the human alpha I chain of type I collagen. The peptide, named 
P713 has the following sequence: CGA(HYP)-GA(HYP)GSQGA, where HYP refers to 
hydroxyproline 140. It was identified in a one peptide-one bead screening method and was 
shown to interact specifically with the CBD, as well as to abrogate the binding of both the 
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CBD and MMP-2 to gelatin in a concentration-dependent manner 181. Following up on these 
early observations, authors also measured the chemical shifts caused by the binding of this 
peptide to the CBD of MMP-2 by NMR. 
The NMR results from these different groups have been pooled, and residues which were 
identified in one or several of these studies and which belong to the binding pocket of each 
module were mapped onto the protein structure of the CBD (PDB Accession Number 1CK7). 
For clarity, each module will be described and discussed individually in the following 
paragraphs (Figures 4-1 to 4-3). 
  
 
Figure 4-1: Three-dimensional surface representation of module 1 of the CBD of MMP-2 
showing the position of the residues that underwent shift changes in the presence of PPG6, 
P713 or p33-42 and that belonged to the binding pocket. Residues in red form the 
hydrophobic binding pocket, while those in grey are further away from the binding site. The 
structure shown is from the reported crystal structure of MMP-2 (PDB Accession Number 
1CK7). 
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Figure 4-2: Three-dimensional surface representation of module 2 of the CBD of MMP-2 
showing the position of the residues that underwent shift changes in the presence of PPG6, 
P713 or p33-42 and that belonged to the binding pocket. Residues in red form the 
hydrophobic binding pocket, while those in grey are further away from the binding site. The 
structure shown is from the reported crystal structure of MMP-2 (PDB Accession Number 
1CK7). 
Figure 4-3: Three-dimensional surface representation of module 3 of the CBD of MMP-2 
showing the position of the residues that underwent shift changes in the presence of PPG6, 
P713 or p33-42 and that belonged to the binding pocket. Residues in red form the 
hydrophobic binding pocket, while those in grey are further away from the binding site. The 
structure shown is from the reported crystal structure of MMP-2 (PDB Accession Number 
1CK7). 
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Overall, these studies enabled the identification of a cluster of aromatic residues forming the 
binding site in each module. This observation also confirms the prevalence of hydrophobic 
interactions for the binding of the proteins to gelatin. 
 In the study with P713, mutations were performed on residues involved in the binding in 
each of the three module, and the change in affinity towards native and denatured type I 
collagen was measured with a plate binding assay 140. The results are summed up in            
Table 4-1 below. They correlate with the chemical shifts measurements on the peptide, 
except for E321, which is located outside of the hydrophobic binding pocket.  
Table 4-1: Effect of the mutations of single residues for alanines on the affinity of the CBD 
for type I collagen and gelatin, as reported by Xu et al. 140 
Mutation Binding on both native and 
denatured type I collagen 
Module Kd values increase 
for type I gelatin 
R252A Moderate decrease Module 1 2-fold 
E321A No effect 
Module 2 
No change 
R296 A Moderate decrease No change 
F297A, Y302A 
Strong reduction 
5-fold 
Y323A,Y329A 20-fold 
R368A, W374A, Y381A Strong reduction Module 3 20-fold 
 
4.2. Aim of the chapter 
 
As previously mentioned, all of these NMR data as well as the affinities studies by Bányai et 
al. were obtained on either gelatin-like peptides or type I gelatin. As our project focuses on 
the binding of the CBD to type II gelatin, we considered it to be crucial to acquire data on 
this substrate instead. Which CBD module binds most strongly to a particular target is 
unclear, highlighting ligand-driven specificity.  Indeed previous studies had shown that the 
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relative affinity of the individual modules of the CBD was ligand-dependent 160,158,180. Module 
1, which was described as the weakest module for type I gelatin, was shown to have the 
highest affinity for PPG6, while module 3 was the weakest to bind to this peptide, but 
displayed the highest affinity towards p33-42.  Finally, module 2, which was described by 
many authors as the most potent module for type I gelatin, had the lowest affinity for p33-
42 160,158,180. 
Taking all the above results, work in this thesis will focus on understanding the binding of the 
CDB to both type I and II gelatin, in order to acquire data on more relevant substrates. 
It was first decided to study and characterize the binding of the individual modules on their 
own, as each of them has a binding site for gelatin. The aim was not only to identify the key 
residues constituting the binding site in each of the modules, but also to determine if any of 
the modules showed a stronger affinity for type II gelatin compared to the others. The 
former approach could lead to the design of single-point mutants with increased affinity, 
while the latter could enable the design of chimeric proteins made of the most potent 
module. 
Finally, we thought it was important to also test the binding of both substrates onto the full-
length CBD, in order to determine if the mechanism of binding observed with single modules 
differed within the trimodular protein. 
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4.3. Materials and Methods 
 
4.3.1. Cloning  
 
The sequence of the individual modules were as follows: 
Module 1: VKYGNADGEYCKFPFLFN GKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTM 
Module 2: ALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETA 
Module 3: MSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQG 
The synthetic DNA constructs (GeneArt, ThermoFisher) encoding for these sequences were 
codon optimised and cloned into the pOPINS vector using the ligase 
independent InFusion cloning methodology. The constructs which were generated carried 
a His6-SUMO tag, followed by a cleavage site for the SUMO protease. 
4.3.2. Expression in E.coli strains 
  
E.coli Shuffle cells were transformed with the sequenced expression plasmids. Conditions of 
expression such as the temperature and length of the production phase as well as the 
concentration of inducer were optimised on a small scale.   
On a larger scale, protein expression was carried out in 2L flasks. Cells were grown either in 
LB or minimal media at 37°C, induced for protein expression with IPTG, harvested following 
the production phase and stored at -80°C.  
4.3.3. Purification strategy  
Following cell lysis, the released recombinant protein was captured on a nickel column, 
exploiting the affinity of the hexahistidine tag for this resin. The protein was eluted with a 
gradient of imidazole, and the tag cleaved with a histidine-tagged SUMO protease (produced 
in-house).  A reverse nickel purification enabled to isolate the cleaved protein from the tag 
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and protease The polishing step was performed with an Ion Exchange column, and the mode 
of elution (either linear or step) was optimized for each protein. 
4.3.4. Characterisation  
The expressed proteins were characterised for their identity using Mass Spectrometry, as 
well as for their folding. The integrity of the three-dimensional tertiary structure was 
assessed by 2D NMR, while the number of disulfide bridges was quantified with a DTNB 
assay. Finally, their activity was tested on a gelatin sepharose resin. 
4.3.5. NMR for ligand-binding studies 
For NMR studies, proteins were expressed in either 15N-labelled minimal media or, in the 
case of module 2, in 15N-rich media purchased from Silantes, Germany. The conditions of 
expression and purification were kept the same as for production in LB. Proteins were then 
buffer exchanged into 25 mM sodium phosphate, pH 6.5 and 1D and 2D spectra of the free 
proteins were obtained. Stock solutions of type II gelatin (500 μM to 1 mM) or type I gelatin 
(485 μM) were obtained and added into the protein solutions at the following protein:gelatin 
ratios: 40:1, 20:1, 10:1, 5:1, 2:1, 1:1, 1:5 and 1:10. Spectra were acquired at each substrate 
concentration and the shift of peaks, indicative of binding, were studied. Data were analysed 
using the softwares TopSpin and CCPN. 
4.3.6. Plate binding assay 
The affinity of the single modules for both type I and type II gelatin was tested using the 
plate binding assay which was described in the previous chapter. Briefly, proteins were 
biotinylated and added over a concentration range onto gelatin-coated plates. Alkaline 
phosphatase coupled to streptavidin was added to the bound proteins, and its substrate was 
transformed into a coloured product. The absorbance of the product was used as an indirect 
indication of the amount of bound protein. 
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4.4. Results 
 
4.4.1. Expression and purification of individual modules 
The sequences of the individual modules were taken from previously published                   
papers 158,180,159. Cloning and amplification of the recombinant plasmids were performed as 
described in the Materials and Methods section, and all constructs were confirmed by 
sequencing.  
Shuffle cells were used to screen for optimal expression conditions, which appeared to be an 
overnight expression phase at 18°C, with an IPTG concentration of 200 µM (not shown). All 
modules were expressed using the same conditions. 
All three modules were successfully expressed in Shuffle cells on a large scale and purified 
following the same strategy as that used for the full-length CBD. Modules 2 and 3 were eluted 
from the Q FF Ion Exchange column with a linear gradient with no impurities (Figure 4-4). 
The first module, however, required a step elution at 12 % of IEC Buffer B (1 M NaCl, 20 mM 
Tris, pH 8) to remove contaminants. This strategy yielded two different peaks, the first one 
running at the expected size on the SDS PAGE gel (Figure 4-5). The second one contained a 
mixture of the same protein and another one with a higher molecular weight at around 15 
kDa (Figure 4-5). Although the gel was ran in both denaturing and reducing conditions, the 
possibility of the second band being a covalently-bound dimer could not be ruled out at this 
stage. All subsequent work was carried out with the protein obtained from Peak 1 of this 
chromatogram. 
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Figure 4-4: SDS PAGE gel showing the expression of the modules 2 and 3 in LB (A) and 
corresponding chromatograms (B). A - The modules 2 and 3 of MMP-2, originally carrying a 
His6-SUMO tag, were expressed in Shuffle E.coli cells and purified by nickel column and 
reverse nickel column purification, as previously described. The protein samples were then 
desalted and loaded onto a 5 mL Q FF column, and eluted with a linear gradient of sodium 
chloride. FT: Flowthrough; 4-7: Ion Exchange fractions. B - Chromatogram corresponding to 
the Ion Exchange purification of the Module 2 (left) and Module 3 (right) proteins. Fractions 
4 to 7 were loaded on the gel. Blue line: UV trace; Green line: Concentration of IEC B buffer; 
Brown line: conductivity.   
 
 
 
 
A 
B 
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Figure 4-5: SDS PAGE gels showing the expression of module 1 in LB (A) and corresponding 
chromatogram (B). Module 1 of MMP-2, originally carrying a His6-SUMO tag, was expressed 
in Shuffle E.coli cells and purified by nickel column and reverse nickel column purification, as 
previously described. The protein sample was then desalted and loaded onto a 5 mL Q FF 
column, and eluted with a step gradient of sodium chloride. This step elution led to two 
peaks, each with a different protein content. FT: Flowthrough; 3-13: Ion Exchange fractions. 
B - Chromatogram corresponding to the Ion Exchange purification of Module 1. Fractions 3 
to 13 were loaded on the first gel, and fractions 16 to 26 on the second. Blue line: UV trace; 
Green line: Concentration of IEC B buffer; Brown line: conductivity.   
A 
B 
138 
 
4.4.2. Characterisation 
4.4.2.1. Identity and structure 
 
All modules were confirmed by Mass Spectrometry. Protein samples were digested 
overnight with trypsin and ionised on a MALDI-TOF instrument. The peptides which were 
obtained had masses corresponding to those expected for the predicted cleavage for each 
module (not shown). 
The number of disulfide bridges was also quantified with a DTNB assay, which indicated the 
presence of two disulfide bridges in all the modules. This result definitely ruled out the 
possibility for the first module to be forming a covalently-bound dimer resulting in the 
additional band and peak observed on Figure 4-5. 
4.4.2.2. NMR on individual modules 
 
1H-15N 2D HSQC spectra of all 3 free modules were obtained, and their folding verified as the 
peaks of the backbone amide protons are well dispersed with all peaks showing similar 
intensities (Figures 4-6 to 4-8).  Module 1 showed a tendency to aggregate, especially for 
peaks in the central region of the spectrum (Figure 4-6), a phenomenon which was already 
observed in the original spectrum of the CBD (Figure 3-16). This might indicate that the 
module is naturally less stable, or less folded, than the other two, which do not show any 
region of overlapping peaks (Figures 4-7 and 4-8 for modules 2 and 3, respectively). Spectra 
were assigned using previously published results 159,158,180. It was decided to leave 
overlapping peaks or peaks with more than one possible assignment unassigned. 
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Figure 4-6: 1H-15N HSQC spectrum of the first module of the CBD at 298K in 25 mM sodium 
phosphate, pH 6.5, 10 % D2O, 45 µM. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
first module. The peaks were assigned to their corresponding amino acid using previously 
published results and are labelled with their one-letter amino acid code and residue number. 
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Figure 4-7: 1H-15N HSQC spectrum of the second module of the CBD at 298K in 25 mM sodium 
phosphate, pH 6.5, 10 % D2O, 20 µM. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
second module. The peaks were assigned to their corresponding amino acid using previously 
published results and are labelled with their one-letter amino acid code and residue number.  
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Figure 4-8: 1H-15N HSQC spectrum of the third module of the CBD at 298K in 25 mM sodium 
phosphate, pH 6.5, 10 % D2O, 30 µM. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
third module. The peaks were assigned to their corresponding amino acid using previously 
published results and are labelled with their one-letter amino acid code and residue number. 
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4.4.2.3. Activity: gelatin sepharose 
 
The binding of the modules to the gelatin sepharose resin was studied; both modules 2 and 
3 were able to bind (Figure 4-9). However, module 1 was mostly recovered in the unbound 
fraction (FT lane, Module 1, Figure 4-9). This could be due to the very weak binding of the 
module to this substrate, which was previously described in various papers 140,144. 
 
Figure 4-9: SDS PAGE showing the binding of the individual modules to gelatin sepharose. 
The individual modules from the Ion Exchange were tested for their ability to bind gelatin 
using a gelatin sepharose resin. 100 µL of resin was spun down, washed with ethanol and 
equilibrated before applying the samples. The mixture was spun again and the flow through 
removed (FT) before washing two times with the binding buffer (W: Washes). The bound 
proteins were mixed with 2X SDS loading buffer and loaded on the gel (Gel: gelatin-bound). 
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4.4.3. Characterisation of the binding of the single modules  
4.4.3.1. NMR ligand studies 
 
The binding of the single modules to both type I and type II gelatin was then tested in order 
to identify which residues form the binding pocket for both substrates. 
4.4.3.1.1. Binding of module 1 
 
Chemical shifts could be observed for module 1 when comparing the free protein to that 
mixed at a 2:1 (protein:gelatin) ratio, for both types of gelatin (Figures 4-10 and 4-11). Higher 
concentrations in gelatin gave more significant shifts with type II gelatin, but led to line-
broadening for many peaks with type I gelatin. For clarity and comparison purposes, it was 
therefore decided to focus on the 2:1 ratio. 
The spectra for the complexes formed using both substrates look very similar, with many of 
the same residues being affected identically (Figures 4-10 and 4-11). Residue N245 showed 
broadening in both spectra while residue K234 showed broadening following addition of type 
I gelatin only, although it was also highly affected by the binding to type II gelatin (Figures 
4-10 and 4-11). 
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Figure 4-10: 1H-15N HSQC spectra of module 1 before and after addition of type II gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free module 1 
(black) and of module 1 in the presence of type II gelatin (red) are superimposed. A 2:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument Each peak on the spectrum corresponds to an amide proton in the 
first module. The peaks were assigned to their corresponding amino acid using previously 
published results, and are labelled with their one-letter amino acid code and residue 
number. 
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Figure 4-11: 1H-15N HSQC spectra of module 1 before and after addition of type I gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free module 1 
(black) and of module 1 in the presence of type I gelatin (red) are superimposed. A 2:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
first module. The peaks were assigned to their corresponding amino acid using previously 
published results, and are labelled with their one-letter amino acid code and residue 
number. 
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In order to directly compare the results, the shift distance observed between the free and 
bound spectra was plotted for each residue, except those with broadened peaks, for both 
type I and type II gelatin (Figures 4-12 and 4-13). A threshold value had to be set for 
identifying the key residues involved in the binding. R252 was previously shown to be 
involved in the binding of module 1 on its own or within the CBD to all the different gelatin-
like peptide substrates that were described in the introduction of this chapter 140,158,160. It is 
therefore very likely that this residue is involved in the binding to type I gelatin. In our 
analysis, its chemical shift was 0.01935, which was the 15th biggest. It was therefore decided 
to set the threshold for type I gelatin at 0.019, in order to include this residue as a key one 
for the binding of the CBD to type I gelatin. The threshold for type II gelatin was then 
adjusted accordingly so that the ratio (maximum shift distance:threshold) was constant 
between both analyses, giving a threshold value of 0.00825.  
From these figures (4-12 and 4-13), we could observe that many of the same residues were 
undergoing the most important shifts for both substrates: K234 (broadened for type I 
gelatin), F239, N240, G241, K242, E243, Y244, C247, T248, R252, D254, L257, W258, T261, 
F265 and K267. However, a few residues reached the set threshold for only type II gelatin: 
F237, G251, G255, N264 and G269. This could indicate a slightly different mode of binding 
for module 1 on type I and type II gelatin. 
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Figure 4-12: Magnitude of the chemical shift changes for the residues of the first module in 
the presence of type II gelatin at a protein:gelatin ratio of 2:1. Chemical shifts distances were 
calculated in the CCPN analysis software. A threshold for significant chemical shift distance 
was set at 0.00825. 
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Figure 4-13: Magnitude of the chemical shift changes for the residues of the first module in 
the presence of type I gelatin at a protein:gelatin ratio of 2:1. Chemical shifts distances were 
calculated using the CCPN analysis software. A threshold for significant chemical shift 
distance was set at 0.019. 
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The residues identified in this experiment were then mapped onto the structure of the CBD 
in Pymol, in red for those common to both substrates, and in brown for those involved in the 
binding to type II gelatin only (Figure 4-14). Most of them were located on or around the 
binding pocket of the module, confirming the validity of the results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14: Three-dimensional surface representation of the CBD of MMP-2 showing the 
position of the residues in module 1 that underwent shift changes in the presence of type I 
and type II gelatin at a 2:1 protein:gelatin ratio. Residues undergoing changes with both 
substrates are indicated in red, while residues affected by the binding to type II gelatin only 
are indicated in brown. The structure shown is from the reported crystal structure of MMP-
2 (PDB Accession Number 1CK7).  
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4.4.3.1.2. Binding of module 2 
 
Chemical shifts could be observed for module 2 when comparing the free protein to that 
mixed at a 10:1 (protein:gelatin) ratio, for both type I and II gelatin (Figures 4-15 and 4-16). 
More significant shifts were observed at higher gelatin concentrations, with many important 
residues showing line-broadening as a consequence of their involvement in the binding (not 
shown). For clarity and comparison purposes, it was therefore decided to focus on the 10:1 
ratio. 
The spectra for both substrates looked very similar, with many of the same residues being 
affected identically. Residues Y323, G309, G313 and T319 showed broadening in both 
spectra, while R310 and G299 showed broadening following type I and II gelatin binding 
respectively, although they were also highly affected by the binding of the other substrate 
(Figures 4-15 and 4-16). 
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Figure 4-15: 1H-15N HSQC spectra of module 2 before and after addition of type II gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free module 2 
(black) and of module 2 in the presence of type II gelatin (red) are superimposed. A 10:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
second module. The peaks were assigned to their corresponding amino acid using previously 
published results, and are labelled with their one-letter amino acid code and residue 
number. 
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Figure 4-16: 1H-15N HSQC spectra of module 2 before and after addition of type I gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free module 2 
(black) and of module 2 in the presence of type I gelatin (red) are superimposed. A 10:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
second module. The peaks were assigned to their corresponding amino acid using previously 
published results, and are labelled with their one-letter amino acid code and residue 
number. 
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In order to directly compare the results, the shift distance observed between the free and 
bound spectra were plotted for each residue, except those with broadened peaks (Figures  
4-17 and 4-18). A threshold value had to be set for identifying the key residues involved in 
the binding. Y302 was previously shown to be involved in the binding of module 2 on its own 
and within the CBD to all but one of the different gelatin-like peptide substrates that were 
described in the introduction of this chapter 140,180,160. It is therefore very likely that this 
residue is involved in the binding to type I gelatin. In our analysis, its chemical shift value was 
0.04782, which was the 15th highest. It was therefore decided to set the threshold for type I 
gelatin at 0.047, in order to include this residue as a key one for the binding of the CBD to 
type I gelatin. The threshold for type II gelatin was adjusted accordingly so that the ratio 
(maximum shift distance:threshold) was constant between both analyses, giving a threshold 
value of 0.03268.  
From these figures (Figures 4-17 and 4-18), we could observe that the exact same residues 
were undergoing the most important shifts for both types of gelatin: M282, G284, N285, 
R296, F297, Q298, G299 (broadened for type II gelatin binding), T306, R310 (broadened for 
type I gelatin), Y314, W316, E321, D326, Y329 and C332. Only residues R315 and Y302 
reached the set threshold for only type I gelatin, but they were also affected by the binding 
of the other substrate. Overall, it was therefore shown that module 2 binds to type I and 
type II gelatin with the same mechanism, and through the same residues. 
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Figure 4-17: Magnitude of the chemical shift changes for the residues of the second module 
in the presence of type II gelatin at a protein:gelatin ratio of 10:1. Chemical shifts distances 
were calculated using the CCPN analysis software. A threshold for significant chemical shift 
distance was set at 0.03268 
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Figure 4-18: Magnitude of the chemical shift changes for the residues of the second module 
in the presence of type I gelatin at a at a protein:gelatin ratio of 10:1. Chemical shifts 
distances were calculated in the CCPN analysis software. A threshold for significant chemical 
shift distance was set at 0.047. 
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The residues identified in both experiments were then mapped onto the structure of the CBD 
in Pymol. Most of them were located on or around the binding pocket of the second module, 
confirming the validity of the results (Figure 4-19). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-19: Three-dimensional surface representation of the CBD of MMP-2 showing the 
position of the residues in module 2 that underwent shift changes in the presence of both 
type I and type II gelatin at a 10:1 protein:gelatin ratio. Residues undergoing changes are 
indicated in red. The structure shown is from the reported crystal structure of MMP-2 (PDB 
Accession Number 1CK7). 
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4.4.3.1.3. Binding of module 3 
 
Chemical shifts could be observed for module 3 when comparing the free protein to that 
mixed at a 1:5 (protein:gelatin) ratio, for type II gelatin (Figure 4-20). As the concentration 
of the type I gelatin stock was lower, only a 1:4 (protein:gelatin) ratio could be reached, and 
this experiment was used to compare the results (Figure 4-21).  
The spectra for both substrates looked very similar, with many of the same residues being 
affected identically. Residue G367 showed broadening in both spectra, while residues L356 
(not shown) and R368 showed broadening following type I gelatin addition only, although 
they were also highly affected by the binding of type II gelatin (Figures 4-20 and 4-21). 
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Figure 4-20: 1H-15N HSQC spectra of module 3 before and after addition of type II gelatin 
at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free 
module 3 (black) and of module 3 in the presence of type II gelatin (red) are 
superimposed. A 1:5 protein:gelatin molar ratio was used. The spectra were acquired on 
a 800 Hz Bruker spectrometer instrument.   Each peak on the spectrum corresponds to 
an amide proton in the third module. The peaks were assigned to their corresponding 
amino acid using previously published results, and are labelled with their one-letter 
amino acid code and residue number. 
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Figure 4-21: 1H-15N HSQC spectra of module 3 before and after addition of type I gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free module 3 
(black) and of module 3 in the presence of type I gelatin (red) are superimposed. A 1:4 
protein:gelatin molar ratio was used. The spectra were acquired on a 800 Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in 
the third module.  The peaks were assigned to their corresponding amino acid using 
previously published results, and are labelled with their one-letter amino acid code and 
residue number. 
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In order to directly compare the results, the shift distance observed between the free and 
bound spectra was plotted for each residue, except those with broadened peaks (Figures      
4-22 and 4-23).  
A threshold value had to be set for identifying the key residues involved in the binding. W387 
was previously shown to be involved in the binding of module 3 on its own and within the 
CBD to one gelatin-like peptide substrate, namely PPG6 159,160. In addition, the residue lies 
within the binding pocket of this module, as outlined in the introduction of this chapter. It is 
therefore very likely that this residue is involved in the binding to type I gelatin. In our 
analysis, its chemical shift value was 0.041, which was the 21st highest. It was therefore 
decided to set the threshold for type I gelatin at 0.040, in order to include this residue as a 
key one for the binding of the CBD to type I gelatin. The threshold for type II gelatin was 
adjusted accordingly so that the ratio (maximum shift distance:threshold) was constant 
between both analyses, giving a threshold of 0.03823. 
From these figures (Figures 4-22 and 4-23) we could observe that the exact same residues 
were undergoing the most important shifts for both type I and type II gelatin: G342, F353, 
F355, L356 (broadened for type I gelatin), Y360, T364, A366, R368 (broadened for type I 
gelatin), D370, W374, C375, T377, A379, Y381, D382, D383, D384, R385, W387, G388, F389, 
C390. Only one residue reached the set threshold for only one of the two substrates: M373 
for type I gelatin. However, it was also affected by the binding of the module to the other 
substrate. Overall, it was therefore shown that module 3 binds to type I and type II gelatin 
with the same mechanism, and through the same residues. 
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Figure 4-22: Magnitude of the chemical shift changes for the residues of the third module in 
the presence of type II gelatin at a protein:gelatin ratio of 1:5. Chemical shifts distances were 
calculated using the CCPN analysis software. A threshold for significant chemical shift 
distance was set at 0.03823. 
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Figure 4-23: Magnitude of the chemical shift changes for the residues of the third module in 
the presence of type I gelatin at a protein:gelatin ratio of 1:4. Chemical shifts distances were 
calculated using the CCPN analysis software. A threshold for significant chemical shift 
distance was set at 0.04. 
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The residues identified in both experiments were then mapped onto the structure of the CBD 
in Pymol (Figure 4-24). Most of them were located on or around the binding pocket of the 
third module, confirming the validity of the results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-24: Three-dimensional surface representation of the CBD of MMP-2 showing the 
position of the residues in module 3 that underwent shift changes in the presence of both 
type I and type II gelatin at a 1:5 and 1:4 protein:gelatin ratio, for type II and type I gelatin, 
respectively. Residues undergoing changes are indicated in red. The structure shown is from 
the reported crystal structure of MMP-2 (PDB Accession Number 1CK7). 
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4.4.3.1.4. Analysis of titration data 
 
The initial aim of the NMR experiments with the single modules was not only to identify the 
residues forming the binding site, but also to determine a dissociation constant for each 
module. However, the binding constants for all three modules appeared to be too tight for 
the dissociation constants to be accurately determined using ligand-induced chemical shift 
changes in increasing ligand concentrations until saturation is reached. As the anticipated 
Kds are in the micromolar range, it would be necessary to use lineshape fitting analyses of 
the NMR line-broadening. It was, therefore, decided to test the binding of the modules to 
type I and II gelatin on the plate binding assay in order to get a quantitative measurement 
of their affinities for these substrates. 
4.4.3.2. Binding assay 
 
The plate binding assay described earlier was then developed in order to quantify the 
affinities of the individual modules for type II gelatin. Skin gelatin was also included as a 
control of the behaviour of the modules on a gelatin mostly composed of type I. The 
apparent Kd for all proteins and their binding curves are presented in Figure 4-25. It was 
shown that module 1 binds approximatively three times better to type II than to skin gelatin, 
while module 3 binds three times better to skin gelatin compared to type II gelatin, although 
these differences were not significant. Finally, module 2 was shown to bind equally well to 
both types of gelatin. These data, combined to those obtained on the gelatin sepharose 
column (i.e. type I gelatin), suggested that module 1 could be specific for binding to type II 
gelatin, while module 3 would bind more preferentially to type I gelatin.  
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Overall, performing these experiments on the single modules has enabled us to identify the 
key residues belonging to the binding sites of each module, as well as to determine the 
affinities of each module for both type I and type II gelatin. However, it seemed important 
to confirm these results on the full-length CBD protein, as our end goal was to design a 
trimodular protein with a higher affinity for type II gelatin than the CBD itself. We therefore 
expressed and purified an 15N labelled CBD and studied its binding to both type I and type II 
gelatin by NMR. 
Figure 4-25: Binding of the individual modules of the CBD to type II and type I gelatin 
plates. The binding assay relies on the use of plates coated with either type II or skin 
gelatin (thermodenatured collagen). The biotinylated proteins were added over a 
concentration range before adding streptavidin-coupled alkaline phosphatase. Its 
substrate, namely PNPP, was added and converted into a coloured product which 
formation was measured by absorbance at 405 nm. Examples of representative binding 
curves are shown for each module. Error bars represent standard deviations of three 
replicates. The apparent Kd values for each module on each substrate is indicated in the 
table (Kd ± Standard error). The differences in the affinity of each module for the two 
substrates were not significant (paired two-tailed t-test, p values of 0.1488, 0.8579 and 
0.1073 for module 1, module 2 and module 3, respectively). 
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4.4.4. Characterisation of the binding of the full-length CBD by NMR 
196 spectra of the free protein at 50 μM in 25 mM sodium phosphate buffer, pH 6.5 were 
acquired with a 800 kHz Bruker spectrometer before adding the ligand at a 33:1 
(protein:gelatin) ratio (Figure 4-26). 
Disappearing peaks were observed following the addition of the ligand, indicating their 
involvement in the binding to type II gelatin (Figure 4-26). For clarity, the spectra in Figure 
4-26 was divided into four quadrants which are zoomed in in Figures 4-27 to 4-30. 
Residues with broadened peaks included M282, N285, G288, Q289, F297, G299, Y302, C305, 
E308, G309, D312, G313, Y314, W316, T319, E321, Y323, D326, Y329 and G330. Residues 
F280, E287, F295, R310, R315, C317, D324, R325, K327, G330 and F331 were also shown to 
undergo chemical shifts upon the addition of the ligand (Figures 4-27 to 4-30). They were 
mapped onto the PDB structure of the CBD (Accession Number 1CK7) and belonged to the 
identified binding site of the second module (Figure 4-31). 
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Figure 4-26: 1H-15N HSQC spectra of the CBD before and after addition of type II gelatin at 
298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free CBD (black) 
and of the CBD in the presence of type II gelatin (red) are superimposed. A 33:1 
(protein:gelatin) molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in the 
CBD. Broadening of the peaks, leading to their disappearance, upon addition of the ligand 
indicates that the residues corresponding to these peaks are involved in the binding of the 
protein to the substrate. The peak within the square is one example of peaks showing 
broadening: there is no corresponding red peak. 
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Figure 4-27. Part A of Figure 4-26. 1H-15N HSQC spectra of the CBD before and after addition 
of type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of 
ligand-free CBD (black) and of the CBD in the presence of type II gelatin (red) are 
superimposed. A 33:1 (protein:gelatin) molar ratio was used. The spectra were acquired on 
a 800Hz Bruker spectrometer instrument. Each peak on the spectrum corresponds to an 
amide proton in the CBD. Broadening of the peaks, leading to their disappearance, upon 
addition of the ligand indicates that the residues corresponding to these peaks are involved 
in the binding of the protein to the substrate. The peaks were assigned to their corresponding 
amino acid using previously published results, and are labelled with their one-letter amino 
acid code and residue number. 
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Figure 4-28. Part B of Figure 4-26. 1H-15N HSQC spectra of the CBD before and after addition 
of type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of 
ligand-free CBD (black) and of the CBD in the presence of type II gelatin (red) are 
superimposed. A 33:1 (protein:gelatin) molar ratio was used. The spectra were acquired on 
a 800Hz Bruker spectrometer instrument. Each peak on the spectrum corresponds to an 
amide proton in the CBD. Broadening of the peaks, leading to their disappearance, upon 
addition of the ligand indicates that the residues corresponding to these peaks are involved 
in the binding of the protein to the substrate. The peaks were assigned to their corresponding 
amino acid using previously published results, and are labelled with their one-letter amino 
acid code and residue number. 
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Figure 4-29: Part C of Figure 4-26. 1H-15N HSQC spectra of the CBD before and after addition 
of type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of 
ligand-free CBD (black) and of the CBD in the presence of type II gelatin (red) are 
superimposed. A 33:1 (protein:gelatin) molar ratio was used. The spectra were acquired on 
a 800Hz Bruker spectrometer instrument. Each peak on the spectrum corresponds to an 
amide proton in the CBD. Broadening of the peaks, leading to their disappearance, upon 
addition of the ligand indicates that the residues corresponding to these peaks are involved 
in the binding of the protein to the substrate. The peaks were assigned to their corresponding 
amino acid using previously published results, and are labelled with their one-letter amino 
acid code and residue number. 
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Figure 4-30: Part D of Figure 4-26. 1H-15N HSQC spectra of the CBD before and after addition 
of type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of 
ligand-free CBD (black) and of the CBD in the presence of type II gelatin (red) are 
superimposed. A 33:1 (protein:gelatin) molar ratio was used. The spectra were acquired on 
a 800Hz Bruker spectrometer instrument. Each peak on the spectrum corresponds to an 
amide proton in the CBD. Broadening of the peaks, leading to their disappearance, upon 
addition of the ligand indicates that the residues corresponding to these peaks are involved 
in the binding of the protein to the substrate. The peaks were assigned to their corresponding 
amino acid using previously published results, and are labelled with their one-letter amino 
acid code and residue number. 
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Figure 4-31: Three-dimensional surface representation of the CBD of MMP-2 showing the 
position of the residues that underwent peak broadening or shift changes in the presence of 
type II gelatin at a 33:1 protein:gelatin ratio. Residues undergoing peak broadening are 
indicated in red while residues undergoing shift changes are indicated in brown. The 
structure shown is from the reported crystal structure of MMP-2 (PDB Accession Number 
1CK7) 
 
These data on the CBD showed that module 2 was the strongest module for binding to type 
II gelatin. When the same experiment was performed with type I gelatin, the exact same 
residues were affected upon the addition of this ligand (not shown). These results suggest 
that module 2 is the strongest, within the CBD, for binding to either type I or type II gelatin, 
providing a strong affinity, but no specificity for one type of gelatin over the other. 
Unfortunately, higher concentrations of either type I or type II gelatin did not enable to 
detect shifts in either module 3 or module 1 (not shown), meaning that the specificity of 
these modules for each type of gelatin could not be tested in the full-length protein. 
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4.5. Discussion 
 
4.5.1. General conclusion 
This chapter has described the expression, purification and the characterisation of the 
binding of each of the individual modules of the CBD to both type I and type II gelatin. All 
three modules were successfully expressed in Shuffle cells and purified following the method 
established for the CBD. Characterisation of the proteins confirmed their proper folding, with 
the DTNB assay showing the presence of two disulfide bridges in each module, and 2D NMR 
spectra confirming the correct tertiary structure of each module.  Modules 2 and 3 were also 
shown to be able to bind to gelatin sepharose, although module 1 was mostly recovered in 
the flowthrough. This observation corroborates with the low affinity of this module for type 
I gelatin, which has been reported by others 140,144. The functionality of this protein was later 
demonstrated when it was shown to bind to gelatin by NMR. 
NMR ligand binding studies enabled to identify residues involved in the binding to gelatin for 
each module. Most of them were shown to belong to the hydrophobic binding pockets of 
the modules, and also correlated with residues identified with collagen-like peptides in 
previous publications. Overall, module 2 showed the exact same mechanism of binding for 
type I and type II gelatin, and similar dissociation constants on the plate binding assay. Slight 
differences in the identity of the residues involved in the binding to each substrate could be 
observed for module 3 and module 1: residue M373 in module 3 was slightly more affected 
by the binding to type I gelatin, while residues F237, G251, G255, N264 and G269 in module 
1 were more affected by the binding onto type II gelatin. These differences could be due to 
experimental errors, but the fact that module 1 seemed to have a slightly higher affinity for 
type II gelatin, while module 3 seemed more specific to type I in the plate binding assay 
further reinforces the hypothesis that these modules could each be specific to one type of 
gelatin. 
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Following up on these observations on the individual modules, it was then decided to 
perform the same NMR ligand binding studies with the full-length CBD. These experiments 
showed that both type I and II gelatin bind the CBD primarily through its second module. 
More residues were affected by the binding in this configuration than when testing module 
2 alone, which could be explained by the flexibility of the domains within the CBD.  
To the best of our knowledge, this is the first time that NMR has been used to characterise 
the binding of the CBD of MMP-2 to type II gelatin. Data were available on type I gelatin like 
peptides, but the study on the full-length ligand had not been done before either. 
4.5.2. Future work 
How do the residues identified in these experiments compare to previously published 
results? 
Several collagen-like peptides have been tested against either single modules or the full-
length CBD in order to identify key residues involved in the binding. As outlined in the 
introduction of this chapter, it seemed crucial to test the binding of our proteins on more 
relevant substrates, which is why we carried out the above mentioned experiments on type 
I and type II gelatin. 
However, it is interesting to compare the results obtained in all these different experiments. 
Below are the representations of the single modules used in the introduction of this chapter 
(Figure 4-32). All of the residues in red and grey, which were identified in previous 
experiments, were also shown to be involved in the binding of type I and type II gelatin, 
except for T250, F273 (not assigned), and residues in grey in module 1, and N358 in module 
3. Residues F295 and D312 in module 2 did not reach the set threshold, but were affected 
by the binding of each ligand and their peaks broadened when looking at the full-length CBD.  
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Residues in cyan have been added to this figure (Figure 4-32). Those left unlabelled are 
residues which had been previously shown to be shifting upon the addition of some or all of 
the gelatin-like peptides, and which also showed significant shifts in our experiments. Most 
of them do not belong to the hydrophobic pocket, meaning that their shifts must be a 
consequence of a change in conformation instead of a direct involvement in the binding.  
Finally, residues in cyan which are labelled are those which had never been reported to be 
involved in the binding with any of the peptides, but which showed some important shifts 
following the binding of either type of gelatin in our experiment. Again, most of them are 
located at the back of the binding pocket, which means that their shift must originate from 
a further change in conformation of the modules upon the binding of gelatin. However, it is 
interesting to note that other residues lie close to the hydrophobic pocket, such as G269 in 
module 1, Q298 in module 2 and G342 in module 3. It is particularly interesting to note that 
G269 was shown to be only involved in the binding to type II gelatin in our experiment, a 
substrate which had never been tested before. 
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Figure 4-32: Three-dimensional surface representation of module 1 (A), module 2 (B) and 
module 3 (C) of the CBD of MMP-2 showing the position of the residues that underwent shift 
changes in the presence of collagen-like peptides and type I and type II gelatin. Residues 
undergoing changes in all situations are pictured in red and grey. Residues in cyan which are 
unlabelled were identified in previously published papers as well as in our experiment. 
Labelled residues in cyan were identified only in our experiments. The structures shown are 
from the reported crystal structure of MMP-2 (PDB Accession Number 1CK7). Left and right 
structures are front and back, respectively. 
A 
B 
C 
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Residues which showed some of the most important shifts following the addition of gelatin 
in our experiments were also identified as key residues by authors who mutated them for 
alanines. This includes residues Y302, Y323, D326 and Y329, which were shown to be critical 
for structure integrity 168 and Y314, which was shown to be involved in the binding 168. 
Another paper reported that mutations of both W316 and W374 by alanines abrogated the 
binding of the CBD to both type I gelatin and collagen 147. Finally, as outlined in the 
introduction of this chapter, the mutations  R252A, R296A, F297A, Y302A, Y323A, Y329A, 
R368A, W374A and Y381A all affected the binding of the CBD to type I gelatin 140. Again, 
these residues were all involved in the binding to both types of gelatin in our experiment. 
Can the modules of the CBD be specific to different substrates? 
As mentioned earlier, we observed that module 1 could bind better to type II gelatin in a 
plate binding assay, while module 3 seemed to bind with a slightly higher affinity to type I 
gelatin. Considering the high degree of sequence identity between the modules (58.5 % for 
modules 1 and 2, 55.7 % for modules 1 and 3, 58.9 % for modules 2 and 3), these differences 
could be surprising. However, previously published results have identified differences in the 
relative affinities of the modules for various substrates, suggesting that specificity could be 
possible.  
As mentioned in the introduction of this chapter, the first module was often described as the 
weakest of the three for its binding to type I gelatin, but it had the highest reported Ka for 
binding to the PPG6 peptide 160,159. Similarly, module 3 had the smallest affinity for the PPG6 
peptide, but the highest for a peptide with a different sequence, namely p33-42 160,159. In a 
different context, the first module of the CBD was also shown to bind with the highest affinity 
to fatty acids, enabling them to inhibit the gelatinolysis activity of MMP-2 182. Taken together, 
these data confirm that the modules, in spite of their sequence similarity, can have different 
affinities towards the same substrate.  
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Another argument in favour of module specificity lies in the CBD of MMP-9. It was shown 
that the second module on its own binds better to gelatin than the full-length CBD 161. The 
maintenance of the other two modules through natural selection must mean that they are 
required to bind to other substrates. Other matrix components, such as elastin, were 
hypothesised as potential targets for the first and third modules of the CBD of MMP-9 183.  
When mapping the different residues involved in the binding onto the alignment of the three 
modules (Figure 4-33), we could observe that residues belonging to the hydrophobic pockets 
were mostly conserved in each module. Residues F237, G251, G255 in module 1 
(corresponding to residues F18, G32, G36 in Figure 4-33 below), which showed a preference 
for type II gelatin over type I in module 1, are also conserved in all three modules, while 
N264 in module 1 (N45 below) is conserved in the third one. It is therefore unlikely that these 
residues can confer any specificity for one substrate over the other in module 1. However, 
residues G269 (G50 in Figure 4-33) in module 1 and M373 (M38 in Figure 4-33)  in module 3, 
which both showed preference for type II and type I gelatin, respectively, are not conserved 
in the other two modules, and could therefore contribute to gelatin specificity. However, 
M373 was shown to be present at the back of the binding pocket, and might be involved in 
a conformational change more than in a direct binding with the substrate. 
 
Considering all of these aspects, and based on our findings, we think it would be possible 
that the second module of the CBD of MMP-2 provides strong affinity towards both type I 
and type II gelatin, while module 1 would be more specific to type II gelatin, and module 3 
Figure 4-33: Alignment of modules 1, 2 and 3 of the CBD highlighting the residues involved 
in the binding to type I and type II gelatin. Residues common to both substrates are 
highlighted in red, while residues showing higher shifts for type II gelatin are in pink, and 
those showing higher shifts for type I gelatin in grey. 
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to type I.  In order to investigate this hypothesis further, and with the aim of generating more 
potent proteins than the CBD, it was therefore decided to design the chimeric proteins 111, 
222 and 333 and to test their affinities for type I and type II gelatin. 
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5. Generation of more potent gelatin binding proteins 
5.1. Introduction: chimeric proteins 
 
Proteins are often subdivided into domains or modules, which are autonomous both 
functionally and structurally 184. The study of these subdomains has been made easier with 
the development of genetic engineering techniques, which have enabled study of the 
function of the domains individually, as well as to generate chimeric proteins 184. 
A common example is antibodies, which are Y-shaped proteins made of an effector domain 
(the Fc), and two antigen binding domains (the Fabs), both directed towards the same      
target 185. Swapping these independent fragments has enabled the generation of new 
versions of antibodies with enhanced functions. One example is bispecific antibodies, where 
the Fab of two different antibodies are linked to the Fc of another, generating a new antibody 
with an unaltered structure and the ability to bind to two different antigens at the same     
time 185,186. Other variants have also emerged with new combinations of the different 
domains, leading to constructs such as TriFabs, which contain three antigen-binding regions, 
fused at their C-terminus by a peptide linker 187. The latest advance in the field has seen the 
fusion of an antigen-binding region of a monoclonal antibody to the transmembrane domain 
of a T-cell, enabling the elimination of cancerous cells through the recognition of their 
tumour-associated antigen by the chimeric T-cell receptor 188. 
However, not all domains of all proteins are as interchangeable as those found in antibodies. 
Domain-domain or module-module interactions are often observed, and can influence both 
the structure and the function of the protein 184. Care should therefore be taken when 
designing chimeric proteins in order to preserve the overall structure of the original       
protein 184.  
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As demonstrated in the previous chapter, we identified that module 2 is the strongest at 
binding to both type I and type II gelatin within the CBD. Other results showed that modules 
1 and 3 could be specific for type II and type I gelatin, respectively. Finally, the CBD was 
previously shown to have a much tighter affinity than the single modules 144, which suggests 
a cooperative mechanism between the modules within the trimodular construct. We decided 
to exploit these observations by designing chimeric proteins made of new combinations of 
the individual modules, generating the chimeric proteins 111, 222 and 333. The goal was to 
design these proteins with the same fold as the original CBD in order to preserve the function 
of the protein as well as the cooperative mechanism between modules. Additionally, as each 
module constitutes a binding site, we wanted to investigate whether trimodular proteins 
made of the same module would conserve the specificity of the modules observed earlier. 
Our hypothesis was that 222 would provide a protein with a tight affinity for both types of 
gelatin, while 111 and 333 would have a high affinity for type II and type I gelatin, 
respectively. 
5.2. Materials and Methods 
 
5.2.1. Designing of chimeric proteins 
All three proteins were designed in an attempt to maintain the module-module interactions 
present in the CBD. These interactions were studied using the PISA (Proteins, Interfaces, 
Structures and Assemblies) online tool. The residues involved in either hydrophobic, 
aromatic-aromatic, aromatic-sulphur, ionic or cation-pi interactions, as well as those forming 
hydrogen bonds, were conserved as in the original CBD sequence, as shown in blue in Figure 
5-1. The modules are highlighted in red, and the linkers in black. 
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Figure 5-1: Sequences of the chimeric proteins 111, 222 and 333. The residues which might 
be involved in intramolecular interactions, and which were therefore left as in the native 
CBD, are shown in blue. The modules are highlighted in red, and the linkers in black. 
5.2.2. Cloning  
 
The synthetic DNA constructs (GeneArt, ThermoFisher) encoding for these sequences were 
codon optimised and cloned into the pOPINS vector using the ligase 
independent InFusion cloning methodology. The constructs which were generated carried 
a His6-SUMO tag, followed by a cleavage site for the SUMO protease. 
5.2.3. Expression in E.coli strains 
  
E.coli Shuffle cells were transformed with the sequenced expression plasmids. Conditions of 
expression such as the temperature and length of the production phase as well as the 
concentration of inducer were optimised on a small scale.   
On a larger scale, protein expression was carried out in 2L flasks. Cells were grown either in 
LB or minimal media at 37°C, induced for protein expression with IPTG, harvested following 
the production phase and stored at -80°C.  
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As 111 was shown to be highly insoluble, the refolding protocol described by Steffensen et 
al. 141 was tested. Briefly, the insoluble pellet was washed, solubilized in 6M Guanidine 
Hydrochloride and incubated for 1 hour at room temperature. The non-dissolved aggregates 
were removed by centrifugation while the supernatant was dialysed from 2 hours to 
overnight against aerated 0.1 M sodium borate buffer, pH 10.0. The sample was then 
dialysed against chromatography buffer and subjected to the same purification protocol as 
for the other two constructs. 
5.2.4. Purification strategy  
Following cell lysis, the released recombinant protein was captured on a nickel column, 
exploiting the affinity of the hexahistidine tag for this resin. The protein was eluted with a 
gradient of imidazole, and the tag cleaved with a histidine-tagged SUMO protease (produced 
in-house).  A reverse nickel purification enabled the isolation of the cleaved protein from the 
tag and the protease. The polishing step was performed with an Ion Exchange column, and 
the mode of elution (either linear or step) was optimized for each protein. 
5.2.5. Characterisation  
The expressed proteins were characterised for their identity using intact mass analysis by 
Mass Spectrometry (ElectroSpray Ionisation), as well as for their folding, as the number of 
disulfide bridges was quantified with a DTNB assay. The activity of 222 and 333 was also 
tested on a gelatin sepharose resin. Finally, the integrity of the three-dimensional tertiary 
structure of 222 was assessed by 2D NMR. 
5.2.6. Plate binding assay 
The affinity of the constructs for both type I and type II gelatin was tested using the plate 
binding assay which was described in the previous chapter. Briefly, proteins were 
biotinylated and added over a concentration range onto gelatin-coated plates. Alkaline 
phosphatase coupled to streptavidin was added to the bound proteins, and its substrate was 
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transformed into a coloured product. The absorbance of the product was used as an indirect 
indication of the amount of bound protein. 
5.2.7. Binding of 222 to type II gelatin by NMR 
For NMR purposes, 222 was expressed in 15N-labelled minimal media. The conditions of 
expression and purification were kept the same as for production in LB. The protein was then 
buffer exchanged into 25 mM NaP, pH 6.5 and 1D and 2D spectra of the free proteins were 
obtained. Type II gelatin was then added at protein:gelatin ratios of 40:1 and 20:1. Spectra 
were acquired at each substrate concentration and the shift or broadening of peaks, 
indicative of binding, were observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
5.3. Results 
 
5.3.1. Small scale screening for optimal conditions of expression 
E.coli Shuffle cells were transformed with the sequence-checked pOPINS vector containing 
the inserts for 111, 222 or 333.  The concentration of the inducer, the temperature of growth 
and the length of the production phase were screened to find optimal conditions for protein 
expression. Cells were cultured at 37°C before induction, induced with a range of 
concentrations in IPTG (20 – 1000 µM), and then either left for a further 5 hours at 25°C 
(Figure 5-2, B and D) or overnight at 18°C (Figure 5-2, A and C).  
Results showed that 111 was poorly expressed, with both low levels of expression and a high 
degree of insolubility (Figure 5-2, A and B). Concentrations in IPTG of 200 and 1000 µM and 
an expression phase at 25°C for 5 hours seemed to give the highest ratio of soluble : insoluble 
protein (Figure 5-2, B), and both of these were selected for a scale-up.  
The constructs 222 and 333 showed higher levels of expression and solubility (Figure 5-2, C 
and D, respectively), with around 50 % of 222 recovered in the pellet (Figure 5-2, C).  A 
production at 18°C induced with 1 mM was selected for 222, while a production at 25°C 
induced with 800 µM of IPTG was scaled-up for 333, as these conditions gave the highest 
ratios of soluble over insoluble protein. 
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C D 
Figure 5-2: SDS PAGE showing the screening for expression of the His6-SUMO-111 (A and B), 
His6-SUMO-222 (C), and His6-SUMO-333 (D) in LB. E.coli Shuffle cells were transformed with 
plasmids encoding for either 111, 222 or 333, each carrying a His6-SUMO tag. Cells were 
grown in 10 mL LB until reaching an OD (600 nm) of 0.6. Cells were induced with various 
concentrations of IPTG overnight at 18°C (A and C), or for 5 hours at 25°C (B and D). Cells 
were then lysed and the soluble (S) fraction was subjected to a nickel purification. The 
insoluble fraction was solubilised in 8M urea and loaded on the gel (P: Pellet). The same 
conditions were tested for each construct, but only a subset is presented in this figure.  
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5.3.2. Large scale expression with the optimised conditions 
The selected conditions were scaled-up to 2L flasks. 222 (Figure 5-3) and 333 (Figure 5-4) 
were successfully expressed, although 222 showed a high level of insolubility (Figure 5-3, gel 
A, lane I). Both proteins were purified as previously described for the CBD and its individual 
modules, with a linear elution from the Ion Exchange Q column (Figure 5-3, B and Figure        
5-4, B). 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 5-3: Expression and purification of 222. A-The chimeric protein 222, originally 
carrying a His6-SUMO tag, was expressed in Shuffle E.coli cells and purified by nickel column 
and reverse nickel column purification, as previously described. B-The protein sample was 
then desalted and loaded onto a 5 mL Q FF column, and eluted with a linear gradient of 
sodium chloride. L: Lysate; S: Soluble; I: Inclusion Bodies; FT: Flowthrough; PDS: Post-Dialysis 
soluble; FTD: Flowthrough Desalt; Er: Elution Reverse. FTi: Flowthrough Ion Exchange. The 
numbers labelled on the gels correspond to the fractions of the His Trap chromatogram 
(Part A) and of the Ion Exchange one (Part B). On the chromatograms: Blue line: UV trace; 
Green line: Concentration of IEC B buffer; Brown line: conductivity. 
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Figure 5-4: SDS PAGE gel showing the expression of the chimeric protein 333 in LB (A) and 
corresponding chromatogram (B). A-The 333 protein, originally carrying a His6-SUMO tag, 
was expressed in Shuffle E.coli cells and purified by nickel column and reverse nickel column 
purification, as previously described. The protein sample was then desalted and loaded onto 
a 5 mL Q FF column, and eluted with a linear gradient of sodium chloride. FT: Flowthrough; 
6-13: Ion Exchange fractions. B - Chromatogram corresponding to the Ion Exchange 
purification of 333. Fractions 6 to 13 were loaded on the gel. Blue line: UV trace; Green line: 
Concentration of IEC B buffer; Brown line: conductivity. 
 
However, 111 was mostly found in the insoluble fraction, as shown in Figure 5-5 (A), where 
the protein production was induced with 1000 µM IPTG. The same was observed when 
inducing with 200 µM (not shown). The protein recovered from the reverse purification 
(Figure 5-5, lane FTr, gel A) was submitted to desalting and Ion Exchange Chromatography. 
Only a very low amount of protein was obtained, and impurities could still be observed 
(Figure 5-5, lane IEC, gel B). No protein was lost in the flowthough of the His Trap (Figure 5-
5, FT1, FT2 and FT3, gel B) nor in the flowthrough or washes of the Ion Exchange (Figure 5-5, 
lane FTi and Wi, gel B). Lowering the temperature to 18°C was tested, as well as shortening 
the production phase to 2.5 hours, but none of these conditions improved the level of 
solubility of 111 (not shown). 
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Figure 5-5: SDS PAGE gel showing the insolubility of 111. A-The 111 protein, originally 
carrying a His6-SUMO tag, was expressed in Shuffle E.coli cells and purified by nickel column 
and reverse nickel column purification, as previously described. B-The protein sample was 
then desalted and loaded onto a 5 mL Q FF column, and eluted with a linear gradient of 
sodium chloride (IEC lane, gel B). Gel A: L: Lysate; S: Soluble; I: Inclusion Bodies; HT fractions: 
fractions from the His Trap chromatography; PDS: Post-Dialysis soluble; FTr: Flowthrough 
Reverse; Er: Elution Reverse. Gel B: FT: Flowthrough from the His Trap; HT: Sample from a 
His Trap fraction; FTi: Flowthrough from the Ion Exchange; Wi: washes from the Ion 
Exchange; IEC: 111 sample recovered after the Ion Exchange Chromatography. 
 
Considering the low amount of soluble protein which was recovered, as well as the large 
amount of 111 present in the pellet, it was decided to test the refolding protocol that was 
first described on the CBD 141. Briefly, the insoluble pellets from the production phase at 25°C 
for both 2.5 and 5 hours were washed and dissolved in 6M guanidine hydrochloride. The 
non-dissolved aggregates were separated from the denatured protein by centrifugation, and 
the supernatant was allowed to refold through dialysis against 0.1 M aerated sodium borate 
buffer, pH 10.0, for 2 hours at 20°C, followed by an overnight dialysis against 100 mM sodium 
phosphate, 0.5 M NaCl, pH 8.0. The sample was then spun again, and the supernatant 
dialysed against His Trap A buffer, before being subjected to the same chromatography 
method as 222 and 333. 
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Results showed that, although some protein was lost in the flowthrough of the His Trap 
chromatography (Figure 5-6, lane FT, gel A), some could also be recovered on the resin 
(Figure 5-6, lanes 6-16, gel A). After desalting and Ion Exchange Chromatography, the 
recovered protein was pure (Figure 5-6, lanes 7 to 17, gel B). The next step was to confirm 
whether or not this protein, as well as 222 and 333, were correctly folded. 
 
 
Figure 5-6: SDS PAGE gel showing the purification of the refolded 111. A-The 111 protein, 
originally carrying a His6-SUMO tag, was refolded from the insoluble pellet from Shuffle E.coli 
cells and purified by nickel column and reverse nickel column purification, as previously 
described. B- The protein sample was then desalted and loaded onto a 5 mL Q FF column, 
and eluted with a linear gradient of sodium chloride. FT: Flowthrough; PDS: Post-Dialysis 
soluble; FTr: Flowthrough Reverse; Er: Elution Reverse. FTHT: Flowthrough from the His trap 
chromatography; the numbers labelled on the gels correspond to the fractions of the His 
Trap chromatogram (Gel A) and of the Ion Exchange one (Gel B). 
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5.3.3. Characterisation 
5.3.3.1. DTNB assay 
 
The assay showed that no free cysteines were present in either of these proteins, suggesting 
that the refolding protocol on 111 had worked. An intact Mass Spectrometry analysis on 222 
confirmed the presence of 6 disulfide bridges. The measured intact mass of the sample was 
20 638 Daltons, which corresponds to a 12-dalton deficit compared to the theoretical mass 
derived from the sequence (20 650 Da). This difference correlates with the formation of 6 
disulfide bridges and the concomitant loss of 12 hydrogens. 
5.3.3.2. Gelatin sepharose 
 
As low amounts of 111 were available, it was decided to keep this protein sample for the 
plate binding assay on both type I and type II gelatin. 222 and 333 were however used on 
the gelatin sepharose resin, and both showed binding to the column, although, in both cases, 
some protein was recovered in the flowthrough (Figure 5-7).  
 
 
 
 
 
 
 
Figure 5-7: SDS PAGE showing the binding of 222 and 333 to gelatin sepharose. The 222 and 
333 protein samples from the Ion Exchange were tested for their ability to bind gelatin using 
a gelatin sepharose resin. 100 µL of resin was spun down, washed with ethanol and 
equilibrated before applying the protein samples. The initial samples (I) were loaded and 
allowed to bind for 1 minute before collecting the flowthrough (FT). The resin was washed 
twice with the binding buffer (W1 and W2). The bound proteins were mixed with 2X SDS 
loading buffer and loaded on the gel (Gel, Gelatin-bound protein) 
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5.3.3.3. Plate binding assay 
 
We then studied the binding of these chimeric proteins onto type I and II gelatin using the 
plate binding assay previously described (Figure 5-8, Part B and A, respectively). Results 
showed that 333 binds with a much tighter affinity to type I than type II gelatin, confirming 
the preference of module 3 for the former. Interestingly, 222 bound to type II gelatin with a 
14-fold higher affinity than the CBD (Figure 5-8 and Table 5-1), as could be expected from 
the observation that module 2 was the strongest to bind to type II gelatin. However, 222 
showed even tighter affinity towards type I gelatin, suggesting that module 2 could have a 
slight preference towards type I gelatin over type II (Figure 5-8 and Table 5-1).  
Unfortunately, the refolded 111 did not show any strong binding to either type I or type II 
gelatin (Figure 5-9). The concentration in 111 that was used did not allow to reach saturation, 
meaning that the determination of a dissociation constant was not possible.  
In order to investigate this further, the foldedness of the protein was checked by 1D NMR, 
which showed that the protein was folded like a molten-globule (not shown). A new refolding 
procedure was performed with longer dialysis times, in an attempt to allow more time for 
the protein to refold. Unfortunately, this did not improve the folding of the protein (not 
shown). 
As 222 showed the highest affinity of all the proteins tested for type II gelatin, which we 
aimed to target in damaged cartilage, we then wanted to further confirm the binding of the 
protein to this substrate by NMR. 
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Table 5-1: Apparent dissociation constants of the CBD, 222 and 333 on both type I and type 
II gelatin. The dissociation constants were calculated from the binding assay described in 
Figure 5-8, using a 4PL regression in Prism. Numbers represent average ± standard error, and 
the number of replicates is indicated in brackets. Only the affinity of 333 to type II gelatin 
was shown to be significantly different to that of the CBD and 222 on the same substrate (p 
<0.005, ANOVA for multiple comparisons with Tukey correction). No significant difference 
was observed in the affinity of each protein onto type I gelatin (p-values> 0.05, ANOVA for 
multiple comparisons with Tukey correction). 
 Kd on Type II gelatin  Kd on Type I gelatin 
FL CBD 20.4 ± 2.83 nM (n = 3) 1.56 ± 0.723  nM (n = 2) 
222 1.46 ± 0.53 nM (n = 4) 0.315 ± 0.128 nM (n = 2) 
333 117 ± 18.9 nM (n = 3)* 0.132 ± 0.039 nM (n = 3) 
 
A 
B 
Figure 5-8: Binding of the CBD, 222 and 333 to type II (Part A) and type I (Part B) gelatin 
plates. The binding assay relies on the use of plates coated with gelatin (thermodenatured 
collagen). The biotinylated proteins were added over a concentration range before adding 
streptavidin-coupled alkaline phosphatase. Its substrate, namely PNPP, was added and 
converted into a coloured product which formation was measured by absorbance at 405 
nm. Examples of representative binding curves are shown for each protein. Error bars 
represent standard deviations of three replicates. The apparent Kd values for each protein 
on each substrate are indicated in the table below (Table 5-1). 
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Figure 5-9: Binding of the refolded 111 to type I and type II gelatin plates. The binding assay 
relies on the use of plates coated with gelatin (thermodenatured collagen). The biotinylated 
protein was added over a concentration range before adding streptavidin-coupled alkaline 
phosphatase. Its substrate, namely PNPP, was added and converted into a coloured product 
which formation was measured by absorbance at 405 nm. Error bars represent standard 
deviations of three replicates. 
 
5.3.3.4. NMR binding study of 222 on type II gelatin 
 
1H-15N 2D HSQC spectra of the free 222 were first acquired (Figure 5-10 A). They confirmed 
the correct folding of the protein, even though some overlapping peaks were observed. This 
was due to the intrinsic nature of the protein, as it is made of three identical repeats. When 
overlapping this spectra with that of module 2 (Figure 5-10 B), we could observe that most 
of the peaks from the single module were found at the same position on the spectra of 222, 
although two to three peaks could be observed for some amino acids on the latter. For the 
ligand binding analysis, it was decided to transfer the assignments from the second module 
onto the spectra of 222. We therefore assumed that the cognate residues in all three 
modules of 222 were found at the same position on the spectra.  
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A 
B 
Figure 5-10: 1H-15N HSQC spectrum of the free 222 (A) and overlay of the spectra of the free 
222 (black) and module 2 (green) (B) at 298K in 25 mM sodium phosphate, pH 6.5, 10 % 
D2O, 50 µM. The spectra were acquired on a 800Hz Bruker spectrometer instrument. Each 
peak on the spectrum corresponds to an amide proton.  
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Type II gelatin was then added to 222 at a 40:1 and a 20:1 protein:gelatin ratio. Shifts could 
be seen in both cases but were clearer with the 20:1 ratio (Figure 5-11). For clarity, the 
spectra in this figure was divided into four quadrants which are zoomed in in Figures 5-12 to 
5-15. 
Residues which showed peak broadening and/or chemical shift changes corresponded to 
residues F280, M282, N285, A286, Q289, R296, F297, G299, G309, R310, G313, Y314, R315, 
W316, T319, E321, Y323, D326, G330, C332 and E334 in module 2. Residues G284, Y302, 
T306 and Y329, which were identified previously as being involved in the binding of module 
2 to gelatin, also showed some small shifts in the spectra of 222. Overall, all of the residues 
identified to be involved in the binding of 222 to gelatin also showed similar chemical shift 
perturbations in the single module 2 bound to gelatin, or the CBD, except for A286 and E334.  
It is, however, important to notice that it was impossible to determine if the residues 
corresponding to these amino acids were affected in all three modules of 222, nor to know 
which of the three modules was more affected than the other two. Residues have been, 
arbitrarily, mapped onto the second module of 222, as shown in Figure 5-16. 
Overall, these NMR data confirm the specificity of the binding of 222 to our substrate of 
interest, and indicate that the binding occurs through the same mechanism as within the 
CBD. 
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D 
Figure 5-11: 1H-15N HSQC spectra of 222 before and after addition of type II gelatin at 298K 
in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-free 222 (black) and 
of 222 in the presence of type II gelatin (red) are superimposed. A 20:1 protein:gelatin 
molar ratio was used. The spectra were acquired on a 800Hz Bruker spectrometer 
instrument. Each peak on the spectrum corresponds to an amide proton in 222. Broadening 
of the peaks, leading to their disappearance, upon addition of the ligand indicates that the 
residues corresponding to these peaks are involved in the binding of the protein to the 
substrate. The peaks clustered at around 8 ppm (1H dimension) are from the unfolded 
species of the protein. 
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Figure 5-12: Part A of Figure 5-11. 1H-15N HSQC spectra of 222 before and after addition of 
type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-
free 222 (black) and of 222 in the presence of type II gelatin (red) are superimposed. A 20:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in 
222. Broadening of the peaks, leading to their disappearance, upon addition of the ligand 
indicates that the residues corresponding to these peaks are involved in the binding of the 
protein to the substrate. The peaks were assigned to their corresponding amino acid using 
the assigned spectra of module 2 and are labelled with their one-letter amino acid code and 
residue number. 
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Figure 5-13: Part B of Figure 5-11. 1H-15N HSQC spectra of 222 before and after addition of 
type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-
free 222 (black) and of 222 in the presence of type II gelatin (red) are superimposed. A 20:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in 
222. Broadening of the peaks, leading to their disappearance, upon addition of the ligand 
indicates that the residues corresponding to these peaks are involved in the binding of the 
protein to the substrate. The peaks were assigned to their corresponding amino acid using 
the assigned spectra of module 2 and are labelled with their one-letter amino acid code and 
residue number. 
δ 
δ 
δ 
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Figure 5-14: Part C of Figure 5-11. 1H-15N HSQC spectra of 222 before and after addition of 
type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-
free 222 (black) and of 222 in the presence of type II gelatin (red) are superimposed. A 20:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in 
222. Broadening of the peaks, leading to their disappearance, upon addition of the ligand 
indicates that the residues corresponding to these peaks are involved in the binding of the 
protein to the substrate. The peaks were assigned to their corresponding amino acid using 
the assigned spectra of module 2 and are labelled with their one-letter amino acid code and 
residue number. 
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Figure 5-15: Part D of Figure 5-11. 1H-15N HSQC spectra of 222 before and after addition of 
type II gelatin at 298K in 25 mM sodium phosphate, pH 6.5, 10 % D2O. The spectra of ligand-
free 222 (black) and of 222 in the presence of type II gelatin (red) are superimposed. A 20:1 
protein:gelatin molar ratio was used. The spectra were acquired on a 800Hz Bruker 
spectrometer instrument. Each peak on the spectrum corresponds to an amide proton in 
222. Broadening of the peaks, leading to their disappearance, upon addition of the ligand 
indicates that the residues corresponding to these peaks are involved in the binding of the 
protein to the substrate. The peaks were assigned to their corresponding amino acid using 
the assigned spectra of module 2 and are labelled with their one-letter amino acid code and 
residue number. 
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Figure 5-16: Three-dimensional surface representation of 222 showing the position of the 
residues that underwent peak broadening or shift changes in the presence of type II 
gelatin at a 20:1 protein:gelatin ratio. Residues undergoing peak broadening are indicated 
in red while residues undergoing shift changes are indicated in brown. Residues have 
arbitrarily been coloured on the second module of 222. The structure shown is derived 
from the reported crystal structure of MMP-2 (PDB Accession Number 1CK7). Residues 
from this structure were individually mutated in Pymol to match the sequence of 222. 
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5.4. Discussion 
 
5.4.1. General conclusion 
This chapter has described the generation of three unique proteins, namely the chimeric 
proteins 111, 222 and 333. They were carefully designed by ensuring that the residues 
involved in intramolecular interactions within the CBD were conserved in each construct. 222 
and 333 were successfully expressed as soluble proteins in the cytoplasm of Shuffle cells, and 
purified as previously described. 111, however, was insoluble and had to be refolded, using 
a previously published method 141. 
Although the DTNB assay indicated that all disulfide bridges were formed in all constructs, 
111 was shown to be not properly folded by 1D NMR. The folding of this protein was 
investigated after the plate binding assay showed a very weak binding on both type I and 
type II gelatin. 
222 and 333, on the other hand, showed a tight affinity in the plate binding assay as well as 
on the gelatin sepharose resin. As expected from the previous chapter, 333 was shown to 
bind better to type I than to type II gelatin. 222 was shown to bind with a slightly stronger 
affinity to type I gelatin than to type II, but, more importantly, displayed a dissociation 
constant which was nearly 14 times lower than that of the native CBD. The specificity of the 
binding of this protein to type II gelatin was further confirmed by NMR ligand binding 
studies, which showed that the residues involved in the binding were the same as those 
identified when studying module 2 alone or within the CBD. 
Unfortunately, the impossibility of expressing 111 as a fully folded protein meant that we 
were not able to fully confirm the specificity of module 1 for type II gelatin, although the 
data on 333 do suggest that module 3 is more specific to type I. 
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5.4.2. Future work 
Have there been other descriptions of gain of function mutations for the CBD? 
To the best of our knowledge, this is the first time that mutational work has enabled an 
improvement in the affinity of the CBD of MMP-2 to one of its substrates. Most of the 
previously published mutational work performed on this protein were indeed alanine 
substitutions, which were done in an attempt to identify key residues involved in the     
binding 140,168. 
However, one paper has reported mutations on the first module of the CBD of MMP-9 which 
improved its affinity 161. In this paper, each module of the CBD9 as well as the full-length 
protein were fused to beta-galactosidase and their binding affinities to type I gelatin were 
measured. Module 2 was shown to provide most of the binding properties of the CBD, and 
to have a higher affinity for gelatin on its own than when combined to modules 1 and 3. The 
non-conserved residues within the boundaries of the conserved regions of modules 1 and 2 
were then mutated. Residues A228 and A229 in module 1 were mutated for the cognate 
residues found in module 2 at these positions, i.e. K286 and P287. Similarly, a second 
construct was generated by mutating L253 and P254 in module 1 by the cognate residues 
Y311 and R312 found in the second module. Results showed that both of the mutants 
improved the binding of module 1 to gelatin, by nearly 8-fold and 6-fold, for the first and the 
second construct, respectively. However, even the first construct displayed an affinity which 
was still more than 3 times weaker than that of the second module of the CBD9, suggesting 
that other residues might be involved. Interestingly, these mutated residues are also non-
conserved in each of the module of the CBD of MMP-2, as they correspond to residues 12 
and 13 and 37 and 38 on Figure 5-17. In addition, residue 38 in module 3 corresponds to 
M373, an amino acid which we showed to be involved in the binding with type I gelatin only.  
This may indicate that these two regions are key for conferring specificity and affinity, and 
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performing mutations similar to those described in the CBD9 might provide further insights 
into the differences in affinity and specificity of each module of the CBD of MMP-2. 
Are there any other mutations that could be done on the trimodular proteins to improve 
binding, specificity or solubility? 
The insolubility of 111 was an issue that could not be solved, and the refolding procedure did 
not yield a properly folded protein. Module 1 alone was not more difficult to express than 
the other two, meaning that the insolubility is not due to the intrinsic sequence of the 
module, but rather due to difficulties in protein folding during protein expression. 
Mutations could be designed in order to minimise insolubility, and to get a sequence which 
resembles more that of the original CBD. As the residues which are critical for the binding of 
module 1 to gelatin were identified in the previous chapter (showed in red and pink in Figure 
5-17), one could decide to mutate only their cognate residues in modules 2 and 3, giving 
three modules with all the amino acids that are required for module 1 to bind.  
Another potential option would exploit the fact that we identified G269 in module 1 
(corresponding to G50 in Figure 5-17) as a potential reason for the specificity of this module 
for type II gelatin. It would therefore be interesting to mutate the cognate residue of G269 
in the other modules, in order to see if this would confer specificity for type II gelatin over 
type I. This would involve mutating K327 in module 2 and R385 in module 3 for a glycine. 
This mutation could also be performed on the 3 residues equivalent to K327 in 222, i.e K269, 
K327 and K385 as outlined in the Figure below (Figure 5-18). 
Figure 5-17: Alignment of modules 1, 2 and 3 of the CBD highlighting the residues involved 
in the binding to type I and type II gelatin. Residues common to both substrates are 
highlighted in red, while residues showing higher shifts for type II gelatin are in pink, and 
those showing higher shifts for type I gelatin in grey. G269 is at position 50 on this figure, 
and M373 at position 38, as shown by the black rectangles. 
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Figure 5-18: Sequence of 222 highlighting, in red, the position of the lysines 269, 327 and 
385 which could be mutated for a glycine. 
 
Overall, 222 was the protein with the highest affinity for type II gelatin, and this was the 
protein progressed forward and used to coat MSCs in order to achieve the objective of 
increasing their binding to damaged cartilage in osteoarthritis. 
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6. Development of a new method for coating MSCs with 222 
The previous chapter described the generation of a new protein, namely 222, with a high 
affinity for type II gelatin. The next phase of the project was to test whether coating MSCs 
with this protein would enhance their adhesion onto this substrate. Selecting the best 
method for coating these cells with 222 was therefore necessary. 
6.1. Introduction: existing methods for cell surface engineering of MSCs 
 
Cell therapy is a promising approach which relies on the delivery of cells to the target tissue. 
This is often not achieved, especially for MSCs 127 . When injected systemically, these cells 
are often trapped in the lungs 189, a phenomenon which is thought to be due to the strong 
adhesive properties of MSCs as well as to the small size of the capillaries 120. Local delivery 
directly into the tissue of interest by-passes the lung barrier, but most of the time involves 
invasive surgery 189. In addition, MSCs directly injected at the site of damage do not show 
high retention, with only 1 % of injected cells found in the heart following myocardial 
infarction 190. 
Methods are therefore being developed to try to improve the efficiency of the delivery of 
MSCs to a damaged tissue. Achieving this goal could improve their therapeutic effects, but 
also reduce the required cell dose as well as the secondary effects due to their off-target 
accumulation 191.  
Cell surface modification is one way to do so. It relies on coating the surface of MSCs with 
various proteins whose ligands are found in the tissue of interest. Three main ways can be 
used to achieve this coating: covalent coupling to proteins found at the cell surface, charge 
modification, or hydrophobic interaction of the protein of interest with the cell         
membrane 190. The latter seems to be the most popular, as it reduces the risks of cytotoxicity 
and avoids permanent modification 190,192. 
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6.1.1. Palmitated Protein G (PPG) 
One common method exploiting hydrophobic interactions relies on the use of a Palmitated 
Protein G (PPG), which intercalates into the cell membrane. The protein of interest, either 
an antibody or a protein fused to a Fc region, can then be bound to the PPG anchor, leaving 
the antigen binding site exposed outwards of the cell surface 127. This method has been used 
to treat different conditions, such as osteoarthritis 127, inflammatory bowel disease 193, or 
cardiac diseases 194. 
In all cases, the cells were successfully coated, and the modification was stable for a 
minimum of 3.4 hours 193 and up to more than 24 hours 194. 
The coating method did not affect the cell viability nor the proliferation properties of           
cells 127,194. The differentiation potential of the progenitors was also not affected in the work 
reported by Dennis et al. 127. Fluorescent-labelled chonroprogenitors showed higher 
adhesion to a rabbit articular cartilage explant with a partial thickness defect when coated 
with antibodies directed against matrix molecules. A similar observation was made in the 
paper by Whitaker et al. 194, where 28 % of the infused functionalized Cardiosphere-Derived 
Cells (CDCs) were retained at the site of injection after 3h, due to their binding to P-selectins. 
Even though the use of PPG has been proven to be efficient, the use of antibodies or fusion 
proteins can be cost-prohibitive. Other methods have therefore been developed to exploit 
the hydrophobic interaction of the protein of interest with the cell membrane. 
6.1.2. Palmitated peptides 
In two very similar papers 191,195, peptides of interest have been synthetically coupled to 
palmitic acids to provide a membrane anchor. Peptides were screened for their ability to 
bind to substrates found in either the ischemic heart or brain. MSCs were successfully coated 
with the palmitated peptides, and no cytotoxicity nor modification of their proliferation 
properties were observed. The coating was stable for periods from 3.5 up to 24 hours 191,195 
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which was enough to enhance the engraftment of injected cells in the targeted tissues, 
although a clear quantification is lacking in both cases. In the paper by Huang et al.191, 
however, the increased number of cells proved to have clinical benefits, as a reduction in 
brain deficits and a differentiation in neural cells were observed. However, it has to be noted 
that these MSCs were first transfected with the microRNA miR-133b, which could explain 
these observations. Although this method has shown some success, the coupling to palmitic 
acid seems to be limiting this methodology to the use of peptides as coating agents. 
6.1.3. Polyethylene glycol (PEG) 
The use of PEG as a membrane anchor has been shown to be successful for coating MSCs 
with both peptides 196 and proteins 190. In the first case, MSCs were coated with PEG coupled 
to three different heparin binding peptides in order to prevent thromboinflammation by 
binding to heparin sulfate. Cells were successfully coated for up to 25 hours, and shown to 
bind to heparin sulfate. Their differentiation potential was not affected, and the method 
seemed to not be toxic, except for one of the peptides used. Coated cells reduced markers 
of complement activation and suppressed coagulation and platelet aggregation, showing the 
expected gain-of function from their cell surface modification.  
In the second paper 190, MSCs were coated with the protein CXCR4 coupled to a lipid-PEG, in 
order to enhance their migration to the ischemic myocardium by exploiting the affinity of 
the exposed protein for SDF-1, which is upregulated in myocardial infarction for only 48 
hours. The coating of cells with CXCR4 did not alter their proliferation and adhesion 
properties, and was not cytotoxic. The membrane-bound CXCR4, which was stably exposed 
at the surface for up to 180 minutes, was shown to be able to bind to SDF-1 by confocal 
microscopy, an interaction which favoured the migration of the coated cells towards a       
SDF-1 gradient.  
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6.1.4. Wheat Germ Agglutinin (WGA) 
A similar approach was adopted by Kim et al. 189, except that the anchor to the protein 
membrane was Wheat Germ Agglutinin (WGA). It was covalently coupled to hyaluronate 
(HA) to favour the migration of coated MSCs to the liver, which expressed HA-binding 
partners. Again, the coating was shown to be non-cytotoxic, and was stable for one hour at 
37°C, with no alterations of the cell properties. The exposure of HA at the cell surface was 
enough to direct them to the liver, while cells coated with WGA only remained trapped in 
the lungs 189.  
6.1.5. Covalent modification 
All of the previous cell surface modifications relied on hydrophobic interactions between the 
protein of interest and the cell membrane. Although most of them have shown, if not clinical 
benefits, at least an efficient targeting of cells to the tissue of interest, longer modification 
might be needed to improve the efficacy of MSCs treatment even further 192.  
This has been explored by Takayama et al. 192, using a covalent modification of the cell surface 
by exploiting the avidin-biotin complex method. The method described in this paper used 
two fluorescent model proteins, namely Green Fluorescent Protein (GFP) and Nluciferase. 
The procedure relied on first biotinylating the amines of the proteins naturally present at the 
cell surface, prior to adding avidin. The biotinylated GFP or Nluc proteins were then added 
and could react with the avidinated cells. The covalent coupling did not affect the cell viability 
nor the differentiation potential, and was stable for 14 days, achieving a much longer 
modification than with non-covalent methods. Much more GFP-positive cells were obtained 
with the coating method compared to transfection (95 % against 7.3 %, respectively), which 
highlights the benefit of adopting a cell surface modification over a genetic one. Finally, 
coated cells injected into mice were still detected after 7 days, showing the persistence of 
the labelling in vivo. 
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6.1.6. Surfactant corona method 
An ideal balance would be found if a non-covalent modification method was providing long-
lasting effects. Both goals have been achieved using a new method 197, in which the protein 
is first cationised through the conversion of its aspartate and glutamate residues into 
synthetic amino acids containing amine side-chains. The cationised protein can then be 
electrostatically coupled to a negatively charged, PEG-based surfactant, which surrounds the 
protein like a corona. The conjugated protein can then be delivered into the cell membrane, 
with the surfactant acting as the membrane anchor. The method was first described with 
GFP and myoglobin. Coating MSCs with myoglobin led to the reduction of necrosis within 
cartilage constructs, due to the recruitment of oxygen at their centre by the exposed 
myoglobin 197. 
This method not only is simpler than those described earlier, but also enables the exposure 
of the protein of interest at the cell surface for longer periods of time. It was therefore 
decided to use this surfactant-corona method for coating MSCs with 222 in an attempt to 
improve their binding to type II gelatin and, later, to damaged cartilage. 
6.2. Materials and Methods  
 
6.2.1. Protein conjugation 
A FITC tag was added, when appropriate, to the 222 protein according to the manufacturer’s 
instructions, giving FITC-222. 
Protein samples were buffer exchanged against either 20 mM HEPES, pH 6.5 or 20 mM 
sodium phosphate (NaP), pH 6.5 using a PD 10 Sephadex G-25 M column. The protein was 
then concentrated up to 0.7 mg/mL before proceeding to the cationisation. 
N,N`-dimethyl-1,3-propanediamine (DMPA) and N-(3-Dimethylaminopropyl)-N`-
ethylcarbodiimide hydrochloride (EDC) were added to the protein samples and the pH 
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adjusted to 6.5. Samples were incubated for 20 to 24 hours at 4°C with stirring, before being 
purified from the excess reagents by spinning 5 times through Amicon Ultra 15 centricons 
with a 10 kDa Molecular Weight Cut-Off (MWCO). The negatively charged surfactant glycolic 
acid ethoxylate 4-nonylphenyl ether was then added to the cationised protein and incubated 
overnight at 4°C with stirring, giving the proteins Surfactant-222 or Surfactant-FITC-222. 
6.2.2. Dynamic Light Scattering (DLS) 
Particle size and zeta potential analysis were performed using a ZetaSizer Nano ZS (Malvern 
Instruments, UK) and ZetaSizer software (Malvern Instruments, UK). Samples were filtered 
through a 0.22 µm filter prior to the analysis. Zeta potential measurements were made after 
a 120-second equilibration with 10-100 runs per sample. Size measurements were made 
after a 120-second equilibration, with the backscatter measured at 173°. The values reported 
in this report correspond to the radius expressed in number of the total sample. Each zeta 
potential and DLS measurements were performed in triplicates.  
6.2.3. Coating of adherent MSCs with Surfactant-FITC-222 
The media from cells cultivated in T25 flasks was removed, and cells were treated with 18 
µM of Surfactant-FITC-222 for 30 min at 37°C. The protein solution was then removed and 
cells were washed with 0.04 mg/mL heparin ammonium salt resuspended in PBS. Phenol-
free DMEM medium was then added prior to imaging with a confocal microscope. 
6.2.4. Coating MSCs in suspension with Surfactant-FITC-222 
Cells cultivated in DMEM medium were trypsinised, counted, and resuspended at 1 million 
cells/mL. 
The cells were then spun down before being resuspended in 300 μL of 5 μM Surfactant-222 
or Surfactant-FITC-222, while control samples were incubated with 300 μL of native 222. Cells 
were incubated for 30 minutes at 37°C with shaking and manually agitated every 10 minutes 
to prevent cell aggregation. 
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Cells were then spun down and washed with 300 μL of 0.04 mg/mL heparin ammonium salt 
resuspended in PBS before being spun down again and resuspended in 1 mL of imaging 
medium.  
6.2.5. Cell adhesion assay 
MSCs were coated with 5 µM of either Surfactant-222 or Surfactant-FITC-222, and 
resuspended in DMEM media containing P/S and Glutamax only. Cells were seeded on either 
non-treated tissue culture plates, or gelatin-coated tissue culture plates (0.5 µg type II 
gelatin/well) and serially diluted over the plate. 4 replicates were used for each condition, 
and Wild Type (WT) cells were used as a control. Cells were cultivated for 24 hours and 
washed once with phenol-free DMEM before being imaged with an epifluorescent 
microscope following their staining with the membrane dye FM-4-64. 
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6.3. Results 
 
6.3.1. Protein conjugation 
The aim of the conjugation, which was first described by Armstrong et al. 197 is to surround 
the protein with a surfactant corona, enabling the protein to be incorporated into the 
membrane of stem cells via hydrophobic interactions, as illustrated in Figure 6-1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: Anchoring of a surfactant-protein complex onto the cell membrane. The 
surfactant, represented in yellow and red, surrounds the protein, here represented in blue, 
creating a corona. In solution, the hydrophobic non-phenyl chains of the surfactant, in red, 
are buried by the PEG chains. At the contact with the hydrophobic membrane, a structural 
reorganisation occurs, enabling the alkyl chains to be exposed and to anchor the protein at 
the cell surface. Figure from 197. 
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The protein modification is a two-step process, with an initial cationisation following the 
surfactant addition. The cationisation involves the covalent coupling of N,N’-dimethyl-1,3-
propanediamine (DMPA) to the carboxylic residues of the protein (Figure 6-2, (3 and 4)). 
Those carboxylic moieties first need to be activated by a carbodiimide (Figure 6-2, (1 and 2)), 
namely, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC).  
 
Figure 6-2: Chemical reaction describing the covalent coupling of DMPA to the carboxylic 
groups of amino acids 153. The addition of DMPA enables the conversion of negatively 
charged residues, i.e. aspartate and glutamate (1), into synthetic amino acids containing 
amine side-chains (5). An isourea byproduct is also formed (6). 
 
Following covalent coupling with DMPA, the cationised protein can then interact 
electrostatically with the negatively charged surfactant glycolic acid ethoxylate 4-
nonylphenyl ether, which is obtained from the oxidation of Igepal CO-890, as shown in Figure 
6-3. 
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Figure 6-3: Chemical reaction describing the oxidation of IGEPAL CO-890 into the anionic 
surfactant used for the conjugation. This synthesis was performed by an external 
collaborator. 
This process was applied to both 222 and FITC-222 in either 20 mM HEPES buffer, pH 6.5 or 
20 mM sodium phosphate (NaP), pH 6.5, which were each used for different proteins in the 
paper published by Armstrong et al 197. The two-step reaction was followed using Dynamic 
Light Scattering (DLS), as it enables the measurement of both the hydrodynamic radius and 
the zeta potential of a protein. As presented in Tables 6-1 and 6-2, the measurements were 
very similar for both 222 and FITC-222, suggesting that the presence of the fluorescent tag 
did not interfere with the process. In both buffers, the cationisation induced an increase in 
the charge of the protein and only a small change in the hydrodynamic radius. The fact that 
this radius could be slightly reduced after cationisation could come from a compaction of the 
molecule following the change in charge. The hydrodynamic radius was then increased 
following the addition of the surfactant, confirming the creation of a corona surrounding the 
protein. The surfactant addition also caused a neutralization of the charge which had been 
increased after the cationisation. Interestingly, the fold change was higher for both the 
charge and the size in HEPES compared to sodium phosphate. If it is known that the zeta 
potential is dependent on the dielectric constant of the buffer used for the measurement, it 
is unclear to us as to why the buffer would also have an influence on the hydrodynamic radius 
of the protein.  
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Table 6-1: DLS measurements of the hydrodynamic radius and the zeta potential of 222 in 
both sodium phosphate (NaP) and HEPES buffers. 222 was cationised and conjugated to the 
surfactant as previously described, in either 20 mM HEPES, pH 6.5 or 20 mM NaP, pH 6.5. A 
ZetaSizer instrument was used to measure both the hydrodynamic radius (size) and the zeta 
potential (charge) on each version of the protein. Each measurement was performed in 
triplicates, and the values reported below are their average. 
 
 
 
 
 
Table 6-2: DLS measurements of the hydrodynamic radius and the zeta potential of FITC-222 
in both sodium phosphate (NaP) and HEPES buffers. 222 was cationised and conjugated to 
the surfactant as previously described, in either 20 mM HEPES, pH 6.5 or 20 mM NaP, pH 6.5. 
A ZetaSizer instrument was used to measure both the hydrodynamic radius (size) and the 
zeta potential (charge) on each version of the protein. Each measurement was performed in 
triplicates, and the values reported below are their average. 
 
 
 
 
 20 mM HEPES, pH 6.5 20 mM NaP, pH 6.5 
222 Size Charge Size Charge 
Native 3.26 -12.13 3.92 -2.26 
Cationised 2.19 14.53 4.74 6.53 
Surfactant 12.63 -2.31 6.89 -1.45 
 20 mM HEPES, pH 6.5 20 mM NaP, pH 6.5 
FITC-222 Size Charge Size Charge 
Native 3.133 -15.133 3.652 -1.308 
Cationised 3.179 9.110 4.721 3.890 
Surfactant 13.42 -4.817 7.352 -0.588 
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6.3.2. Coating of adherent cells 
The Surfactant-FITC-222 protein was then used at 18 µM in 20 mM HEPES, pH 6.5 to coat 
MSCs seeded onto plastic, as described in the original method 197. Cells were imaged by 
confocal microscopy, which confirmed the presence of the protein at the cell surface (Figure 
6-4). 
 
 
 
 
 
 
 
 
 
 
 
Overall, this experiment validated the method developed by Armstrong et al. when applied 
to our new protein 222. However, several issues were encountered with this methodology: 
the amount of protein required to coat attached cells was very high, and was not normalised 
to the number of cells but to a surface area. Finally, it would be preferable for our project to 
be able to inject cells immediately after their coating, with no trypsinisation step, as such a 
step could, in theory, alter the integrity of the membrane and potentially remove the newly 
coated 222 from the cell surface. It was therefore decided that adapting the coating method 
for cells in suspension would be better for the purpose of this project. 
 
Figure 6-4: Confocal microscopy image showing the successful coating of MSCs attached 
to plastic with Surfactant-FITC-222. Cells were treated with 18 µM of Surfactant-FITC-222 
for 30 min at 37°C before being washed with heparin ammonium salt. Phenol-free DMEM 
was added to the cells for imaging. Both the FITC and transmitted channels were used to 
acquire images. 
FITC TRANS MERGE 
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6.3.3. Coating of cells in suspension  
The new method, illustrated in Figure 6-5, involved trypsinising cells prior to incubating them 
with 300 µL of protein/million cell. Cells were incubated with the protein for 30 min with 
shaking, before being washed with the same volume of heparin ammonium salt and 
resuspended in phenol-free media. 
 
 
Figure 6-5: Schematic representation of the method for coating cells in suspension. Cells 
were trypsinised and 1 million cells were spun down before being resuspended in 300 µL of 
either Surfactant-222 or Surfactant-FITC-222. Various concentrations of protein were tested 
in the initial experiments. Cells were incubated with the protein for 30 minutes at 37°C with 
shaking. Cells were then spun down, washed in heparin ammoniun salt and resuspended in 
phenol-free medium for imaging.  
 
The methodology for coating cells in plate described the use of 18 µM of protein 197, but we 
aimed to reduce the concentration even further in order to improve the feasibility of this 
new method. It was therefore decided to test a range of concentrations, from 10 to 1.25 µM, 
all in HEPES buffer. Results showed successful coating at all concentrations tested, except for 
1.25 µM, which gave a very weak signal (not shown). Overall, using a protein concentration 
of 5 µM seemed to give the best balance between intensity of signal and required amount 
of protein, and it was therefore decided to further optimise the coating with this condition. 
Cells coated with 5 µM of Surfactant-FITC-222 in both NaP and HEPES were therefore imaged 
by confocal microscopy. The images confirmed the successful coating in both HEPES and NaP 
buffers (Figure 6-6, A and B, respectively), with a very similar staining pattern and intensity 
observed in both buffers when looking at a single cell. No signal was observed when 
incubating cells with the native FITC-222 protein (Figure 6-6, C), confirming that the observed 
fluorescence was due to the coating with Surfactant-FITC-222. 
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Figure 6-6: Confocal microscopy images showing the successful coating of MSCs in 
suspension with Surfactant-FITC-222. Cells were treated with 5 µM of Surfactant-FITC-222 
for 30 min at 37°C in either 20 mM HEPES (A) or 20 mM NaP (B).  Cells were also treated with 
Native-FITC-222 as a control (C, in NaP). Cells were then washed with heparin ammonium 
salt, and phenol-free DMEM was added to the cells for imaging. Both the FITC and 
transmitted channels were used to acquire images. 
 
5 uM, Bristol surfactant 
5 uM, Bristol surfactant 
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The protein was also shown to be co-localised with the membrane dye FM 4-64 (Figure 6-7), 
confirming its presence at the cell surface. However, some cells showed an internalisation of 
the dye, indicative of cell death (Figure 6-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When acquiring images with a lower magnification, we observed a much higher proportion 
of cells showing internalisation of the dye in HEPES than in NaP, suggesting that the latter 
might be better tolerated by MSCs, and that its use might result in a higher cell viability 
(Figure 6-8). 
 
Figure 6-7: Confocal microscopy image showing the co-localisation of Surfactant-FITC-222 
and the membrane dye FM 4-64. Cells were coated as previously described with 10 µM of 
Surfactant-FITC-222 and imaged with a confocal microscope. FM 4-64 was added at a              
1: 1000 dilution to label the cell membrane. The merged image shows a yellow signal, 
indicative of the superposition of the signals coming from the FITC tag and the membrane 
dye. Some cells show internalisation of the dye, indicative of cell death. 
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Figure 6-8: Confocal microscopy images showing the difference in coating for cells treated 
in 20 mM HEPES buffer (A) or 20 mM NaP buffer (B). Cells were coated as previously 
described with 5 µM of Surfactant-FITC-222 and imaged with a confocal microscope. FM 
4-64 was added at a 1: 1000 dilution to label the cell membrane. The merged images show 
a yellow signal, indicative of the superposition of the signals coming from the FITC and 
the membrane dye. Some cells show internalisation of the dye, indicative of cell death. 
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It was then decided to investigate this observation further, by monitoring the viability of cells 
after coating with a trypan blue assay (Figure 6-9). Results showed that, even though each 
buffer on their own was not toxic for MSCs, coating MSCs with 5 µM of 222 in HEPES had 
deleterious effects on the cell viability, giving an average of 47.4 % of viable cells, compared 
to nearly 83 % in sodium phosphate. The difference in viability between the Surfactant-222 
treated cells in HEPES and those left in DMEM was significant, while all the other treatments 
did not show any significant difference when compared to the DMEM sample. 
The reason behind the difference in viability between cells treated with Surfactant-222 in 
HEPES and sodium phosphate is unclear. One hypothesis could be that coating MSCs 
weakens their membrane, leading to a leakage of the surrounding buffer into the cells. 
Sodium phosphate, which is more biologically relevant than HEPES, might be better tolerated 
in this process.  
 
Figure 6-9: Viability of coated MSCs. The viability of cells was measured after coating with 
a trypan blue assay. MSCs were also incubated with either of the buffers, PBS and DMEM. 
Viability measurements were performed on at least 4 biological replicates for each sample. 
Error bars indicate standard deviation. ns: non significant, *: p < 0.05 compared with DMEM 
only, by Kruskall Wallis ANOVA with a Dunn post-hoc correction for multiple comparisons.  
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Overall, these results showed that using 5 µM of Surfactant-222 in 20 mM NaP, pH 6.5 were 
the optimal conditions for coating MSCs in suspension. The next step was to test whether 
this coating would improve the binding of MSCs to type II gelatin. 
6.3.4. Cell adhesion assay 
MSCs were then coated with either Surfactant-FITC-222 or Surfactant-222 and their binding 
to type II gelatin was monitored, and compared to that of Wild-Type (WT) cells. Cells were 
stained with the membrane dye FM 4-64 and imaged with an epifluorescent microscope. 
In a first preliminary experiment, the coating was confirmed to be successful on the cells 
treated with Surfactant-FITC-222, as shown in Figure 6-10, where both the red channel for 
the membrane dye and the green channel for the FITC-tag were used to acquire images. 
For each condition, 4 replicates were performed, and consistent results were obtained at 
both high (i.e. 200 000 cells/well) and low (i.e.  25 000 cells/well) density, as shown in Figure 
6-11. 
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Figure 6-10: Epifluorescent images showing the successful coating of MSCs with Surfactant-
FITC-222. MSCs were coated with 5 µM of Surfactant-FITC-222 as previously described 
before being seeded onto type II gelatin coated tissue culture plates and incubated for 24 
hours. Cells were then washed once and phenol-free media was added before imaging. FM 
4-64 was added at a 1:1000 dilution to enable the detection of the cells. This image 
corresponds to a cell seeding density of 200 000 cells/well. Both FITC (A) and FM 4-64 (B) 
channels were used. 
 
Figure 6-11: Epifluorescent images showing the consistency of 222-MSCs binding onto type 
II gelatin across 4 replicates, at both high (A) and low (B) cell density. MSCs were coated with 
5 µM of Surfactant-222 as previously described before being seeded onto type II gelatin 
coated tissue culture plates and incubated for 24 hours. Cells were then washed once and 
phenol free media was added before imaging. FM 4-64 was added at a 1:1000 dilution to 
enable the detection of the cells. 
 
A B 
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The next step was therefore to compare the binding of MSCs in each condition, both on 
plastic and on gelatin. Overall, images showed that coated MSCs were able to bind better to 
type II gelatin than WT cells at each of the cell density tested (Figure 6-12, A). There did not 
seem to be any difference in the binding properties of cells coated with Surfactant-222 and 
Surfactant-FITC-222 (Figure 6-12, A, 222 and FITC-222 rows), meaning that the FITC tag does 
not interfere with the coating nor with the activity of 222. Finally, WT cells formed aggregates 
on gelatin (Figure 6-12, A, WT cells row). Interestingly, this phenomenon was not observed 
on plastic, except at the highest cell density (Figure 6-12, B, WT cells row). This difference 
could indicate that the aggregates observed on gelatin arise from some cell-cell interactions 
occurring to counterbalance the inability of these cells to bind directly to gelatin. 
Finally, when looking at the binding properties of cells onto plastic, the opposite trend was 
observed compared to gelatin, as WT cells seemed to be able to bind better than coated 
MSCs (Figure 6-12, B). The difference was clearer at lower cell densities while, again, no clear 
difference was observed between cells coated with Surfactant-222 or Surfactant-FITC-222. 
The reduced attachment of coated cells on plastic might indicate that the presence of the 
protein at the cell surface creates a steric hindrance which prevents them from attaching.  
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Figure 6-12: Epifluorescent images showing the difference in adhesion between WT, 222-
MSCs, and FITC-222 MSCs on type II gelatin (A) and plastic (B). MSCs were coated with 5 
µM of either Surfactant-222 or Surfactant-FITC-222 as previously described before being 
seeded onto type II gelatin coated tissue culture plates and incubated for 24 hours. Cells 
were then washed once and phenol-free media was added before imaging. FM 4-64 was 
added at a 1:1000 dilution to enable the detection of the cells. WT cells were used as a 
control. Cell densities are indicated at the top of each column. 
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The difference in attachment between WT and coated cells seeded at 25 000 cells/well was 
then quantified by counting the number of cells present in each well. In order to ensure that 
a representative sample was imaged, a tiling was performed with 16 squares (800 µmeters x 
800 µmeters) being acquired in each well. This method allowed comparison of cell counts in 
the equivalent location of each culture well, although the method is at best semi-quantitative 
and hindered by the clumping of cells in some of the wells. The percentage of attached cells 
compared to plastic was calculated for each square, and the median and interquartile range 
determined (Figure 6-13). Results showed that the median attachment for coated cells on 
gelatin was 224.4% (range 31.6% - 5160 %) against 23.67 % for the WT (range 4.478 % –       
78.39 %). This difference was shown to be significant when comparing both medians. 
The trend observed here strongly suggests that coating of MSCs with 222 can enhance their 
gelatin-binding properties.  This should in future be confirmed in repeat studies using cells 
from a range of patients and at a range of different passages. 
 
  
 
 
 
 
 
 
Figure 6-13: Difference in percentage of cell attachment of coated and WT MSCs on type 
II gelatin. 16 squares of 800 microns length were acquired in each of the wells seeded 
with 25 000 cells/well. Cells were automatically counted using the Image J software, and 
the percentage of attached cells on gelatin compared to plastic was calculated for each 
corresponding square. Results represent median with interquartile range. The difference 
was shown to be significant (P< 0.0001, Wilcoxon matched-pairs test). 
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6.4. Disucssion 
 
6.4.1. Conclusion 
This chapter has described the successful coating of MSCs with our most potent protein for 
binding to type II gelatin, namely 222. The chemistry on the protein was performed as 
previously described, and the presence of the surfactant around the protein was confirmed 
by the increase in its hydrodynamic radius. The charge was also neutralised by the addition 
of the surfactant following the cationisation of the protein.  
The method for cell coating was however optimised compared to previously published 
results, as it was decided to coat MSCs in suspension, which helped to reduce the amount of 
protein needed as well as to inject cells directly after the coating. This method was shown to 
be toxic in HEPES buffer, but viability could be maintained when coating cells with 5 µM of 
protein in 20 mM NaP, pH 6.5 to levels as high as 80 %. 
The presence of the protein at the surface of MSCs was then confirmed by confocal 
microscopy, which showed that Surfactant-FITC-222 was equally distributed around the cells 
and co-localised with the membrane dye FM-4-64. 
Following up on this validation, we then tested the ability of MSCs to bind to type II gelatin, 
and compared it to that of WT cells. The results showed that the presence of the protein at 
the cell surface caused an increase in cell adhesion, confirming the initial hypothesis that 
coating MSCs with a gelatin binding protein would improve their binding onto type II gelatin, 
and could potentially improve their binding to damaged cartilage. The latter is currently 
being investigated with in vivo studies in osteoarthritic mice. 
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6.4.2. Future work 
How could we confirm the improved binding properties of coated MSCs compared to WT 
cells? 
Although the cell adhesion assay showed an increased binding for coated cells compared to 
WT ones, other experiments could be performed to further confirm this trend. First, repeats 
of this assay on at least 3 more patients will be needed. Comparing 222-coated MSCs with 
CBD-coated MSCs could also be interesting in order to determine if the difference in affinity 
observed at the protein level is maintained once the protein is exposed at the cell surface. 
Another important point to consider in the design of this experiment is that we used tissue-
culture plastic plates which are pre-treated to favour cell adhesion. Even though the 
adhesion of both WT and coated cells onto gelatin was normalised to this plastic control, we 
could in the future use low-adherence plastic plates to get a better control. Using these 
plates would indeed rule out any effect of the pretreatment on the adhesion of WT and 
coated MSCs. 
In order to further extend this work, it would also be interesting to study the difference in 
binding of coated and WT cells ex-vivo, onto cartilage explants from both normal and 
osteoarthritic patients. This would indicate whether improving the binding of MSCs to type 
II gelatin is enough to also improve their engraftment onto damaged cartilage. 
Finally, the in vivo experiments which are currently underway should indicate whether or not 
coated MSCs are able to bind better to damaged cartilage, and, at a later stage, whether they 
lead to cartilage repair. 
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How could we characterise the coated protein further? 
Although 222 was characterised in the previous chapter, more information could be obtained 
on the protein once it is cationised and conjugated to the surfactant.  
Even though the presence of the protein at the cell surface seemed to confer more affinity 
to MSCs for gelatin, suggesting that the protein has remained structurally and functionally 
active following its insertion into the membrane, several tests should be done to confirm it. 
The residues modified during the cationisation could be identified by NMR, and the overall 
fold of the protein checked. It would also be interesting to study whether or not the residues 
that are modified are the same from one cationisation experiment to the other.   
Carrying out this set of experiments would also indicate whether the chemistry affects the 
mechanism of binding of 222 onto gelatin. Indeed, we know that the cationisation modifies 
the residues aspartate and glutamate. When looking back at our NMR data on 222, we 
identified that residues E321, D326 and E334 were involved in the binding. If these residues 
are modified during the cationisation, it is likely that the binding affinity of 222 would be 
affected. If that was the case, one could imagine replacing the cationisation step by some 
site-directed mutagenesis work, where the aspartates and glutamates which are further 
away from the binding site would be mutated for lysines and arginines. According to our 
NMR data, the glutamates 287 and 308 as well as the aspartates 312, 322 and 324, which did 
not show involvement in the binding to gelatin, could be targeted for this mutagenesis work. 
However, it is important to note that it would be harder to do a similar work for the 
surfactant addition step. As this chemical reacts with lysines and arginines, a strategy to 
protect the lysines 296, 310 and 315, which were shown to be involved in the binding, would 
be useful. 
This work should be coupled to more investigation on the functionality of the protein after 
the cationisation and the surfactant addition. However, this has proven to be difficult when 
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first working on the CBD and GFP as model proteins, as the surfactant made both proteins 
“sticky”, leading to a binding to gelatin which was not necessarily specific. This means that it 
would be difficult to estimate the binding affinity of 222 once it is conjugated to the 
surfactant, although this test could be done on the cationised version. 
Which further characterisation is needed for the coated cells? 
As outlined in the papers mentioned in the introduction, it is important to check whether the 
cells coated with the protein of interest still retain the properties of their native 
counterparts. It would therefore be interesting to determine whether 222-coated MSCs can 
still proliferate and differentiate. The previous work from Armstrong et al. seems to suggest 
that they would, as it was shown that MSCs coated with GFP with this surfactant could still 
proliferate and differentiate into cartilage, bone and adipose cells 197. However, confirming 
it with 222 will be needed. 
Another point to investigate would be to determine the duration of 222 exposure at the cell 
surface. Again, previous findings from Armstrong et al. showed that GFP was maintained at 
the cell surface for up to 10 days, before being endocytosed via clathrin-mediated          
vesicles 197. Early stage studies on MSCs coated with the CBD have shown that cells were 
coated for at least 5 days (not shown). It would however be interesting to find out whether 
222 exposure at the cell surface is stable for the same amount of time. The mechanism by 
which the protein is endocytosed could also be investigated in order to determine whether 
the mode of clearance is surfactant or protein-specific.  
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How does this method compare to the previously published ones? 
Overall, this chapter has described how we have developed a new, simple, one-step method 
for coating MSCs with a protein which binds to type II gelatin with a very high affinity. Our 
coating method is simpler than those relying on PPG or avidin described in the introduction 
of this chapter, which are both two-step methods. Our method is also more versatile, as, 
contrary to those which rely on the use of palmitic acid or even PPG, various proteins can be 
used to be conjugated to the surfactant. However, the cationisation step could alter the 
function of proteins with a binding site rich in aspartates and glutamates. The method is 
finally cheaper, as it does not require the use of protein G nor antibodies. Finally, it should 
enable the persistence of the protein at the cell surface for up to 10 days, which is longer 
than all the other non-covalent coating methods which have previously been described. 
Whether this is long enough to provide clinical benefits, through the secretion of trophic 
factors by the injected MSCs or through their direct differentiation, remains to be seen. 
In conclusion, when comparing our method to that described in the introduction for the 
treatment of osteoarthritis, it appears that the method discovered in this thesis has the 
additional advantage of targeting a substrate which is specific to damaged cartilage, namely, 
type II gelatin. Indeed, the work performed by Dennis et al.127 described the use of antibodies 
directed against molecules from the ECM. Even though the authors reported an enhanced 
adhesion of coated cells to damaged compared to healthy cartilage, our method still appears 
to be more specific. Indeed, 222 binds to type II gelatin, and the original CBD showed no 
binding to type II collagen 145. Even though it would be interesting to check, it is likely that 
222 would also show a low affinity for the native type II collagen found in healthy cartilage, 
as module 2 does not seem to have any affinity for this substrate. Mutations on 222 could 
also be envisioned to further increase the specificity of the protein for our substrate of 
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interest, as mentioned in the previous chapter. This would further reinforce the novelty of 
our method and would provide better specificity to damaged cartilage. 
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7. General conclusion 
Previous clinical studies on the injection of MSCs in OA joints have described promising 
results in terms of pain management and improved motor functions. However, the structural 
benefits of this therapy were unclear and inconsistent results were obtained. In parallel, lack 
of engraftment was also observed in both clinical and preclinical studies. This issue was 
addressed in preclinical models by enhancing the attachment of MSCs to the site of damage, 
leading to MSCs differentiation and cartilage repair. However, no such strategies were 
translated in clinical trials. 
The aim of this project was to develop a strategy to improve the delivery of MSCs when 
injected into OA joints, by enhancing their retention at the site of injection, where their 
properties are the most needed. The strategy relied on the coating of MSCs with a protein 
that binds to type II gelatin, a substrate which is specifically found in OA cartilage. 
This thesis has described the successful expression of a fully folded and functional CBD of 
MMP-2 in the E.coli Shuffle cells. To the best of our knowledge, this is the first time that this 
protein was expressed as a soluble protein in the cytoplasm of a bacterial host. The protein 
was shown to bind to type II gelatin with a Kd of 20.4 nM in a plate binding assay, which was 
in line with previous findings. This result also validated the correct folding of the protein in 
the bacterial host, which was further confirmed by Mass Spectrometry, NMR and a DTNB 
assay assessing the number of disulfide bridges formed.  
Further detailed characterisation of the interaction of the CBD with type II gelatin by NMR 
enabled the identification of module 2 as the most potent module. The expression, 
purification and characterisation of these individual modules further validated this 
observation, and a specificity of binding was observed for modules 1 and 3. The former 
displayed some specificity towards type II gelatin, while the latter seemed more specific 
towards type I gelatin. The binding site of each module was also investigated and a difference 
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in the residues involved in the binding of module 1 to each substrate was observed, which 
could explain the difference in specificity observed with this protein. 
The generation of the chimeric proteins made of identical modules 111, 222 and 333 partially 
validated the different specificities of each module: 333 was shown to have a much tighter 
affinity for type I gelatin than for type II. Unfortunately, 111 was highly insoluble, and 
refolding strategies failed to obtain a correctly folded protein. However, and more 
importantly for this project, 222 was shown to bind with the highest affinity for type II 
gelatin. Its Kd was measured at 1.46 nM, which corresponds to a 14-fold improvement 
compared to that of the original CBD. 
This protein was therefore used to coat the membrane of MSCs. The coating method relies 
on the use of a surfactant which surrounds the cationised protein and enables its delivery 
within the cytoplasmic membrane. This method was initially developed on adherent cells, 
and work presented in this thesis has enabled its translation onto cells in suspension. This 
optimisation renders the injection of coated cells into OA joints easier and safer, as no 
trypsinisation step is required, hence avoiding the risk of damaging the membrane and 
removing the newly incorporated 222 from the cell surface. Extensive optimisation of the 
conditions of coating also led to a reduction in the amount of 222 needed for the coating. 
The success of the coating was validated by confocal microscopy, which demonstrated the 
co-localisation of 222 with the membrane dye FM-4-64. Cell viability was not significantly 
decreased after the coating, and MSCs coated with 222 were shown to bind significantly 
better to type II gelatin than WT cells in an in vitro binding assay, suggesting that 222 
retained its ability to bind to its substrate once incorporated in the cell membrane. 
As mentioned in the last chapter, more detailed characterisation could be carried out on the 
cationised and conjugated forms of 222 in order to determine their binding affinity. Another 
important point to consider would be the retention time of the protein at the cell surface, 
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which was not investigated fully in this thesis. Previous work has however shown that 
proteins coated with this method remained at the cell surface for up to 10 days 197. Whether 
the protein is exposed at the cell surface for long enough to lead to an increased engraftment 
of injected MSCs in vivo is currently being investigated in a mouse model of OA. 
Another validation which is lacking in this thesis is whether or not MSCs coated with 222 
maintain their trilineage differentiation potential, as well as their proliferative properties. As 
mentioned in the previous chapter, these properties were shown to be maintained when 
using the same coating method to introduce GFP and myoglobin in the membrane of         
MSCs 197,153. However, it would be important to validate this observation with 222.  
The importance of the ability of coated MSCs to differentiate into chondrocytes will however 
depend on their mode of action once injected. As mentioned in the introduction of this 
thesis, MSCs are thought to act mostly through paracrine effects, by releasing factors that 
induce the differentiation of resident cells and decrease inflammation. This hypothesis was 
advanced not only in cartilage, but also in other tissues, by several authors who have 
demonstrated that, in spite of the lack of engraftment of MSCs at the injected site, 
therapeutic effects were observed for sustained period of times.  
One study showed that adipose derived stem cells, which only engrafted for 4 weeks and 
had previously shown limited potential for osteogenic differentiation, contributed to cranial 
defects repair 198.  
Another study showed that, in spite of improving the engraftment of MSCs to the infarcted 
myocardium using MCP-3 as a homing factor, MSCs did not differentiate into 
cardiomyocytes, but rather induced a favourable remodelling of the infarct zone, leading to 
improved heart function 199. This observation led the authors to suggest trophic factors as 
the main mode of action of MSCs in the infarcted myocardium. This hypothesis was further 
confirmed by other groups, who proceeded to either intra-venous 200 or intramuscular 
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injection of MSCs for the treatment of infarcted myocardium 201. Only 0.02 % of the injected 
cells reached the target tissue in the first study 200, while cells were shown to not have 
migrated to the heart in the second 201. In both cases, however, cardiac function was 
improved, an observation which was accompanied by a reduction of the size of the infarct 
and of inflammatory responses in the first study 200, while the second also reported tissue 
remodelling, reduced apoptosis and fibrosis, recruitment of bone marrow progenitor cells 
and increased mobilisation of myocardial progenitors and myocytes 201. Notably, both 
studies observed increased levels of proteins such as the anti-inflammatory protein             
TSG-6 200, and IGF, VEGF and Leukemia Inhibitory Factor (LIF) 201, which strongly suggest that 
MSCs acted through paracrine effects. This hypothesis was further supported by the fact that 
MSCs transduced with an anti TSG-6 siRNA did not exert any therapeutic effects in the first 
study  200, and that MSCs conditioned medium had the same effect as MSCs on the 
improvement of cardiac function in the second  201. 
Altogether, these observations have led several groups to think that MSCs act via a “hit and 
run” effect 202, and some have even suggested to modify their name to “medicinal signalling 
cells” in order to reflect this mode of action 203. 
However, other authors have suggested that, if MSCs were acting via paracrine effects on 
distant organs, this mode of action would involve the release of bioactive molecules in a 
burst and at high concentrations, a phenomenon which could be toxic. Another explanation 
which was advanced was that it is the small portion of cells engrafted into the target tissue 
that secrete these cytokines, but their short-term engraftment does not seem to correlate 
with the duration of the therapeutic benefits 204.  
One could also argue that it is the lack of engraftment of MSCs at the site of damage which 
prevents their differentiation into the correct cell type. As mentioned in the introduction of 
this thesis, several pre-clinical studies have indeed shown that, when engrafted, MSCs could 
236 
 
differentiate into chondrocytes. However, these studies were limited to small animals, and 
were not recapitulated in larger animals with joints that more resemble those of humans.  
These observations on the engraftment and differentiation of MSCs, however, are again not 
limited to the cartilage tissue. In patient suffering from Osteogenesis Imperfecta, a genetic 
disease which causes osteoblasts to produce a faulty type I collagen, MSCs were used in an 
attempt to promote bone differentiation. Several studies have reported a very low level of 
engraftment of the injected cells (between 1 and 2 %, 205,206). However, these cells were 
shown to differentiate into osteoblasts, promoting bone growth and providing a better bone 
structure 206. Interestingly, a potential correlation was observed between the cell dose and 
the therapeutic effect, meaning that improving engraftment of MSCs in this condition would 
be crucial 206. Finally, a study by Cowan et al. on the regeneration of cranial defects following 
injection of adipose derived MSCs showed exceptionally high levels of engraftment. After 12 
weeks, 95 % of the cells in the newly regenerated bone were donor-derived 198.  
Overall, it seems that improved engraftment of MSCs onto a target tissue could lead to their 
subsequent differentiation into the desired cell type and enhance therapeutic benefit. If 222-
coated MSCs show increased engraftment compared to WT cells in vivo, it would therefore 
be interesting to determine the fate of the coated cells once injected.   
Interestingly, targeting MSCs to the damaged tissue is not only pursued in OA, but also in 
Osteogenesis Imperfecta and in the infarcted myocardium. Notably, this thesis has described 
the generation of a protein which is very potent to bind to type I denatured collagen, namely 
333. As degradation of type I collagen was shown to be increased in infarcted         
myocardium 207, 208, one could envision the use of 333-coated MSCs for targeting cells to this 
tissue.  
Finally, even if the mode of action of MSCs rely on paracrine effects only, the concentration 
of these cells at the site of injury will likely improve their therapeutic effects.  Better cartilage 
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repair could be observed, as well as longer-lasting benefits. Another advantage on increased 
engraftment would be a reduction in the cell dose required for beneficial effects. These 
potential outcomes will be investigated in this project in the next phase of the in vivo trials. 
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